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Abstract
Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder that affects the
development of haematopoietic cells and has an incidence of 2300 cases / year in the UK.
Whilst treatment with conventional cytotoxic agents has significantly increased cure rates in
AML, only 35-50% patients under the age of 60 years will be long term survivors.  There is
a need to develop novel agents targeting molecular lesions or dysregulated pathways to
improve clinical responses.  This study identified commonly dysregulated pathways and
genes using Affymetrix gene expression profiling of AML patients.  Analysis of gene
expression data using MetacoreTM online gene ontology pathway analysis identified WNT
proteins to be one of the most frequently dysregulated processes associated with AML.
TCF7L2 was the most significantly dysregulated WNT transcription factor gene and was
subsequently examined in greater detail. The expression of TCF7L2 was validated by RQ-
PCR. These data significantly correlated with the normalised array expression data
(R=0.748; P<0.01) which in turn correlated with overall protein expression determined and
quantified by western blotting. TCF7L2 mRNA overexpression was found to be
independently prognostic for reduced complete remission rate (P<0.05), OR=5.19 [95%
C.I.=1.39 - 19.39]. The TCF7L2 gene undergoes exon splicing which yields multiple
isoforms which have been reported to yield functionally distinct proteins. TCF7L2 mRNA
isoform expression in AML patients was compared with that in normal human bone marrow
and a human cord blood derived from CD34+ haematopoeitic progenitor cells.  Extensive
variability of TCF7L2 splicing at the 3’ end of the gene (exons 13-18) was identified. AML
patients were heterogeneous in the isoform expression pattern, but aberrant exon
composition (compared to normal cells) was not observed.  At the protein level, expression
of the 58 kDa isoform (exons 1-14 and 18) and 56 kDa isoform (exons 1-13 and 18) were
detected. In both normal and AML cells, expression of the 56 kDa and 58 kDa isoforms
were dominant. To determine the functional significance of TCF7L2 overexpression
lentiviral shRNA vectors targeting TCF7L2 was transduced in leukaemic cell lines co-
expressing a TCF-GFP reporter which enabled simultaneous analysis of the effect on TCF-
dependent transcription.  Reporter activity was inhibited by shRNA vectors targeting
TCF7L2, and the cells became non-responsive to WNT agonists (WNT3A and BIO)
demonstrating that canonical WNT signalling is dependent on TCF7L2 expression in these
cells. Phenotypically, shRNA expression was found to strongly inhibit proliferation and to
promote apoptosis indicating that TCF7L2 expression is required for the proliferation and
survival of myeloid leukaemia cells.  Paradoxically, overexpression of individual TCF7L2
isoforms (72 kDa, 58 kDa and 56 kDa) suppressed WNT agonist responses in myeloid
leukaemia cell lines but not in epithelial cells. Overexpression of TCF7L2 in normal CD34+
cells was found to promote monocytic differentiation. In summary, this study presents
novel data identifying WNT signalling as the most commonly dysregulated process in
AML. TCF7L2, a WNT transcription factor was found to be significantly overexpressed in
AML and associated with poor clinical outcome.  This protein was found to be required to
maintain the proliferation and viability of myeloid leukaemia cells suggesting that targeting
TCF7L2 maybe a valid approach in AML therapy.
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1 - General Introduction
____________________________________
1.1 THE HAEMATOPOIETIC SYSTEM
1.1.1 Overview of normal haematopoiesis
Haematopoiesis results in the continuous production of separate lineages of mature
blood cells including erythrocytes, monocytes, macrophages, neutrophils, platelets and
lymphocytes. In foetal life this process starts in the yolk sac and later migrates to the foetal
liver and spleen (Medvinsky et al, 1993; Muller et al, 1994; Godin et al, 1995). Following
birth, normal haematopoiesis is restricted to the bone marrow (BM), but also can be found
in umbilical cord blood (CB) and peripheral blood (PB). Approximately 1 in every 104 BM
cells is thought to be a haematopoietic stem cell (HSC) (Spangrude et al, 1988a; Morrison et
al, 1996). The ability to commit and to self-renew are defining properties of HSCs (Till &
McCulloch, 1961) and as they differentiate and become committed to certain lineages, they
express end-stage markers representative of each cell type. Differentiation of HSC is
associated with a loss of self-renewal capacity or multipotency, thus requiring HSCs to self-
renew to maintain the HSC pool. The ability of HSC to balance self-renewal and
commitment to differentiation is accompanied by long periods of quiescence (G0).  Once
commitment to differentiation takes place, active cell division occurs (Suda et al, 1983;
Ogawa, 1993).
Cytokines play an important role in regulating haematopoiesis. While self-renewal
of HSC appears to be a stochastic process (Nakahata et al, 1982; Tsuji & Nakahata, 1989),
survival and proliferation and, to a certain, extent lineage fate of blood cells is regulated by
growth factors and cytokines. The commitment of bipotential granulocyte-macrophage
(GM) progenitor cells is regulated by interleukin-3 (IL-3), granulocyte-macrophage colony
stimulating factor (GM-CSF), and interleukin-4 (IL-4) after they exit from G0 and begin
active cell proliferation (Metcalf, 1980; Metcalf & Burgess, 1982). GM-CSF can also
interact synergistically with granulocyte CSF (G-CSF) on HSC progenitors to produce
distinct colonies (McNiece et al, 1989). Instructive cytokine signalling can alter the balance
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of endogenous lineage determining transcription factor (TF). Lineage conversion by ectopic
overexpression of cytokine receptor shows strong context dependence. For example,
expression of the GM-CSF receptor can instruct myeloid lineage conversion in common
lymphoid progenitors (CLP) and pro-T cells but not in pro-B cells or megakaryocyte-
erythroid progenitors (Sarrazin & Sieweke, 2011). Besides a direct instructive effect on an
uncommitted cell, a permissive role of cytokine supporting the selective survival or
proliferation of a daughter cell could also be derived from a cytokine independent
commitment division. In support of this, the development of monocytes / macrophages has
been reported previously in macrophage CSF (M-CSF) deficient mice (Lagasse &
Weissman, 1997).
Proliferation and maturation of committed HSC is stimulated by several late-acting
lineage specific cytokines such as erythropoietin, M-CSF, G-CSF, and interleukin-5 (IL-5)
(Ogawa, 1993). For example, G-CSF stimulates the formation of colonies of granulocytes
(Burgess & Metcalf, 1980) and IL-1, IL-3, IL-6, IL-11 and stem cell factor (SCF) have been
shown to stimulate production of megakaryocytes and to increase platelet production
(Bruno et al, 1991; Briddell et al, 1992). For erythrocyte production, erythropoietin is a an
absolute requirement, otherwise the erythroid progenitor cells fail to proliferate and will
undergo apoptosis (Silva et al, 1996).
The proliferation of quiescent HSC can also be activated in response to injury or
injection of cytokines, such as G-CSF that induce the exit of HSCs from their niches and
mobilisation of the cells into the circulation.  In addition, the self renewal and maintenance
of HSC progenitors have been linked to extracellular signals such as the Notch and
Wingless-type MMTV integration site family (WNT). This was demonstrated by the
inhibition of Notch signalling diminishing the capacity of HSCs to maintain an
undifferentiated state but allowing normal proliferation and survival that must be intact for
WNT proteins to enhance HSC renewal (Duncan et al, 2005).
Chapter 1: General Introduction
__________________________________________________________________________
3
1.1.2 Characteristics of HSC
HSCs can be classified into long-term, short-term and multipotential progenitor cells
(MPPs), based on the extent of their self-renewal abilities and specific cell surface markers
as shown in Figure 1.1.  It has been reported that only 25% of the non-cycling or quiescent
HSCs are long-term MPPs (Osawa et al, 1996; Muller-Sieburg et al, 2002), and others are
transient or short-term (Morrison & Weissman, 1994). Although 75% of long-term HSCs
are quiescent at any one time, over 90% of long-term HSCs actually enter the cell cycle at
least once every 30 days to generate additional HSCs to retain the HSC pool (Cheshier et al,
1999).
Both the long-term or short-term HSCs cannot be recognised morphologically as
they resemble lymphocytes. In mice HSCs can be identified by cell surface markers and
Lin- Sca-1+ c-kit+ has been generally used as a canonical marker set for HSC enrichment
(Spangrude et al, 1988b; Ogawa et al, 1991). However studies have suggested that the HSC
compartment in adult BM is heterogeneous since different HSCs show clearly
distinguishable repopulation patterns and distinct intrinsic properties of clonality (Muller-
Sieburg et al, 2002; Dykstra et al, 2007; Morita et al, 2010). Studies also suggest that the
Lin- Sca-1+ c-kit+ CD34- CD150+ CD48- fraction in adult BM contains truly dormant HSCs
and this population is the most primitive long-term HSC, whereas Lin- Sca-1+ c-kit+ CD34+
cells revealed early but only short-term reconstitution.  These dormant cells could reversibly
switch from dormancy to self-renewal stage and have been reported to divide
approximately five to six times during the murine life span (Wilson et al, 2008). In humans,
overwhelming evidence suggests a primitive population of stem cells expressing Lin- CD34-
CD38- HSC in human BM with long-term multilineage repopulating ability (Osawa et al,
1996; Goodell et al, 1997; Nakamura et al, 1999).
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Figure 1.1: Haematopoietic development in the mouse. Classification of HSC into long-
term, short-term, and MPP, based on surface expression markers.  Shown are Common
lymphocyte progenitor (CLP), common myeloid progenitor (CMP), granulocyte-monocyte
progenitor (GMP), megakaryocyte-erythrocyte progenitor (MEP), natural killer (NK) cells.
Adapted from (Reya, 2003) and (Kokolus & Nemeth, 2010).
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1.1.3 HSC microenvironment
Self-renewal and the developmental capacity of HSCs can be controlled in a non-
autonomous manner by their cellular microenvironment. Such a microenvironment is
usually referred to as a stem cell niche (Nagasawa, 2006; Hsu & Fuchs, 2012a). HSCs
populate the BM niches that consist of adherent cells known as stromal cells which also
control HSC dormancy and the balance between HSC self-renewal and differentiation.
Although HSCs are mostly quiescent, they can be mobilised from their niche to proliferate
and differentiate. As shown in Figure 1.2, the dormant long-term HSCs are mostly located
close to the osteoblast lining or the endosteal niche. This niche contains osteoblastic cells
and reticular cells expressing adhesion molecules such as CXC chemokine ligand-12
(CXCL12). These stromal cells of the BM containing fibroblasts, endothelial cells and
CXCL12 react with corresponding ligands on HSC and maintain their viability (Wilson &
Trumpp, 2006; Nagasawa, 2006). It has been recently determined that chemokine
stimulation of HSCs by CXCL12 leads to an enhancement in stromal migration via
activation of adhesion molecules, in addition to its well-known ability to stimulate motility
(Greenbaum et al, 2013) and also modulates adhesion receptor function via CD44 (Avigdor
et al, 2004).  In human CD34+ cells, CXCL12 promotes a rapid increase in the affinity of β1
integrin for its ligands, vascular cell adhesion molecule (VCAM1) and fibronectin (Hidalgo
et al, 2001).
The HSCs that reside in the BM can be found in endosteal and perivascular niches.
HSCs located on the endosteal side tend to be more quiescent, whereas HSCs located at the
perivascular side are more active and the most dormant HSCs have been reported to locate
near osteoblast progenitor cells. With the exception of osteoclasts, all of the cellular
components in the BM niches have been reported to modulate HSC behaviour (Sugiyama et
al, 2006; Nagasawa, 2007).
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Figure 1.2: Overview of the complex environment of the HSC niche and the molecules
that mediate interactions between HSCs, osteoblasts and reticular cells. Available from
http://www.nature.com/nri/posters/hsc/nri0707_hsc_poster.pdf. Information was adapted
from (Nagasawa, 2006) and (Hsu & Fuchs, 2012b).
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1.1.4 Transcription factors in haematopoiesis
A large number of transcription factors (TFs) are involved in the control of blood
cell generation and development, for instance Stem Cell Leukaemia (SCL / TAL1 ), GATA
binding protein GATA1, GATA2, Runt-related transcription factor 1 (RUNX1),
CCAAT/enhancer-binding protein alpha (C/EBP) and PU.1 (Scott et al, 1997; Lichtinger
et al, 2012). The transcription factors PU.1 and C/EBP are responsible for normal
myeloid differentiation from stem cells to monocytes or granulocytes as shown in Figure
1.3. In particular, PU.1 induces expression of the M-CSF receptor and the development of
monocytes, whereas C/EBP increases the expression of the G-CSF receptor and leads to
mature granulocytes (Behre et al, 1999). Dual expression of PU.1 and GATA1 leads
development of HSCs to CMPs, but dominant expression of PU.1 is restricted to GMPs
(Zhu & Emerson, 2002). During multilineage development of CD34+ cells, C/EBP proteins
appear to be expressed at high levels in neutophilic but not monocytic or erythroid cells
(Tenen et al, 1997).
Some TFs regulate HSC self-renewal such as Homeobox protein B4 (HOXB4), a
key TF that has been reported to induce the in vitro expansion of HSCs via self-renewal
(Beslu et al, 2004; Sharma et al, 2006). B-lymphoma Mo-MLV insertion region 1 homolog
(Bmi1) on the other hand is important for long-term maintenance of adult HSCs but not for
foetal HSCs (Park et al, 2003). HOXB4 overexpression triggered the expansion of short-
term repopulating HSCs in the absence of Bmi1 showing independent function in both TF
and HSC activities (Faubert et al, 2008). Other HOX genes such as HOXB3 and HOXB1
are expressed at higher levels in populations containing immature HSCs. Other TFs are
known to influence lineage fate. For instance, in the absence of GATA1 or SCL / TAL1,
embryonic erythropoiesis was impaired suggesting crucial roles of these TF to establish
lineage decisions as reviewed previously (Orkin, 1995).
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Figure 1.3: Important TFs for haematopoietic development of myeloid lineage. Shown
are transcriptional regulation of CMP, GMPs and erythroid and megakaryocytic lineages
(EMPs). Adapted from (Zhu & Emerson, 2002).
Chapter 1: General Introduction
__________________________________________________________________________
9
1.2 ACUTE MYELOID LEUKAEMIA
1.2.1 Pathophysiology of Acute Myeloid Leukaemia (AML)
AML is an aggressive malignancy of the BM.  It is a clonal disorder characterised by
the inhibition of differentiation resulting in the subsequent accumulation of cells at various
stages of incomplete maturation. The pathophysiology of AML can be explained by
acquired genetic changes in HSC that cause a complete or partial block in normal HSC
maturation.  AML is a heterogeneous disease and its heterogeneity is evident from
variations in morphology, immunophenotype, cytogenetics and molecular abnormalities
(Schoch et al, 2002a). Genomic and functional studies have demonstrated that multiple
mutations are necessary to transform normal cells into a leukemic clone (Ley et al, 2008;
Mardis et al, 2009). Since HSCs are the only self-renewing cells among BM progenitors, a
model has been proposed that mutations must sequentially accumulate within distinct clones
of HSC over time.  In the case of AML, genome sequencing suggests that up to 10
mutations are serially acquired in a single cell lineage that ultimately generates a dominant
leukaemic clone and from 750 point mutations, only small subsets are relevant for the
development of AML (Jan et al, 2012; Jan & Majeti, 2013), in which most AML mutations
are probably background events in HSCs (Welch et al, 2012).
The molecular pathogenesis of AML has not yet been completely defined.
Recurrent chromosomal structural variations (e.g. t(15;17), t(8;21), inv(16), del5, del7 and
others) and mutations leading to activation of the receptor tyrosine kinase (e.g. Fms-like
tyrosine kinase 3 (FLT3) and c-KIT) signalling are established diagnostic markers,
suggesting that these acquired genetic abnormalities play an essential role in
leukaemogenesis (Betz & Hess, 2010). Expression profiling studies have yielded signatures
that correlate with specific cytogenetic subtypes of AML, but have not yet suggested new
initiating mutations. A two-hit model of AML has been described in which the critical
events are an activating mutation of a kinase combined with a mutation that alters the
function of a haematopoietic TF (Dash & Gilliland, 2001). This model is partially
supported by data from AML samples in which these two types of mutations have been
documented (Schaub et al, 2010; Ding et al, 2012). Recent studies suggest that a third
complementation group of mutations in the epigenome should be added to the two hit model
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(Figueroa et al, 2010; Chen et al, 2013). AML displays global DNA hypermethylation and
a specific hypermethylation signature.
AML can be viewed a disease which retains some of the hierarchical characteristics
of normal haematopoiesis where repopulating activity is restricted to a subset of cells
known as leukaemic stem cells (LSC) (Lowenberg & Terpstra, 1998). In some cases the
immunophenotype of the cells can be similar to that of normal HSCs (e.g. CD34, CD38,
CD71 and HLA-DR), some antigens display leukaemia-specific characteristics (CD90,
CD117 and CD123) (Terpstra et al, 1996; Blair et al, 1998; Blair & Sutherland, 2000).  The
heterogeneity among leukaemic blasts with respect to their capacity to proliferate
(McCulloch et al, 1988), supports a hierarchy within leukaemic blast populations in patients
with AML (Sutherland et al, 1996).  However in AML, LSCs are not necessarily rare which
challenges the hierarchical model.  Other complications with the LSC model include the
lack (as yet) of any consistent phenotype for LSCs, the reliance on immunocompromised
mice for its definition and the evidence for polyclonality within LSC populations, restricting
their potential as therapeutic tagets (Lutz et al, 2013).
In leukaemogenesis, it is presumed that certain oncoproteins could either
inappropriately activate a program of growth or interfere with terminal differentiation
(Kvinlaug et al, 2011).  Normal primitive cells, rather than committed progenitor cells, are
the target for most leukaemic transformation (Bonnet & Dick, 1997), though AML may also
arise from more committed progenitor cells caused by mutations or selective expression of
genes that enhance their otherwise limited self-renewal capabilities. In either case the
consequence is a developmental block giving rise to an accumulation of leukaemic blasts
(Figure 1.4). This impacts on normal haematopoiesis with a reduction in erythrocytes,
granulocytes and platelets due to overcrowding in the BM. The disease is clinically
heterogeneous with biologically distinct subtypes as discussed further in section 31.2.3.
The term ‘acute’ is applied because the disease is usually aggressive and characterised by
large numbers of very immature, undifferentiated cells that, if untreated, can lead to the
rapid death of the patient. These immature leucocytes are called blasts and they represent
an early phase of the normal differentiation process that occurs in the BM.
Chapter 1: General Introduction
__________________________________________________________________________
11
Figure 1.4: Diagram of normal myeloid development and its relationship to both
leukaemic cells and LSCs. The LSCs for AML are restricted to multipotential and
committed progenitor cells, as indicated by the blue boxes. Multipotential stem and
progenitor cells, including long-term repopulating and short-term repopulating HSCs, are
depicted in blue on the left. Differentiating myeloid cells, recognisable by their distinct
morphology, are shown on the right. The malignant cells in AML are indicated by red
boxes; leukaemic blasts for the different French American British (FAB) subclasses of
AML (M0 through M7) correspond approximately to the different normal blasts in each
lineage (Krause & Van Etten, 2007).
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1.2.2 Diagnosis and incidence of adult AML
Patients with AML have excess numbers of blast cells in the BM and usually in the
PB as well. The presence of over 20 – 30% myeloblasts in the BM at clinical presentation
is the basis of defining AML (Harris et al, 1999). AML incidence in the UK is around
2,500 people each year and the risk of developing AML increases with age (Shah et al,
2013). AML is the most common variant of acute leukemia occurring in adults, comprising
approximately 80 to 85% of cases of acute leukemia diagnosed in individuals greater than
20 years of age. It is most common in people over 65 years old, AML accounts for 10 to
15% of newly diagnosed cases of childhood leukaemias. Historically, paediatric AML
patients have a worse prognosis than Acute Lymphoblastic Leukamia (ALL) patients.
Adults with AML remain at increased risk of induction failure (Burnett, 2012), early
relapse, and isolated central nervous system relapse (Meshinchi & Arceci, 2007a).
Diagnosis of AML requires the examination of BM morphology, cytochemistry and
immunophenotyping. Full blood count investigation usually shows features such as
anaemia, thrombocytopenia and variable leucocyte count with or without the presence of
blast cells in the PB. About one-quarter to one-third of cases begin with a low white blood
cell (WBC) count, while about half of patients show some degree of leucocytosis. The most
common presenting symptoms are pallor and fatigue secondary to anaemia, bleeding
problems secondary to thrombocytopenia, infection due to neutropenia and hepatomegaly
and splenomegaly due to infiltration by blasts (Estey & Dohner, 2006). Disseminated
intravascular coagulation occurs more commonly in Acute Promyelocytic Leukaemia
(APL).
Immunophenotyping using flow cytometry and panels of monoclonal antibodies is
very useful to assign lineage to confirm AML diagnosis. This technique can classify the
subtypes of AML or biphenotypic leukaemia if there is evidence of both lymphoid and
myeloid markers.  Monoclonal antibodies directed against antigens (defined within the
cluster of differentiation (CD) system) against CD11b, CD13, CD14, and CD33 are
considered to be restricted to cells committed to myeloid differentiation and are used for
diagnostic distinction (Bradstock et al, 1994; Harris et al, 1999).
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1.2.3 Classification
AML is a highly heterogeneous disease and the subclassification of AML depends
on morphological, immunophenotyping, cytogenetic and molecular criteria. Originally
AML was subdivided based on leukaemic blast morphology according to the FAB
classification in 1976 (Table 1.1). The FAB classification system divides AML into eight
subtypes, M0 through to M7, based on its degree of maturity and the type of cell from
which the leukaemia developed (Bennett et al, 1976). This has now been largely
superseded by a World Health Organization (WHO) classification (Vardiman et al, 2002).
This WHO classification incorporates recurring cytogenetic and molecular genetic
abnormalities as shown in Table 1.2. Molecular characterisation of leukaemia cells enables
more precise diagnosis and prognosis than is possible with the FAB classification.
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FAB
classification
of AML
% of total Prominent features
M0 2 Large and granular blasts with minimal myeloid
differentiation, expression of at least one myeloid antigen
either CD13 or CD33
M1 10-18 The cells in the BM show some evidence of granulocytic
differentiation. Poorly differentiation myeloblasts with
occasional Auer rods (elongated clumps of azurophilic
granule material found in the cytoplasm of leukaemic blasts)
M2 27-29 More than 50% of the BM cells are myeloblasts and
promyelocytes
M3 5-10 Hypergranular abnormal promyelocytes with Auer rods
M4 16-25 Both granulocytic and monocytic differentiation are present
in varying proportions in the BM and PB. M4 resembles M2
in all respects except that the proportion of promonocytes
and monocytes exceeds 20% of the nucleated cells in the BM
M5 13-22 Monoblastic differentiation
M6 1-3 Myeloblastic leukaemia with megablastoid features or
leukaemia with erythroblastic differentiation
M7 4-8 Megakaryoblastic differentiation with frequent BM fibrosis
Table 1.1: AML classification based on FAB criteria. Adapted from (Bennett et al,
1976).
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WHO classification of AML
AML with recurrent genetic abnormalities:
AML with t(8;21)(q22;q22), (RUNX1/ETO)
AML with abnormal BM eosinophils and inv(16)(p13q22) or t(16;16)(p13;q22),
(CBFβ/MYH11)
Acute promyelocytic leukaemia (APL) with t(15;17)(q22;q12), (PML/RARα) and variants
AML with 11q23 (MLL) abnormalities
AML with multilineage dysplasia:
Following MDS or MDS/ myeloproliferative disease (MPD)
Without antecedent MDS or MDS/MPD, but with dysplasia in at least 50% of cells in  two
or more myeloid lineages
AML and myelodysplastic syndromes, therapy related:
Alkylating agent/radiation–related type
Topoisomerase II inhibitor–related type (some may be lymphoid)
AML, not otherwise categorised:
AML, minimally differentiated
AML without maturation
AML with maturation
Acute myelomonocytic leukemia
Acute monoblastic/acute monocytic leukemia
Acute erythroid leukemia (erythroid/myeloid and pure erythroleukemia)
Acute megakaryoblastic leukemia
Acute basophilic leukemia
Acute panmyelosis with myelofibrosis
Myeloid sarcoma
Table 1.2: AML classification based on WHO. Adapted from (Vardiman et al, 2002).
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1.2.4 Prognostic factors
Prognosis is the expected course of a disease and the patient's chance of recovery.
The prognosis predicts the outcome of a disease and therefore the future for the AML
patient and different intensity of treatment is assigned according to the risk groups.
Cytogenetic analysis provides the most powerful independent predictor of disease outcome
in AML allowing the assignment of patients to groups with favourable or unfavourable
(high risk) prognoses as listed in Table 1.3 (Grimwade & Hills, 2009a; Grimwade et al,
2010a).
Favourable prognostic factors have been associated with the presence of the
cytogenetic translocations t(8;21), t(15;17) and inv(16), (Fenaux & Detourmignies, 1994;
Meshinchi & Arceci, 2007b). In contrast, patients with 11q23 abnormalities, monosomy 5,
monosomy 7 or complex karyotypes that involve the presence of more than three
abnormalities carry a poor prognosis. The remainder of AML patients are assigned to a
prognostically intermediate group. This latter group is very heterogeneous because it
includes patients with a normal karyotype as well as those with rare chromosome
aberrations. Currently, risk stratification of AML may be further refined by consideration
of Nucleophosmin1 (NPM1), C/EBP, Fms-like tyrosine kinase 3-internal tandem
duplication (FLT3-ITD) and mixed-lineage leukemia gene-partial tandem duplication (MLL-
PTD) mutations (Foran, 2010). Signiﬁcantly worse outcome with regard to overall survival
(OS) is seen in patients harbouring an NPM1 mutation together with higher FLT3-ITD
expression as compared to those with mutated NPM1 and a low FLT3-ITD expression.  This
is an independent subgroup with a unfavourable prognosis (Schneider et al, 2012). Chou et
al showed that a median 2-log decline in NPM1 mutant copy number was obtained
following induction therapy. Any increase of mutant numbers was always accompanied by
three-fold increased risk of relapse compared to patients with persistently low signals (Chou
et al, 2007). In addition to cytogenetics, WBC count at diagnosis of more or equal to 30 x
109 /L has also been reported as a significant poor prognostic factor, predicting a lower OS
and is independent of the treatment used.
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Risk status Cytogenetics Molecular abnormalities
Favourable t(8;21)(q22;q22)
inv(16)(p13.q22),
t(16;16)(p13.q22)
t(15;17)
Normal cytogenetics with
NPM1 mutation or C/EBP
mutation in absence of
FLT3-ITD
Intermediate Normal cytogenetics
+8
t(3;5)4
t(9;11)(p22q23)
Entities not classified as favourable or
adverse
c-KIT mutation with:
t(8;21)(q22;q22), or
inv(16)(p13.q22), t(16;16)
(p13.q22)
Adverse Complex (≥ 4 unrelated abnormalities)
abn(3q) [excluding t(3;5)(q21 ~ 25;q31
~ 35)],
inv(3)(q21q26)/t(3;3)(q21;q26),
add(5q), del(5q), -5,
−7, add(7q)/del(7q),
t(6;11)(q27;q23),
t(10;11)(p11 ~ 13;q23),
Other t(11q23) [excluding t(9;11)(p21–
22;q23) and t(11;19)(q23;p13)]
t(9;22)(q34;q11),
−17/abn(17p)
High Ecotropic Viral
Integration Site 1 (EVI1)
expression (with or without
3q26 cytogenetic lesion)
Normal cytogenetics with
FLT3-ITD in the absence of
NPM1 mutation
Table 1.3: Prognostic subgroups of AML based upon presenting cytogenetics and
genetic lesions. The revised Medical Research Council (MRC) cytogenetic risk group was
based on multivariable analysis conducted in 5876 adults (16–59 years old) treated in the
MRC AML10, 12 and 15 trials (Grimwade & Hills, 2009b; Grimwade et al, 2010b; Smith
et al, 2011).
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1.2.5 AML treatment and outcome
1.2.5.1 Conventional therapy
Treatment for AML consists of remission induction chemotherapy followed by post-
remission chemotherapy with or without BM transplantation. Achievement of complete
remission (CR) is the essential first step in effective treatment of AML. For most patients,
remission induction regimes usually comprise a combination of anthracycline, (e.g.
daunorubicin), cytosine arabinoside with either etoposide or thioguanine (Stone & Mayer,
1993).  This regimen has been capable of inducing CR rates of 65-75% in adults aged 18-60
years (Tallman et al, 2005). Delivery of high dose anthracycline-cytosine arabinoside (Ara-
C) to younger AML patients aged 15-24 years will provide a 40 - 45 % chance of cure
(Figure 1.5) but there is little evidence for increasing cure rates in older patients (Figure 1.6)
(Burnett, 2012). Cure could not be estimated for patients over 70 years, because survival
was consistently low (<5%) (Shah et al, 2013) and 90% of older adults still die of their
disease (Rowe & Tallman, 2010). Whilst remission will be achieved in up to 80% of those
receiving intensive chemotherapy, the main variables precluding cure are treatment-related
mortality and relapse rates. Only around half of older AML patients with age above 60
years will enter CR and around 85% will relapse within two years (Burnett, 2012). For
patients under 60 years, a remission rate of 80% has been reported, and about half of
patients will survive (Newland, 2002). Younger AML patients will have around 40%
chance of cure by allogeneic transplantation as an alternative to consolidation therapy
(Koreth et al, 2009). For an optimal treatment approach in AML, both a precise diagnosis
and prognostic parameters that determine response to therapy and survival are needed.
1.2.5.2 Targeted therapy of AML
Over the years, treatment outcomes in younger patients with AML have improved,
but optimisation and new combinations of drug therapy are needed. Patients with APL (or
AML with M3 subtype) are given all-trans retinoic acid (ATRA), a vitamin A derivative, to
induce differentiation of promyelocytes (Tallman et al, 1997; Tallman et al, 2002).
Remission induction invariably follows a period of 15 to 25 days of severe BM hypoplasia
and a stable remission must be associated with less than 5% blasts in BM with evidence of
recovery of normal cellular elements. With this regimen, about 75% to 85% of patients will
enter CR. APL patients especially those with a low WBC count have substantial benefit
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from extended ATRA treatment indicated by a high remission rate due to fewer early and
induction deaths and less resistant disease (Burnett et al, 1999). CR rates greater than 90%
can be achieved in newly diagnosed APL by adding Ara C to ATRA from the onset of
treatment or when leucocyte counts rapidly increases.
In contrast, chromosome aberrations with an unfavourable clinical course including -
5/del(5q), −7/del(7q), inv(3)/t(3;3) and complex aberrant karyotypes show cure rates of less
than 10%. CR rates and OS were not improved even by using combined drug treatments
(e.g. multidrug resistance gene-1 (MDR-1) modulator valspodar) as compared to
chemotherapy alone in AML patients with poor-risk AML (Greenberg et al, 2004).  Trials
combining FLT3 inhibitors (e.g. sorafenib) with chemotherapy in which FLT3 mutant AML
patients are enrolled, have shown highly promising activity in early trials with the ability to
achieve more sustained in vivo inhibition of FLT3 (Sato et al, 2011; Knapper, 2011).  The
addition of nucleoside analogues appeared to be beneficial in AML with adverse
cytogenetics. The inclusion of cladaribine but not fludaribine improved remission rate and
OS (Burnett, 2012). Other targeted approaches for AML include immunoconjugate or
antibody-directed chemotherapy such as Gemtuzumab Ozogamicin (Mylotarg), which is
directed to CD33 expressed in most leukemic blast cells but also in normal haematopoietic
cells (Wheatley et al, 1999; Newland, 2002). This has gained approval for treatment of
older patients in relapse who are considered unsuitable for intensive therapy (Larson et al,
2002; Cheson et al, 2003). Randomised trials have found a beneﬁt for Gemtuzumab
Ozogamicin in newly diagnosed patients with favourable-risk AML, as reviewed previously
(Ravandi et al, 2012). Since AML differs widely both clinically and in molecular genetic
heterogeneity, optimal management of AML may eventually encompass a combination of
cytotoxic and targeted therapies.
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Figure 1.5 : Survival for younger AML patients. Adapted from (Burnett, 2012).
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Figure 1.6 : Survival for older AML patients. Adapted from (Burnett, 2012).
1.3 WNT SIGNALLING
1.3.1 Overview of canonical and non-canonical WNT signalling pathways
WNT signalling plays a critical role in the control of cell proliferation and cell
differentiation in many contexts. There are two main pathways of WNT signalling known
as the ‘canonical’ and ‘non-canonical’ (refer Figure 1.7). The main function of the
canonical WNT pathway is its association with Catenin (Cadherin-Associated Protein) Beta-
1 or CTNNB-1 hereafter referred to as -catenin. Canonical and non-canonical pathways
exhibit different signalling events; the canonical WNT pathway employs -catenin to
activate WNT target gene expression through binding to lymphoid enhancer-binding factor
(LEF) / T-cell factor (TCF) TFs which is the primary focus of this thesis; whereas the non-
canonical signalling constitutes the WNT / Ca2+ pathway and the WNT / planar cell polarity
(PCP) pathway involving activity of other downstream genes particularly calmodulin kinase
II (Cam-KII), protein kinase C (PKC) and c-jun kinase (JNK). In some cases, the non-
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canonical WNT signalling cascade can also inhibit nuclear -catenin activity via activation
of WNT5A (Ishitani et al, 2003).
Canonical WNT signalling (also known as WNT / -catenin, or TCF / -catenin
pathway) is a tightly regulated pathway in developmental processes. The most crucial event
in canonical WNT signalling is the cytoplasmic accumulation of β-catenin and its
subsequent nuclear translocation followed by its binding to TCF or LEF proteins (Clevers &
van de Wetering, 1997; Cavallo et al, 1998a; Novak & Dedhar, 1999). Under non-
stimulated conditions, a β-catenin destruction complex formed by AXIN, adenomatous
polyposis coli (APC), and glycogen synthase kinase 3 beta (GSK3) will keep cytoplasmic
levels of β-catenin low through phosphorylation by GSK3 (Eastman & Grosschedl, 1999).
Following WNT agonist binding to a receptor complex such as by WNT family, frizzled
(FZD) family or low density lipoprotein receptor-related protein (LRP) (Cong et al, 2004),
the AXIN-APC-GSK3 complex is inhibited, leading to β-catenin accumulation in the
cytoplasm (Rubinfeld et al, 1996; Eastman & Grosschedl, 1999; Gordon & Nusse, 2006;
MacDonald et al, 2009). When β-catenin enters the nucleus, it replaces repressor proteins
such as Groucho, Transducin-like enhancer protein 1 (TLE) or histone deacetylases from
TCF proteins and converts the complex into a transcriptional activator, thereby activating
transcription of WNT target genes (Aberle et al, 1997; Cavallo et al, 1998b; Clevers, 2006).
As nuclear effectors, they act as multimeric transcription complexes that either repress or
activate WNT target gene expression.
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Figure 1.7: The three types of WNT-dependent pathway. (A) The canonical WNT/β-
catenin pathway. Inactive-state: in the absence of WNT signal, β-catenin is phosphorylated
by the destruction complex composed of Axin, APC, and GSK3. Phosphorylated β-
catenin is then targeted for degradation.  Active-state: WNT binding to the Frizzled and
LRP receptors induces phosphorylation of LRP and recruitment of Axin and the Axin-APC-
GSK3 complex is inhibited, leading to accumulation of cytosolic β-catenin. (B and C) the
non-canonical WNT / Ca2+ and WNT / PCP pathways (Franco et al, 2009).
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1.3.2 Roles of WNT signalling in haematopoiesis and normal development
The requirement of WNT signalling activity in HSC self-renewal and BM
repopulation has been indicated by the positive effect of WNT activation on HSC recovery
in transplantation studies (Reya, 2003; Congdon et al, 2008) and that WNT activation
through TCF / -catenin signalling was necessary for optimal HSC formation (Goessling et
al, 2009) and HSC integrity (Malhotra & Kincade, 2009).  WNT5A, WNT2B or WNT10B
from transduced stromal cells, stimulated expansion of human CD34+ progenitors (Van Den
Berg et al, 1998).  Homeodomain protein TFs such as HOXA9 and HOXA10 can regulate
WNT10B expression in human CD34+ progenitors implying a role in early haematopoietic
differentiation (Ferrell et al, 2005). A number of recent studies suggest that WNT
signalling may play a role in vascular endothelial growth control and differentiation in
which increased accumulation of β-catenin by WNT1 ligand binding causes increased
endothelial proliferation (Wright et al, 1999; Franco et al, 2009). WNT signalling also
regulates a wide range of processes including cell differentiation and promotion of growth
and development during early stages of embryogenesis (Fleming et al, 2008). In
vertebrates, WNT is not only a crucial factor influencing body axis and polarity during early
development (St Amand & Klymkowsky, 2001; Petersen & Reddien, 2009) but also in
directing early precursor cells in multiple organs such as for neuronal (Hirabayashi et al,
2004) and forebrain development (Vacik et al, 2011), liver regeneration (Goessling et al,
2008) and thymocyte differentiation (Verbeek et al, 1995; Castrop et al, 1995). During
normal development, APC proteins play important roles for cytoskeletal functions
regulating morphogenesis and cell-cell adhesion (Barth et al, 1997; Penman et al, 2005;
Nathke, 2006a).
1.3.3 Alteration of WNT signalling in leukaemias and other malignancies
Opposing effects of WNT signalling on haematopoiesis have been reported.
Stabilised forms of -catenin could result in immature phenotype or exhaustion of the HSC
pool. These differences might be explained by different levels of WNT activation (Cobas et
al, 2004; Kirstetter et al, 2006). Dysregulation of WNT signalling has been implicated in
many cancers (Cadigan & Nusse, 1997; Reya & Clevers, 2005) including the progression of
AML and other haematological malignancies (Lu et al, 2004; Simon et al, 2005). While β-
catenin itself appears to be important for normal haematopoiesis (Cobas et al, 2004; Reya &
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Clevers, 2005), some AML patients’ cells strongly overexpress β-catenin (Tsutsui et al,
1996; Chung et al, 2002; Hwang et al, 2002).  In models of T-Acute Lymphoblastic
Leukaemia (ALL), thymus specific expression of activated β-catenin leads to development
of thymic lymphoma (Guo et al, 2007). Different percentages and WNT signaling levels
on a per cell basis have been reported.  Foetal and leukaemic stem cells and thymocyte
development may require higher WNT activity than normal adult HSCs (Luis et al, 2012).
Precise amounts of WNT signals are required to maintain HSC integrity.  Interactions
between HSCs and niche cells may also alter the secretion of WNT proteins, and changes in
balances between these factors may lead to leukaemia or immunodeficiencies (Sengupta et
al, 2007). Studies have also described a correlation of β-catenin expression with poor
prognosis of AML patients (Ysebaert et al, 2006; Xu et al, 2008). Besides -catenin and
the GSK3 complex, relatively little is known about the role of other WNT signalling
molecules such as the FZD receptors in the haematopoietic system or in AML. A number
of studies have demonstrated dysregulation of WNT signalling in AML in terms of
epigenetic alterations particularly of the extracellular WNT antagonists, including secreted
frizzled-related proteins (sFRPs), WNT5a, Dickkopf-1 (DKK1) and WNT inhibitory factor
1 (WIF1) gene promoter hypermethylation (Suzuki et al, 2007; Jost et al, 2008; Valencia et
al, 2009; Martin et al, 2010). In particular, constitutive upregulation of WNT target gene,
cyclin D1, has been shown to result from methylation of WNT5A (Martin et al, 2010).
Epigenetic downregulation of WNT antagonists, such as DKK1 and WIF1 by
hypermethylation has also been implicated in chronic lymphocytic leukaemia (CLL)
(Bennett et al, 2010) and progressive neoplasia of the lung (Licchesi et al, 2008).
Besides dysregulation of WNT stimuli, the accumulation of -catenin may also be
the result of other factors such as the mutation of either APC (Korinek et al, 1997; Rosin-
Arbesfeld et al, 2000), conductin (Behrens et al, 1998) or -catenin itself (Morin et al,
1997a; Sparks et al, 1998). WNT signalling is known to be crucial for intestinal stem cell
activation (Korinek et al, 1998a; He et al, 2004) and mutations in APC are a cause of
colorectal cancer (van Es et al, 2001), medulloblastoma and ovarian cancer. In colorectal
cancer progression, besides loss of APC, the interaction of APC with the cytoskeleton might
also contribute to cancer initiation and progression (Nathke, 2006b).
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1.4 T-CELL FACTOR (TCF) GENES
1.4.1 Overview of the TCF family
Members of the TCF family of high mobility group (HMG) DNA-binding proteins
are responsible for transcriptional regulation of WNT target genes upon -catenin
stabilisation and entry into the nucleus. Humans have four types of TCF proteins namely
Transcription factor 7 (TCF7), Transcription factor 7 like 1 (TCF7L1), Transcription factor
7 like 2 (TCF7L2), and LEF1 (Hurlstone & Clevers, 2002), as illustrated in Figure 1.8.
TCF7, TCF7L1 and TCF7L2 were previously known as T cell factor (TCF), TCF1, TCF3
and TCF4 respectively. TCF proteins are thought to be bimodal regulators of WNT
signalling that function mainly in the nucleus to activate WNT target genes (e.g. cyclin D1,
SP1 CD44, c-MYC) via -catenin transactivation. As shown in Figure 1.9, in the absence of
WNT signals, TCF acts with corepressors to keep WNT target genes silenced. -catenin
binding to TCF protein in the nucleus antagonises this repression and recruits additional
coactivators, inducing target gene expression. Thus, TCF is considered as a transcriptional
switch that requires β-catenin to convert its repression into activation (Willert & Jones,
2006). This mechanism could occur through sequence-specific DNA binding on TCFs and
also a low-affinity binding site on LEF1 (Daniels & Weis, 2005).
The TCF family including LEF1 are known to produce isoforms through alternative
splicing generating proteins with similar basic domain structures (-catenin-binding, HMG
and nuclear localisation signals (NLS) domains) (Hoppler & Kavanagh, 2007). An internal
exon in the context-dependent regulatory domain (CRD) is alternative in all members
except for TCF7L1, and the exon is flanked by small amino acid motifs (LVPQ, SxxSS;
only in TCF7L1 and TCF7L2) also created by alternative splicing, and part of the CRD is
alternatively spliced in LEF1 (Pukrop et al, 2001). Alternative splicing also creates
different C-termini; the CRARF domain is a 33 amino acid motif in the C-tail-E conserved
among all non-vertebrates but not present in vertebrates LEF1 and TCF7L1. The C-tail-E
also contains two C-terminal binding protein (CtBP)-binding motifs found in TCF7L1 and
TCF7L2 (Arce et al, 2006; Atcha et al, 2007).
TCF7L1 appears to have unique functions in early embryonic development (Merrill
et al, 2004). Within the TCF family, TCF7 has been reported to be a feedback repressor of
WNT signalling (Roose et al, 1999). TCF7 and LEF1 produce full-length isoforms that
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mediate WNT signals and their truncated dominant negative (dn) isoforms actually limit
WNT signals and may function as growth suppressors (Waterman, 2002). Expression of
TCF7 is most abundantly expressed in T-lymphocytes, but is also expressed in HSC
(Novershtern et al, 2011) and NK cell development (Held et al, 2003). Similar to TCF7L2
and LEF1, TCF7 has been previously studied to be a partner with nuclear -catenin, which
serves as a downstream transcriptional activator in response to external WNT stimulation.
All TCFs can bind to plakoglobin (aka -catenin) a homolog of -catenin, and
phosphorylation of serine60 in TCF7L2, but not in other TCFs, inhibits plakoglobin binding
(Castano et al, 2002).  LEF1 and TCF7L1 are both expressed during hair and skin
development, however only LEF1 knockout causes loss of hair development indicating
dominant roles in different cell types (Reya & Clevers, 2005). In relation to TCF7L2, LEF1
is preferentially expressed by differentiated proliferative phenotype cells in melanoma
whereas TCF7L2 is preferentially expressed by invasive phenotype cells, this disease
showing differential behaviour of TCF / LEF (Eichhoff et al, 2011).
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Figure 1.8 : Diversity of splicing variants and alternative promoters generated by
TCFs / LEF. The -catenin binding domain (green) is absent in dominant negative isoforms
(dnTCF7, dnLEF1). A context-dependent regulatory domain (CRD; grey/yellow) separates
the -catenin-binding domain from the HMG and NLS. HUGO nomenclature for the
mammalian genes is indicated in parentheses (Arce et al, 2006).
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Figure 1.9: Transcriptional activation by -catenin in the nucleus. Adapted from
(Daniels & Weis, 2005).
1.4.2 Structure and function of TCF7L2
The TCF7L2 is a complex gene of which several different isoforms have been
reported, including isoforms that lack the -catenin binding domain (Korinek et al, 1997).
TCF7L2 gene consists of 18 identified exons encoding different functional domains
(illustrated in Figure 1.10).  This protein is known to display a complex pattern of splicing
producing several alternative exons. Tissue-specific splicing giving rise to several TCF7L2
variants has been detected in pancreatic islets (Prokunina-Olsson et al, 2009), vertebrate
central nervous system (Nazwar et al, 2009), colorectal cancers (Duval et al, 2000;
Cuilliere-Dartigues et al, 2006) and hepatocarcinoma (Tsedensodnom et al, 2011).
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Frameshift mutations causing microsatellite genetic instability have also been reported in
leukaemia models (Chang et al, 2006) and in several solid tumours (Duval et al, 1999).
TCF7L2 isoforms provide a DNA binding moiety through the HMG domain, and -
catenin contributes the transactivation domain, within a TF complex. Both the -catenin
binding domain and HMG are among important domains that exist within coding regions of
all TCF7L2 isoforms used in this current study. The N-terminus region of TCF7L2 is
crucial for -catenin binding, whereas for -catenin, its core armadillo repeat region
interacts, not only with TCF7L2, but also with other TCFs (TCF7, TCF7L1), cadherins and
APC (Poy et al, 2001; Young et al, 2002). The middle region of the TCF7L2 transcript
(exon 11- exon 12) is where the HMG DNA binding domain is located.  The ability of
TCF7L2 to bind DNA can be inhibited by other proteins such as MAD2B (Hong et al,
2009). Pioneering work by Korinek et al has demonstrated blockage of WNT signalling
caused by a dnTCF7L2 that lacks exon 1 sequence (Korinek et al, 1997), and upon WNT
stimulation, this dominant-negative form is unable to bind -catenin. This illustrates the
importance of TCF7L2 interaction with -catenin in the nucleus.  For transcriptional
regulation, TCF7L2-dependent gene responses to WNT signals are primarily mediated by a
Cysteine-clamp (C-clamp) containing TCF7L2 with C-tail type E splice variants.  TCF7L2
isoforms with C-tail type B are much less potent in transactivation compared with C-tail
type E (Wallmen et al, 2012). These data suggest that the diversity of TCF7L2 isoforms
may exist to enable fine control of WNT target gene expression.
CTNNB1-binding
1-53
Interaction with MAD2L2
201-395
Proline-rich region
178-317
LVPQ-Grg-SxxSS
260-334 TLE
335-349
HMG box
350-418
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signal
425-430
Promoter-specif ic
activation
459-505
Figure 1.10: Structural view of the full length TCF7L2 protein and the corresponding
functional domains. Protein sequence annotation for TCF7L2 (Entry # Q9NQB0) was
adapted from The UniProt Consortium accessible from
http://www.uniprot.org/uniprot/Q9NQB0 (Magrane & Consortium, 2011).
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1.4.3 Roles of TCF7L2 in disease and cancer development
Single nucleotide polymorphisms (SNPs) of TCF7L2 have been widely associated
with risk of Type 2 diabetes (Grant, 2012; Boj et al, 2012; Greenawalt et al, 2012; Peng et
al, 2013).  Emerging reports also show that TCF7L2 polymorphisms are associated with an
increased risk of gestational diabetes mellitus (Zhang et al, 2013), diabetic retinopathy (Luo
et al, 2013), breast cancer (Connor et al, 2012) and colon cancer recurrence (Paez et al,
2013). Aberrant activation of TCF7L2 by the accumulation of -catenin in intestinal crypts
has been implicated in colorectal cancer (van der Flier et al, 2007), and mice models lacking
TCF7L2 show loss of the proliferative compartment in the crypt region (Korinek et al,
1997; Korinek et al 1998a), indicating that constitutive activation of TCF7L2 is important
for maintaining the malignant phenotype. Activation of the TCF7L2 / -catenin
transcriptional complex in colorectal disease arises mainly due to activating point mutations
in -catenin (Morin et al, 1997b). It has been reported in renal cell carcinoma that
imbalances in TCF7L2 splicing are associated with inhibition of apoptosis (Shiina et al,
2003). TCF7L2 chromatin occupancy sites have also been validated in colon carcinoma
cells, breast cancer cells and glioma cells by chromatin immunoprecipitation (ChIP) coupled
to PCR, demonstrating direct transcriptional regulation of miRNA by TCF7L2 in epithelial
cells and roles in cancer cell proliferation and invasion (Lan et al, 2012). The precise role
of TCF7L2 and TCF / LEF family members in the maintenance of cell-type-specific WNT
signalling responses is still unknown in the context of AML and haematopoiesis.
1.5 GENE EXPRESSION STUDIES IN AML
Gene expression profiling (GEP) has been incorporated into many studies given its
versatility in high throughput identification of disease classification signatures and the
elucidation of new biomarkers for clinical development. Microarray testing of differential
gene expression signatures in leukaemia subtypes has demonstrated that this approach is not
only useful to confirm diagnosis (e.g. classification of molecular signatures; see below) but
may detect novel associations between aberrant gene expression and gene mutations that
affect the same biological processes. The genetic variations of the different AML subtypes
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often lead to distinct changes in gene expression across more than 30,000 genes, which is
comprehensively analysed by DNA microarrays provided by several manufacturers
including Affymetrix.  This study utilised GEP data generated using the Affymetrix
GeneChip® Human platform shown in Table 1.4.
Previous multi-center studies have identified minimal numbers of genes needed to
identify prognostically important clusters with a high degree of accuracy. Gene expression
profiles of AML patients were used to delineate differential gene expression signatures
corresponding to NPM1 gene mutation (Kohlmann et al, 2010). GEP studies showed that
analysis with whole-genome DNA microarrays leads to a prediction accuracy of 96% with
respect to the classical methods (eg: flow cytometry), and allows further distinction of AML
subtypes. Molecular features unique for NPM1 (Verhaak et al, 2009), C/EBP (Valk et al,
2004; Wouters et al, 2007) and distinct subtypes AML M2 with t(8;21), AML M3 with
t(15;17), or AML M4 with inv(16) have been reported (Schoch et al, 2002b). Unique
molecular and prognostic features have been demonstrated by GEP studies in AML with
t(8;16) and are able to discriminate this subtype from AML with  t(11q23) (Haferlach et al,
2009).
In acute leukaemias, GEP studies not only provide molecular distinction of subtypes
within AML (Kohlmann et al, 2003; Schoch et al, 2005) and ALL (Yeoh et al, 2002), but
also able to distinguished ALL from AML (Kohlmann et al, 2003) and this has become a
tool to further characterise MDS from AML patients (Mills et al, 2009; Theilgaard-Monch
et al, 2011). Clinically-relevant gene changes associated with the granulocytic lineage due
to  aberrant transcriptional activity of RUNX1-RUNX1T1 were identified by GEP studies
(Tonks et al, 2007b) and have previously been validated in a primary AML cohort (Tonks et
al, 2007a; Morgan et al, 2013). Taken together, it is evident that GEP studies carry high
potential for future integrative studies with other genomic technologies, which will continue
to improve our understanding of malignant transformation particularly in myeloid
malignancies and thereby contribute to individualised risk-adapted treatment strategies in
AML.
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Description Human Genome U133
Plus 2.0 array
Human Genome U133A
array
Number of transcripts ~ 47,400 ~18,400
Number of genes >38,500 >14,500
Number of probe sets >54,000 >22,000
Oligonucleotide probe length 25-mer 25-mer
Probe pairs / sequence 11 11
Control sequences included:
Hybridisation controls
Poly-A controls
Normalisation control set
Housekeeping / control genes
bioB, bioC, bioD, cre
dap, lys, phe, thr
100 probe sets
GAPDH, β-Actin, ISGF-3
(STAT1)
bioB, bioC, bioD, cre
dap, lys, phe, thr
100 probe sets
GAPDH, β-Actin, ISGF-3
(STAT1)
Table 1.4: Specifications for Affymetrix GeneChip® Human Genome U133 cartridge
format. Affymetrix, the HG-U133 Plus2.0 set contains more than 50,000 different
oligonucleotide probe sets representing ~48,000 transcripts on the GeneChip.  Both arrays
also contain 100 probe sets for normalisation to control and housekeeping genes. These
controls were selected to reflect a variety of different expression levels and so can be used
as quality control to determine the sensitivity of each hybridization reaction. Adapted from
www.affymetrix.com/analysis/index.affx.
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1.6 AIMS OF THE STUDY
The initial aim of this study was to identify dysregulated pathways in AML.
Subsequent aims focussed on understanding of the contribution of WNT signalling to the
pathogenesis of AML.
Specific aims were:-
1) To identify dysregulated pathways and the corresponding aberrantly regulated genes
in primary AML samples.  This was achieved by comparing GEP of AML blasts to normal
haematopoietic progenitor cells (HPC) using a comprehensive genome wide microarray
analysis.
2) To characterise the selected dysregulated gene (i.e. TCF7L2) involved in WNT
signalling at the transcript and protein level in AML patients and normal samples.
3) To determine the functional significance of TCF7L2 using myeloid leukaemia lines
and normal human haematopoietic progenitor cells.
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2 - General Materials and Methods
2.1 CHEMICALS, REAGENTS AND SUPPLIERS
All chemicals used in this study were Analar grade or tissue culture (TC) tested unless
otherwise stated. Chemicals used are listed below grouped by supplier in an alphabetical
order:
Reagents Source
Foetal calf serum (FCS) BioSera Labtech, Ringmer, UK
Nuclear / Cytosol Fractionation kit BioVision, California, USA
DNA primers and synthetic genes were
synthesized de novo as ordered, and subcloned into
a standard delivery vector (pBS II SK(+) or
pEX-A). TCF7L2 cDNA sequences were
submitted online to
http://www.eurofinsgenomics.eu
Eurofins MWG Operon, Ebersberg,
Germany
Ultra-purified water was obtained from PureLab®
Ultra water purification unit
Elga LabWater, High Wycombe, UK
Ethanol, hydrochloric acid (HCl), methanol
(CH3OH) and sodium chloride (NaCl)
Fisher Scientific, Loughborough, UK
Sterile water for irrigation Fresenius Kabi, Cheshire, UK
Ficoll-Paque PLUS®, Amersham ECL advance
western blot detection kit, ECL advances blocking
agent
GE Healthcare, Buckinghamshire, UK
Hank’s Balanced Salt Solution (HBSS), penicillin-
streptomycin
Gibco®, Paisley, UK
Sterile water TC grade Hameln Pharmaceuticals, Gloucester,
UK
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Dulbecco’s Phosphate Buffered Saline (dPBS),
human IL-3, human IL-6, human G-CSF, human
GM-CSF, human SCF, L-glutamine, NuPAGE® 3-
(N-morpholino)propanesulfonic acid (MOPS)-
SDS Running Buffer, NuPAGE® Transfer Buffer,
OneShot® Stbl3 and OneShot®Top10 chemically
competent E. coli, sodium bicarbonate (NaHCO3)
7.5%, Super-Optimal broth with Catabolite
repression (SOC) medium, Trizol®, Trypsin-
EDTA 0.05%, Tris
(tris(hydroxymethyl)aminomethane) ultra pure
Invitrogen™, Paisley, UK
SeaKem® GTG™ Agarose Lonza, Basel, Switzerland
Benzonase 25 U/µl Novagen®, Nottingham, UK
Human Fms-like tyrosine kinase-3 ligand (FLT3L)
and M-CSF
Peprotech, London, UK
Recombinant human WNT-3A R&D Systems, Abingdon, UK
Human transferrin Roche Diagnostics, Burgess Hill, UK
Gentamycin (Cidomycin®) Manufactured by Sanofi-Aventis,
Guildford, UK and supplied by UHW
Pharmacy
7-Aminoactinomycin D (7-AAD), ampicillin,
bovine serum albumin (BSA) fraction V, Bradford
reagent, calcium chloride (CaCl2), chloroform
molecular grade, chloroquine (N’-(7-
chloroquinolin-4-yl)-N,N-diethyl-pentane-1,4-
diamine), deoxyribonuclease I (DNAse I),
dimethyl sulfoxide (DMSO), Dulbecco’s Modified
Eagle’s Medium (DMEM), ethanol molecular
grade, ethidium bromide (EtBr), ethylenediamine-
tetraacetic acid (EDTA), glycerol, isopropanol, 4-
Sigma-Aldrich®, Poole, UK
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(2-Hydroxyethyl) piperazine-1-ethanesulfonic
acid, N-(2-Hydroxyethyl) piperazine-N′-(2-
ethanesulfonic acid) HEPES buffered saline
(HeBs), Iscove’s Modified Dulbecco’s Medium
(IMDM), Luria Bertani (LB) agar and LB broth,
magnesium chloride (MgCl2), magnesium sulphate
(MgSO4), 2-mercaptoethanol (2-ME), MISSION®
shRNA, phosphatase inhibitor cocktail, Ponceau S
solution, protease inhibitor cocktail, protein
standard (1 mg bovine serum albumin /ml in
0.15 M NaCl), puromycin, Roswell Park Memorial
Institute 1640 culture medium (RPMI-1640),
sodium azide (NaN3), sodium orthovanadate
(Na3VO4), sodium dodecyl sulfate (SDS),
Triethylammonium bicarbonate buffer 1.0 M
(TEAB), Tris-Borate-EDTA (TBE) buffer 10X
concentrate, Tris-Acetate-EDTA (TAE) buffer
10X concentrate, Triton X-100, Tween-20, xylene
cyanol
RetroNectin® Takara, Shiga, Japan
(2'Z,3'E)-6-Bromoindirubin-3'-oxime (BIO) Tocris, Bristol, UK
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2.2 BUFFER AND SOLUTION COMPOSITIONS
The compositions of the most frequently used buffers are listed as below:
Buffer Recipe
DNA gel loading buffer 6X 0.25% (w/v) bromophenol blue, 0.25% (w/v)
xylene cyanol and 30% (v/v) glycerol in
distilled water
ECL Advance western blotting detection Solution A containing Tris buffer in 3.2%
(v/v) ethanol and Solution B containing
proprietary substrate in Tris buffer
Flow cytometry staining buffer 1X PBS containing 1% (v/v) BSA, 3.1 mM
NaN3 in TC grade water
Freezing mix 30% (v/v) FCS, 20% (v/v) DMSO, 50%
(v/v) growth media and 0.45 µM filtered
HBSS 25 mM HEPES, 100 µg/ml gentamycin and
1 U/ml heparin
HeBS 2X 50 mM HEPES, 280 mM NaCl, 1.5 mM
Na2HPO4, pH 7.05
IMDM 1% (w/v) BSA fraction V, 20% (v/v) FCS,
45 µM 2-ME, 360 µg/ml 30% human
transferrin, 100 U/ml penicillin, 100 µg/ml
streptomycin
LB-broth 10 g Bacto-Tryptone, 5 g Bacto-yeast
extract, 10 g NaCl dissolved in I L distilled
water, pH 7.5
Magnetic activated cell sorting (MACS)
buffer
1X PBS, 0.5% (v/v) BSA, 2 mM EDTA, 5
mM MgCl2, pH 7.2, 0.45 µm filtered
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MOPS SDS running buffer 20X 50 mM MOPS, 50 mM Tris Base, 0.1%
SDS, 1 mM EDTA, pH 7.7
Ponceau S solution 1.3 mM (0.1% w/v) Ponceau S in 5% (v/v)
glacial acetic acid
SOC medium 2%  (w/v) tryptone, 0.5% (w/v) yeast
extract, 10 mM sodium chloride, 2.5 mM
potassium chloride, 10 mM magnesium
chloride, 10 mM magnesium sulfate, 20 mM
glucose
TAE buffer 10X 400 mM Tris-acetate and 10 mM EDTA,
pH 8.3
TBE buffer 10X 890 mM Tris, 890 mM boric acid, 20 mM
EDTA, pH 8.3
Tris buffered saline (TBS) 20 mM Tris HCl, 135 mM NaCl, pH 7.6
TBS Tween-20 (TBS-T) TBS with 0.1% (v/v) Tween-20
Tris-EDTA (TE) 10 mM Tris-HCl, 1 mM EDTA, pH 7.5
Transfer buffer 25 mM Bicine, 25 mM Bis-Tris, 1 mM
EDTA, pH7.2
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2.3 GENERAL CELL CULTURE
2.3.1 Subculture of suspension cell lines
Each cell line was processed and cultured according to its own biohazard risk and
standard cell culture technique. Separate bottles of reagents and growth media were used
for each type of cell line to minimise cross-contamination risk. Each cell line was handled
separately under containment level II and the flow cabinet was decontaminated thoroughly
by wiping the internal surfaces using 70% (v/v) ethanol. Cell culture growth medium and
solutions were pre-warmed to room temperature (RT) prior to subculturing. The culture
was first examined for signs of high density growth, infection and medium colour change.
A sample of cells was removed and diluted 1 in 10 for counting in appropriate growth
medium. The media used to culture each cell line are listed in Table 2.1. In order to
maintain the growth of the suspension cells, excess cells were removed directly from the
culture flask by pipetting them off into a waste bottle containing 1% (v/v) chlorine and new
fresh growth medium was added. All cultures were incubated at 37C with 5% CO2
humidified atmosphere for 16-24 hours.
2.3.2 Subculture of adherent cell lines
The cultures were examined microscopically for their level of confluence before
subculturing. The existing growth medium was decanted and 1-2 ml / 25 cm2 trypsin-
EDTA was added directly to the flask followed by tilting (to cover the adherent layer) for
about 3-5 minutes at RT. Subsequently, an equal volume of growth medium was added to
neutralise the trypsin activity and the cells were transferred into a fresh tube. If required,
cells were counted before centrifugation for 10 minutes at 200 x g. Supernatant was
discarded and the cell pellet was resuspended with fresh growth medium.
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2.3.3 Cell quantification
Estimation of cell number was determined using haemocytometer counting
chambers with improved Neubauer ruling (Hawksley, Brighton, UK). Briefly, 8 µl of cell
suspension was aliquoted from culture and directly pipetted under a counting chamber cover
slip. The cellularity of the sample in cells / ml was given by the average number of cells per
cuboid multiplied by 1 x 104, as counted using Eclipse TS100 light transmission microscope
(Nikon, Surrey, UK).
2.3.4 Cryopreservation and resuscitation of cells.
To freeze cells for continued culture at a later date, between 1 – 10 x 106 cells were
collected by centrifugation at 200 x g for 5 minutes and resuspended in the relevant growth
medium into 1.8 ml cryopreservation vials (Nunc).  An equal volume of freezing mix (50%
growth medium (RPMI or DMEM), 30% (v/v) FCS, 20% (v/v) DMSO was added drop-
wise to the cell suspension and the tube was immediately placed inside a Mr. Frosty
freezing container that have been filled with 70% (v/v) isopropanol. The freezing container
was placed at –80°C overnight and the tubes were transferred to liquid nitrogen (LN2) for
long-term storage.
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Prototype/Name
of cell line
Cell phenotype Seeding density
cells / ml
Source
reference
Growth medium
K562 Erythrocytic cell derived from
chronic myeloid leukaemia
1 x 105 (Lozzio &
Lozzio, 1975)
RPMI-1640, 10%
(v/v) FCS, 2mM L-
glutamine, 20 µg/ml
gentamycin
THP-1 Monocytic cell derived from
AML
1 x 105 (Tsuchiya et
al, 1982)
RPMI-1640, 10%
(v/v) FCS, 2mM L-
glutamine, 20 µg/ml
gentamycin
HL-60 Promyelocytic cell  derived
from AML
1 x 105 (Collins et al,
1978)
RPMI-1640, 10%
(v/v) FCS, 2mM L-
glutamine, 20 µg/ml
gentamycin
NB-4 Promyelocytic cell  derived
from AML t(15;17)
1 x 105 (Lanotte et al,
1991)
RPMI-1640, 10%
(v/v) FCS, 2mM L-
glutamine, 20 µg/ml
gentamycin
U937 Monocytic cell derived from
histiocytic lymphoma
1 x 105 (Sundstrom &
Nilsson, 1976)
RPMI-1640, 10%
(v/v) FCS, 2mM L-
glutamine, 20 µg/ml
gentamycin
Kasumi-1 Myeloblastic cell derived
from AML t(8,21)
3 x 105 (Asou et al,
1991)
RPMI-1640, 10%
(v/v) FCS, 2mM L-
glutamine, 20 µg/ml
gentamycin
MV4-11 Biphenotypic B-
myelomonocytic leukaemia
1 x 105 (Lange et al,
1987)
RPMI-1640, 10%
(v/v) FCS, 2mM L-
glutamine, 20 µg/ml
gentamycin
Phoenix &
HEK293T
Amphotropic virus-packaging
cell line derived from Human
embryonic kidney
(HEK293T)
2.5 x 106 (Kinsella &
Nolan, 1996)
DMEM containing
10% (v/v) FCS, 20
µg/ml gentamicin, 2
mM L-glutamine
HeLa Epithelial cell derived from
cervical cancer
2.5 x 106 (Masters,
2002)
DMEM containing
10% (v/v)  FCS, 20
µg/ml gentamicin, 2
mM L-glutamine
Table 2.1: Cell lines used in this study and their growth condition requirements.
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2.4 ISOLATION OF HAEMATOPOIETIC MONONUCLEAR
AND PROGENITOR CELLS
2.4.1 Patient samples
The samples taken for this study were approved by the local and multicentre ethical
committees in the UK. De novo disease (AML presentation BM / PB samples) were
collected with informed ethical consent for research purposes in accordance with the
Declaration of Helsinki.
2.4.2 Ficoll density gradient
For the isolation of mononuclear cells from CB or BM, density centrifugation over
FicollPaque® solution was used. The CB or BM samples were diluted in 1:1 ratio with
HBSS (see 2.2). The diluted sample (8 ml) was then gently layered over FicollPaque®
(5ml) in a 50 ml falcon tube before centrifuging at 400 x g for 40 minutes with slow
acceleration. Differential migration during centrifugation results in the formation of layers
containing different cell types. The bottom layer contained erythrocytes which have been
aggregated by the FicollPaque® solution. The mononuclear leukocytes were found at the
interface between the plasma and the FicollPaque® solution because of their lower density.
The cell layer was aspirated by gentle aspiration in circular motions to ensure collection of
all cells at the edge of tube and was transferred into a new conical tube containing 15 ml of
growth medium (RPMI-1640, 10% FCS, 2mM L-glutamine, 20 µg/ml gentamycin) and
centrifuged at 200 x g for 10 minutes. Additional washing was performed in the same way
until the supernatant was free of platelet contamination as determined by microscopic
inspection.  Mononuclear cells isolated were counted before resuspending in growth
medium (RPMI-1640, 10% FCS, 2mM L-glutamine, 20 µg/ml gentamycin) at 50 x 106 cells
per vial for cryopreservation.
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2.4.3 Immunoselection of normal human haematopoietic CD34+ progenitor cells
Normal human CD34+ HPCs were isolated and purified from the total mononuclear
cells by using a magnetic-activated cell separation (miniMACS™) kit (Miltenyi Biotec,
Bisley, UK). Freshly isolated cells or thawed cells from LN2 were resuspended in 150 μl
MACS buffer per 1 x 108 mononuclear cells.  Cells were incubated at 4˚C for 15 minutes
with 50 μl hapten-conjugated monoclonal CD34 antibody (clone QBEND/10) per 108 cells
in the presence of FcR blocking agent. Cells were then washed with 5 ml of MACS buffer
to stop the reaction and pelleted at 200 x g for 5 minutes. Washed cells were resuspended in
MACS buffer and incubated at 4°C with the addition of 50 μl of anti-hapten microbeads
(per 108 cells) for 15 minutes. In order to isolate the magnetically-labelled CD34 cells,
mononuclear cells were resuspended in MACS buffer and applied to a magnetised column.
The magnetically-labelled CD34+ cells were eluted with 1 ml MACS buffer and flowed
through a second column to maximise enrichment. To assess the CD34 purity, 1 x 104 cells
were resuspended in flow cytometry staining buffer combined with 2.5 μg/ml R-
phycoerythrin conjugated anti-human CD34 monoclonal antibody (Clone 8G12, BD
Biosciences). After incubation for 30 minutes at 4˚C, cells were washed using 1 ml of flow
cytometry staining buffer and pelleted by centrifugation at 200 x g for 5 minutes and
analysed by flow cytometry as described in section 2.9.
2.5 NUCLEIC ACID ANALYSIS
2.5.1 Isolation of total RNA using Trizol
This method utilised a monophasic solution of phenol and guanidine isothiocyanate
which is a Trizol reagent with Phase Lock Gel-Heavy (2 ml) tubes. Between 1-2 x 106 cells
were transferred into a sterile tube and washed with 1X PBS buffer and pelleted by
centrifugation before adding 1 ml of Trizol reagent (Sigma). The Phase Lock Gel-Heavy (2
ml) tubes were centrifuged briefly to collect gel on the tube bottoms by centrifugation at
1500 x g, 30 seconds. The Trizol cell mixture was then transferred into the pre-spun Phase
Lock Gel-Heavy tubes and incubated for  5 minutes at RT. 200 µl of chloroform (1 ml
Trizol : 200 µl chloroform) was added into each microfuge tube. In a vigorous manner, the
mixture of Trizol suspension and chloroform was mixed for 15 seconds and incubated at RT
for 2 minutes. Tubes were centrifuged at 12 000 x g at 4°C for 10 minutes using a
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refrigerated tabletop centrifuge. After centrifugation, two phases were obtained and care
was taken not to disturb the interface layer which contained DNA. During this step, RNA
was separated into the upper aqueous phase of the supernatant and protein was separated
into the lower phase. The upper aqueous layer was carefully transferred into a new 2 ml
RNase free microtube before adding 600 µl of isopropanol.  The tube was gently inverted to
allow adequate mixing. The mixture was incubated at RT for 10 minutes and centrifuged at
12 000 x g, 4°C for 10 minutes. In order to precipitate RNA, 900 µl of 80% (v/v) ice cold
ethanol was added and gently mixed. Next, the tube was centrifuged again but at lower
speed which is at 7500 x g, 4°C for 5 minutes. Then, all the ethanol solution was removed
by pipetting. This step was done carefully to prevent loss of the RNA pellet present in the
tube. The tube was air dried on ice for 30 - 45 minutes. Finally, the RNA pellet was eluted
in an appropriate amount of RNase-free water (20 µl – 35 µl) and treated with DNase I
(refer 2.5.2). The RNA sample was stored in -20°C for immediate use or at -80°C for long
term storage until further use.
2.5.2 Total RNA clean-up by DNase I digestion
RNA isolated above (2.5.1) was subjected to further DNAse treatment. The volume
of RNA sample was adjusted to 100 μl by using sterile water. 350 μl Buffer RLT was
added to the sample and thoroughly mixed before adding 250 μl absolute ethanol to the
lysate. 700 μl of sample mix was applied to an RNeasy mini spin column (Qiagen®, West
Sussex, UK) placed in a 2 ml collection microtube and the column was incubated for 5
minutes. The tube was then centrifuged for 15 seconds at 10 000 x g. The sample was
reloaded again on the RNeasy column a second time to increase binding of RNA to the
RNeasy membrane and centrifuged using the same method. The RNeasy column was
transferred into a new 2 ml collection tube. 350 μl of Buffer RW1 was pipetted onto the
column and incubated for 1 minute before centrifuging at 10 000 xg for 15 seconds.  The
flow through was discarded and inside a separate fresh tube, 10 μl DNase I (Qiagen®) stock
solution was mixed with 70 μl Buffer RDD. Subsequently, 80 μl DNase I mix was pipetted
directly onto the column and incubated at RT for 15 minutes. Following that, 350 μl of
Buffer RW1 was pipetted onto the same column and centrifuged at 10 000 x g for 15
seconds.  The flow through was discarded and the wash was repeated twice using 350 μl
Buffer RW1. After the final wash, 500 μl Buffer RPE was pipetted onto RNeasy column
and incubated for 5 minutes and centrifuged at 10 000 x g for 15 seconds. Flow through
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was discarded and 500 μl RPE buffer was added onto the RNeasy column and centrifuged
for 2 minutes at maximum speed to dry the RNeasy membrane.  The RNeasy column was
placed in a new 2 ml collection tube with the lid opened for 5 to 10 minutes to completely
evaporate the ethanol. Finally, 40 μl of sterile water was pipetted directly onto the center of
the RNeasy membrane and incubated for 5 minutes before centrifuging for 1 minute at 10
000 x g to elute the RNA. This step was repeated a second time by pipetting the flow
through back into the same collection tube (~36 µl) onto the RNeasy membrane. After
incubation for 2 minutes, tube was centrifuged at 10 000 x g for 1 minute. The eluate
containing DNase treated RNA was kept at -80°C.
2.5.3 Reverse-transcriptase Polymerase Chain Reaction (RT-PCR)
For complementary DNA (cDNA) synthesis by RT-PCR, 500 ng of total RNA was
reversed transcribed in a 20 µl reaction mix containing 2.5 U of MuLV RTase, 2.5 µM
random hexamers, 1 U of RNAse inhibitor, 4 mM dNTP mix, 1X PCR buffer II and 5 mM
MgCl2. All reagents were purchased from GeneAmp® RNA PCR Kit (Applied
Biosystems®, Paisley, UK). The RT reaction was carried out in an Applied BioSystem
thermal cycler (Applied Biosystems) using the following cycling parameters; 10 minutes at
25°C followed by 30 minutes at 42°C and 5 minutes at 95°C. RT products were stored at -
20°C.
2.5.4 Quantitative RT-PCR (qRT-PCR)
For each sample, qRT-PCR was performed in duplicate in a 10 µl reaction
containing 1 µl cDNA, 1μl FastStart DNA SYBR Green I master mix (Roche), 4 mM
MgCl2, 0.5 µM forward and reverse TCF7L2 and ABL (Abelson murine leukaemia viral
oncogene homolog 1) primers (Table 2.2). The 45-cycle qRT-PCR programme was
performed using a LightCycler 2.0 (Roche Diagnostics, Burgess Hill, UK). Amplification
was performed using the following cycling parameters; pre-incubation at 95ºC for 10
minutes, followed by 40 cycles of [95°C for 3 seconds, 60°C for 5 seconds, 72°C for 12
seconds], then 1 cycle of melting curve step of [95°C for 0 second, 65ºC for 15 seconds and
95ºC for 0 second] and a final 1 cycle of cooling at 40ºC for 30 seconds.
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Name Orientation Exon Sequence (5’ to 3’) Tm (ºC)
TCF7L2-
exon 7/8
Forward 7/8 CGTAGACCCCAAAACAGGAA 58.4
TCF7L2-
exon 9
Reverse 9 TCCTGTCGTGATTGGGTACA 58.4
TCF7L2-
exon 18
Forward 18 TGCGTTCGCTACATACAAGG 57.3
TCF7L2-
exon 18
Reverse 18 TGGGTCTGCTCAGTCTGTGA 59.4
ABL-A2N Forward 2 CCCAACCTTTTCGTTGCACTGT 60.3
ABL-NA4 Reverse 4 CGGCTCTCGGAGGAGACGTAGA 65.8
Table 2.2: Primer pairs used for qRT-PCR analysis in this study.
2.5.5 PCR product purification using QIAquick PCR Purification Columns
The QIAquick silica membrane (Qiagen®) was used to purify DNA from aqueous
solutions (PCR sample), and up to 10 μg DNA can bind to each QIAquick column. For the
sample mix, 5 volumes of Buffer PB (500 µl) were added to 1 volume (100µl) of each PCR
sample. QIAquick spin column was placed in a provided 2 ml collection tube and the
sample mixture was applied to the QIAquick column and centrifuged for 30 – 60 seconds at
10 000 x g to bind DNA. Flow-through was discarded and the same QIAquick column was
placed back into the same tube. To wash, 750 µl Buffer PE was added to the QIAquick
column and centrifuged for an additional 30 – 60 seconds.  Flow-through was discarded and
the QIAquick column was placed back in the same tube and centrifuged for another minute
to remove the residual ethanol. The QIAquick column was then placed in a clean 1.5 ml
microcentrifuge tube. To elute DNA, 50 μl Buffer EB (10 mM Tris HCl, pH 8.5) was added
to the center of the QIAquick membrane, and following 1 minute incubation at RT, the
column was centrifuged for 1 minute. All centrifugation steps were performed at 10, 000 x
g. The eluate containing purified DNA sample was collected and stored at -20 °C.
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2.5.6 Direct sequencing
The plasmid DNA or purified PCR products (2.5.5) were sequenced using the
BigDye Terminator v3.1 protocol. The Sequencing Buffer (5X) is supplied at a 5X
concentration and was adjusted to a final concentration of 1X in the reaction volume. For
each reaction, a final volume of 20 µl was used containing 1X final concentration of the
following reagents; Ready Reaction premix (4µl), BigDye Sequencing Buffer (2µl), forward
and reverse primer (3.2 pmol), DNA template (50 ng – 500 ng) and sterile water.  The tubes
were placed in the thermal cycler and the following temperature cycling protocol was used:
96 °C for 1 minute followed by 25 cycles of [96°C for 10 seconds, 50°C for 5 seconds,
60°C for 4 minutes], then ramp to 4°C. Subsequently, the extension products (sequencing
reactions) were purified by using the DyeEx 2.0 Spin Kit (Qiagen®) according to
manufacturer’s recommendations prior to BigDye Terminator v3.1 Cycle Sequencing.
2.6 PREPARATION OF RECOMBINANT PLASMID DNA
2.6.1 Restriction enzyme (RE) conditions for creation of TCF7L2 DNA constructs
RE digest for the creation of TCF7L2 expression plasmids (5.3.3.1) was performed
in a total reaction volume of 100 µl using 5 – 10 µg of plasmid DNA containing appropriate
NEB (New England Biolabs Ltd., Hitchin, UK) buffer, RE enzymes, BSA and water. For
Xba1 digestion, 100 U enzyme was used with a compatible NEB4 buffer. For BglII
digestion, 100 U enzyme was used with a compatible NEB3 buffer. For BamH1 and EcoR1
digestion, 50 U of each enzyme was used with a compatible NEB4 buffer. All reactions
were mixed gently by pipetting and incubated at 37°C in a water bath for 1 hour. Aliquot of
digested DNA was taken from the digested product and electrophoresed using 0.8% (w/v)
agarose gel at 80 V for 45 minutes and visualised using EtBr.
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2.6.2 Agarose gel purification of insert DNA
To purify DNA inserts generated by RE or PCR, preparative agarose gel was
prepared by creating a 0.8% (w/v) Seakem agarose solution in 1X TAE buffer (or 3% (w/v)
agarose for PCR products). DNA samples for loading contained 5 - 10 µg digested DNA
(or ~ 1 µg for PCR products), 200 µM bromophenol blue and 120 µM xylene cyanol per
lane. Samples were electrophoresed in 1X TAE buffer at 40 V for 2 hours. The size of
DNA fragments or plasmids was estimated using a 1 kb DNA Ladder. Upon completion of
electrophoresis, agarose gel was stained in EtBr (500 µg/mL) for 20 minutes. Gel was
destained using water for 20 minutes and DNA was visualised by long wavelength UV
transillumination using a LAS-3000 digital imaging device (Fujifilm UK Ltd., Bedford,
UK) before excising the desired DNA band by using a clean scalpel. All apparatus used
was initially wiped with 70% (v/v) ethanol. The excised gel was then placed inside a sterile
15 ml tube and subjected to further purification using the QIAquick Gel Extraction kit
protocol (Qiagen®).
2.6.3 Ligation
For subcloning, vector and insert DNA fragments were purified according to 2.6.2
prior to ligation. A final volume of 10 μl ligation reaction was used, containing insert DNA
combined with vector DNA using a 5:1 ratio of insert:vector ligation, 200 cohesive end
units/μl T4 DNA ligase (1 µl) and 1X T4 DNA ligase reaction buffer (1 µl) (New England
Biolabs Ltd., Hitchin, UK). In order to determine the level of background ligation due to
self-ligation of the linearised vector plasmid, a background reaction tube was also set up as
above, but lacking insert DNA. All reaction tubes were incubated for between 4 - 6 hours at
16˚C then stored at -20˚C before performing the transformation into competent E.coli.
2.6.4 Transformation of competent cells with plasmid DNA
Each plasmid DNA to be propagated by transformation was thawed on ice alongside
one 50 μl vial of OneShot® Stbl3 or OneShot® Top10 chemically competent E. coli
(Invitrogen™). For each reaction, 6 μl of DNA sample was aseptically transferred directly
into the respective vial of competent cells and tapped gently to mix, followed by 30 minute
incubation on ice. Following this, the cells were further incubated at 42˚C for 30 seconds
(or 45 seconds for OneShot® Stbl3 cells), without agitation, before replacing on ice and
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adding 250 μl of pre-warmed SOC medium (Invitrogen™) to each vial to maximise
transformation efficiency. All vials were secured in a shaking incubator at 37°C for 1 hour
at 225 revolutions per minute (rpm). Once the incubation had elapsed, between 50 µl to 100
µl of transformation mixture was spread onto pre-warmed LB-agar plates containing 100
µg/ml ampicillin (or kanamycin as in Table 5.1), using sterile plastic spreaders to generate a
film of bacterial growth, and incubated at 37°C overnight. Transformed colonies were
selected on the following day for large scale purification of plasmid DNA as described
below.
2.6.5 Large scale purification of plasmid DNA
Plasmid DNA was prepared from an E.coli strain using HiSpeed TM Maxi kit
(Qiagen®) based on manufacturer’s recommendations. Firstly, colonies of interest were
picked from LB-agar plates and a single colony was inoculated into 5 mL of LB-broth
containing 5µl of ampicillin or kanamycin (stock 100 mg/ml) by using a sterile inoculation
loop and incubated in 37°C incubator with 225 rpm shaker for 8 hours. Following that, the
starter culture was diluted 1 in 500 into LB-broth with appropriate antibiotic and further
incubated in 37°C with 225 rpm shaker for 16 hours. After overnight incubation, the
bacterial pellet was harvested from 150 ml culture by centrifugation at 6000 x g for 15
minutes at 4°C. Briefly, pelleted bacteria were resuspended in 10 ml Buffer P1 before
mixing with 10ml of Buffer P2, and tube was allowed to stand for 5 minutes at RT.  Next,
10 ml of Buffer P3 was added followed by incubation on ice for 15 minutes, and
centrifugation at 20,000 x g at 4°C for 30 minutes. Supernatant containing plasmid DNA
was removed and centrifuged again, as above, to remove insoluble material. During this
process, QIAGENtip-500 was equilibrated by adding 10 ml Buffer QBT onto the tip. The
bacterial supernatant was transferred to the equilibrated QIAGEN-tip where plasmid DNA
was bound to the column and washed twice with 30ml Buffer QC. Subsequently, DNA was
eluted from the column using 15 ml Buffer QF and precipitated by the addition of 10.5 ml
isopropanol and centrifugation at 15,000 x g for 30 minutes at 4˚C. The DNA pellet was
finally washed using 5 ml of 70% (v/v) ethanol before final centrifugation at 15,000 x g for
10 minutes. Finally, the supernatant was decanted with care, and the purified DNA pellet
was air-dried for 10 minutes before resuspending in 1 ml of TE Buffer and concentration of
DNA was quantified using the NanoDrop® and stored at -20˚C.
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2.7 RETROVIRAL TRANSDUCTION OF HAEMATOPOIETIC
CELLS
2.7.1 Production of retroviruses by transfection
The principle of this method is based on the formation of a precipitate containing
calcium phosphate and DNA. The procedure used is based on Calcium Phosphate
Transfection Kit, Sigma-Aldrich® according to the manufacturer’s guidelines. The quality
of DNA is crucial and is purified using protocols described in section 2.6.5. Briefly, inside
a sterile 1.5 ml microcentrifuge tube with a total volume of 900 µl reaction, the following
reagents were added in the order listed: 45 µg of plasmid DNA (Figure 2.1) was added to
sterile molecular grade water to a volume of  405 µl followed by 45 µl of 2.5 M CaCl2.
Then 450 µl of 2X HeBS pH 7.05 was added drop-wise while bubbling the solution to form
precipitate. This was mixed by vortexing and allowed to incubate at RT for 20 minutes
before addition to the adherent cell culture (Phoenix cells, see Table 2.1). These cells
transfect best at higher density and optimal density is around 7.5 x 106 cells, seeded the
night before. This achieves approximately 60 - 70% cell confluence on the day of the
transfection. Chloroquine (15 μl of 25 mM stock in 15 ml culture) was added to the cell
culture before the last 5 minutes of the incubation. The culture was immediately returned to
33°C incubator supplied with 5% CO2 for 16 hours. The precipitate then adhered to the cell
surface and was internalised. The following day, the chloroquine-containing growth media
(DMEM containing 10% (v/v) FCS, 20 µg/ml gentamicin, 2 mM L-glutamine DMEM) was
replaced using half volume of fresh growth media. The culture flask was gassed with CO2
and incubated overnight at 33˚C for optimal retrovirus production.
Chapter 2: General Materials and Methods
__________________________________________________________________________
52
Figure 2.1: Plasmid map of the PINCO retroviral expression vector used in this study.
All PINCO vectors contain a cytomegalovirus immediate early promoter (CMV) promoter-
driven DsRed expression cassette.  Gel-purified insert DNA sequence was cloned into
unique BamHI and EcoRI sites in the PINCO vector for retroviral long terminal repeats
(LTR)-driven expression and the sequence verified before use (Grignani et al, 1998).
2.7.2 Production of lentiviruses by transfection
Lentivirus particles were generated and packaged using the HEK293T cell line by
co-transfection of three plasmids: the lentiviral vector pLKO.1-puro that contains TCF7L2
shRNA (Figure 2.2), the psL3 [pMD2] as envelope plasmid (Addgene, Cambridge, USA)
and psPAX2 as packaging plasmid (Addgene, Cambridge, USA) with gag, pol, and rev
genes.  The HEK293T cells transfect best at higher density and 1 x 107 cells were plated the
night before. For transfection by the calcium phosphate protocol, inside a sterile 1.5 ml
microcentrifuge tube with a total volume of 900 µl reaction, the following reagents were
added in the order listed: 20 µg of transfer vector DNA, 8 µg of pMD2 DNA and 15 µg of
psPAX2 DNA were added to sterile molecular grade water to a volume of 405 µl followed
by 45 µl of 2.5M CaCl2. Then 450 µl of 2X HeBS pH 7.05 was added drop-wise while
bubbling the solution to form a precipitate. This was mixed by vortexing and allowed to
dsRED
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incubate at RT for 20 minutes before addition to the adherent cell culture (HEK293T cells).
Chloroquine was added to the cell culture before the last 5 minutes of the incubation. The
culture was immediately returned to a 37°C incubator supplied with 5% CO2 for 16 hours.
The precipitate then adhered to the cell surface and was internalised. The following day, the
growth media was replaced using half volume of fresh growth media. The culture flask was
gassed with CO2 and incubated overnight at 37˚C for optimal lentivirus production.
Figure 2.2: Structure of the pLKO.1 puro lentiviral vector backbone for shRNA study.
This image was adapted from http://www.sigmaaldrich.com/life-science/functional-
genomics-and-rnai/shrna/library-information/vector-map.html#pLKO
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2.7.3 Harvesting of retroviral / lentiviral particles
The collection of infective particles was performed on days 2 and 3 following
transfection, and the procedure was carefully handled under class II conditions. The
retroviral / lentiviral supernatants were centrifuged at 200 x g for 10 minutes at RT. The
supernantants were aliquoted into cryovial tubes and briefly snap frozen in LN2 to lyse any
remaining packaging cells and virus stocks were stored at -80°C.
2.7.4 Retroviral / lentiviral transduction of cell lines and haematopoietic cells
RetroNectin from Takara is a recombinant polypeptide of human fibronectin
fragments binding viruses and cell surface proteins. When coated on the surface of culture
plates, it significantly enhances retrovirus or lentivirus mediated gene transduction into
mammalian cells (Tonks et al, 2005). RetroNectin-assisted transduction of cells was
performed by coating a 24-well plate (non TC treated) with 25 µg of RetroNectin (Takara-
Bio, Shiga, Japan) into each well. The culture plate was incubated for a minimum of 2
hours with agitation at RT. Following the incubation, RetroNectin solution was discarded
and 250 µl of sterile 1X PBS containing 1% BSA was added into each well for blocking and
the plate was left at RT for 30 minutes. During the incubation, each virus stock was thawed
rapidly in a water bath set at 37C. At the end of incubation, 1X PBS 1%  (v/v) BSA buffer
was removed from each well and immediately replaced with 1 ml of virus. The plate was
double sealed with a secure carrier and centrifuged for 90 minutes at 3200 x g. During this
process, the target reporter cells (refer 5.3.3.2) were counted and diluted to a density of 4 x
105 /ml in the specified culture media. Upon completion of centrifugation, the viral
containing supernatant was removed from each well and 2 x 105 target cells were added to
each well before any drying of the pre-coated well takes place, followed by overnight
incubation at 37C in 5% CO2.
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2.8 PREPARATION OF PROTEIN FOR WESTERN BLOTTING
2.8.1 Cytosolic and nuclear protein isolation
For protein extraction, samples harvested from 2 x 106 cell lines or 1 x 107 CD34+
HPC were fractionated using a nuclear / cytosol fractionation kit (Biovision, California,
USA). Initially, cells were taken from the culture flask and transferred into a conical tube
and  washed twice with 20 ml of TBS followed by centrifugation at 200 x g for 10 minutes.
Cell pellets were fully resuspended in 200 μl CEB-A (Cytosol Extraction Buffer) containing
1 mM Dithiothreitol (DTT) and 1X protease inhibitor cocktail (PIC) and then transferred
into a pre-chilled 1.5 ml microtube. Cell mixtures were vortexed for 15 seconds and
returned to ice for 10 minutes. Following the incubation, 11 μl of CEB-B buffer was added
to the cell mixture followed by a brief 5 second vortex before resuming incubation on ice
for another 1 minute.  Cells were again vortexed for 5 seconds before undergoing
centrifugation at 16 000 x g for 8 minutes in microfuge set at 4°C. The supernatant
containing cytoplasmic protein extract was carefully pipetted into a fresh 1.5 ml microtube
and held on ice. The residual pellet containing mostly nuclear protein was washed by
carefully applying 500 μl of 1X PBS containing 5 mM MgCl2 and centrifuged as above for
3 minutes. Supernatant containing cytoplasmic contaminants was removed and nuclear cell
pellets were snap frozen in LN2 for nuclear disruption. Nuclear protein was extracted by
thawing the pellet on ice in the presence of 1 mg/ml DNase and 100 μl of NEB (Nuclear
Extraction Buffer) containing 1 mM DTT and 1X PIC. The mixture was vortexed for 15
seconds and a similar process was repeated every 10 minutes during a 40 minute incubation
on ice. Finally the mixture was centrifuged for 15 minutes at 16 000 x g in a 4°C microfuge
to pellet detergent-insoluble material before isolating the supernatant containing nuclear
protein.  Both cytosolic and nuclear protein lysates were stored at -80˚C.
2.8.2 Determination of protein concentration
The concentration of nuclear and cytosolic protein from cell lysates was determined
using the Bradford’s reagent protein assay (Sigma-Aldrich®). Initially, protein calibration
standards were prepared by diluting BSA stock ranging from 0, 10, 40, 70 and 100 µg/ml
BSA in lysis buffer. Before aliquoting the protein extracts, Bradford’s reagent was diluted
with an equal volume of water to create sufficient diluted reagent (190 µl per test well).  An
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aliquot of 10 μl of each protein standard, and 10 μl of each cell lysate was placed into the
well of a 96-well microtitre plate (in duplicate) and 190 μl of diluted Bradford’s working
solution was mixed with each sample.  Absorbance of the samples was measured at 590 nm
using an ASYS Hitech Expert plus spectrophotometer (Biochrom, Cambridge, UK). BSA
standard solutions were assayed in duplicate alongside protein extract samples to create a
standard curve, which enabled calculation of protein extract concentrations.
2.8.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and electroblotting
Protein electrophoresis for western blotting was performed using the NuPAGE® X-
Cell II® electrophoresis and electroblotting systems (Invitrogen™). A maximum of 20 µg
of protein extracts were denatured by incubation for 10 minutes at 70°C in the presence of
1X LDS sample buffer and 50 mM DTT. In order to estimate the molecular weight (MW)
of proteins, outer lanes of SDS-PAGE gels were loaded with 10 µl of 1X LDS buffer
containing a 20 fold dilution of MagicMark XP® Protein Standard (Invitrogen™).
Denatured protein samples (20 µl per lane between 10 – 20 µg) were loaded onto 4 – 12%
(w/v) Bis-Tris gels (Invitrogen™) in the presence of antioxidant using MOPS-SDS running
buffer and electrophoresed at 200 V for 50 minutes inside the X-Cell II® Mini-Cell
apparatus. Upon completion of electrophoresis, the gel was removed from the tank and one
surface of the gel was moistened with transfer buffer containing 10% (v/v) methanol, 1X
NuPAGE® Transfer Buffer and 1 ml antioxidant. During this process, a piece of blotting
pad (or sponge) was soaked inside the similar transfer buffer and was then carefully layered
onto the moistened gel avoiding any air bubbles. The other side of the SDS-PAGE gel was
also moistened with transfer buffer, before layering a pre-soaked nitrocellulose membrane
(0.45 µm pore size) ensuring all trapped air bubbles were removed. Sandwiched between
pre-soaked blotting pads, the SDS-PAGE gel and nitrocellulose membrane (Figure 2.3) was
then inserted into an XCell II™ Blot Module. The blot module was filled to the top of the
pads with transfer buffer and the outside of the tank filled with distilled water and protein
transfer was performed over 1 hour at 30 V (400 mA).
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Figure 2.3: Assembly of nitrocellulose transfer membrane and SDS-PAGE gel for
protein transfer by using the using the X-Cell II® Blot Module. Image was adapted
from http://www.invitrogen.com/site/us/en/home/References/protocols/
2.8.4 Protein detection and chemiluminescent analysis
Upon completion of electrophoresis and electroblotting, the nitrocellulose membrane
was washed twice with 10 ml of distilled water for 5 minutes at RT and incubated with
Ponceau S solution for 30 seconds to check for equal protein loading and transfer before
blocking the membrane. The membrane was rinsed with distilled water for 5 minutes to
remove Ponceau S stain and incubated with 10 ml of TBS-T containing 5% (w/v) membrane
blocking agent ECL Advance® (GE Healthcare, Amersham, UK) for 1 hour at RT.
Blocked membranes were then rinsed with 10 ml TBS-T for 15 minutes and three
subsequent 5 minute washes. Following washing, blocked membranes were incubated for
16 hours at 4°C with shaking in the presence of diluted primary antibody (Table 2.3) in
TBS-T containing 5% (w/v) membrane blocking agent. Following primary antibody
incubation, washed membranes were incubated with diluted HRP-conjugated anti-mouse or
anti-rabbit secondary antibody in TBS-T containing 2% (w/v) membrane blocking agent for
1 hour at RT. Finally, membranes electroblotted with proteins labelled with both primary
and secondary antibodies were visualised using ECL Advance® Western Blotting Detection
Kit (GE Healthcare). Each immunolabelled membrane was incubated for 5 minutes at RT
with an equal volume of Solution A containing Tris buffer in 3.2% (v/v) ethanol and
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Solution B containing proprietary substrate in Tris buffer. Membranes were placed between
two sheets of clean acetate and ECL Advance® chemiluminescence was detected using
LAS3000 digital imaging device (Fujifilm) and images were processed and analysed using
AIDA Image Analyzer v4.19 (Fujifilm).
Monoclonal antibody (mAb) reagent Manufacturer Dilution used
Anti-mouse HRP-linked whole Ab
(from sheep) - NA931V
GE Healthcare,
Buckinghamshire, UK.
1:50k
Anti-rabbit HRP-linked whole Ab
(from donkey) - NA934V
GE Healthcare,
Buckinghamshire, UK.
1:50k
Mouse anti human Histone H1 mAb -
4974-78
AbD Serotech, Kidlington,
UK
1:2k
Mouse anti human GAPDH mAb -
6C5
Santa Cruz Biotechnology
Inc., Middlesex, UK
1:10k
Rabbit anti human TCF7L2  mAb –
C48H11 (anti exon 11)
Cell Signaling, Hitchin,
UK
1:2k
Rabbit anti human TCF7L2 mAb -
EP2033Y (anti exon 1)
Abcam plc, Cambridge,
UK
1:20k
Table 2.3: List of primary and secondary antibodies used for western blotting.
2.9 FLOW CYTOMETRIC PROCEDURE
The principle of flow cytometry is to deliver a single cell to a point of measurement: a
beam of light (usually a laser). The sample is injected into the centre of a stream of liquid
known as the sheath fluid and this sample stream is focused. Combination of fluorescence-
labelled antibodies or chemicals with fluorescent properties, and measurement of scattered
light provide a number of measured parameter including size, protein expression and cell
viability. The basic instrument consists of a source of light, a flow cell, optical components
to focus light of different colours on to the detectors and amplifier, and a computer to
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process the resulting signals (Figure 2.4). The system used was a benchtop model supplied
by Accuri C6 Flow Cytometer™ (Accuri Cytometers, Ann Arbor, MI, USA) equipped with
a ‘blue’ and a ‘red’ laser, two scatter detectors, and four fluorescence detectors with
interference filters as described in Table 2.4.
2.9.1 Sample preparation
Single cells must be suspended at a density of 1 x 105 –107 cells / ml to prevent the
flow cytometer capillary from clogging up. Cells were harvested and washed with 1X PBS
and stained according to section 5.3.5.2 depending on the experiment requirements. Stained
cells were analysed directly using the Accuri flow cytometer using the appropriate optical
filters. For sample preparation, appropriate volume of cells was recovered from growth
medium by centrifugation at 180 x g for 5 minutes. Cell pellet of approximately 1 x 106
cells were washed in 1 ml of flow cytometry staining buffer (refer 2.2) and centrifuged as
above. Before data acquisition, cells to be analysed were resuspended in a maximum of 100
µl flow cytometry staining buffer. Data were acquired using a minimum of 15,000 collected
events. Debris was excluded by gating live cells using forward scatter (FSC) and side
scatter (SSC) characteristics. FSC intensity was used to detect the size of a particle and to
distinguish between debris (events with low FSC signal) and live cells (with higher FSC
signal). Appropriate compensation data were applied to the analysis workflow according to
the dye used. Events were acquired using the Accuri C6 cytometer (Accuri Cytometers,
Ann Arbor, MI, USA) and raw data analysis was performed using FCS Express version 4
(De Novo Software, Los Angeles, CA, USA).
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Parameter Description
Laser Excitation 488 nm
640 nm
Laser Profile 10 x 75 μm
Light Scatter Detection Forward (0°, ±13°)
Side (90°, ±13°)
Emission Detection / Optical filters
(4 colours)
FL1 533/30 nm (eg, FITC / GFP)
FL2 585/40 nm (eg, PE / PI, bio)
FL3 > 670 nm (eg, 7-AAD, PerCP,BIO
PerCP-Cy5.5, PE-Cy™7)
FL4 675/25 nm (eg, APC)
Table 2.4: Optical systems in the Accuri C6 Flow Cytometer™.
2.9.2 Data analysis
2.9.2.1 Histogram analysis for BIO /WNT3A stimulated samples
To determine the percentage of cells showing reporter response in terms of green
flurescent protein (GFP) expression between stimulated (BIO or WNT-3A) and non-
stimulated (vehicle) cells, the histogram Overton subtraction tool was used (Overton, 1988).
The GFP fluorescence from the non-stimulated sample was therefore subtracted from the
stimulated sample.  The positive difference value was subsequently normalised to the
control sample. Cultures transduced with PINCO-DsRed constructs, were first gated for
DsRed positivity. The autofluorescence signals from parental cells were used as a
fluorescence threshold for DsRed gating.
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2.9.2.2 Histogram analysis for surface marker staining
Histogram data analysis was performed similarly to 2.9.2.1 except that each
histogram include the FITC conjugated IgG isotype control for the CD14 and CD15 surface
marker antibodies to account for any background effect of the analysis. In order to calculate
positive differences in each sample, the FITC fluorescence from isotype stained was
subtracted from the lineage marker stained by Overton subtraction.  To calculate relative
positive stained cells, the positive difference in empty vector (EV) transduced control was
divided by the positive difference in TCF7L2 transduced samples.
2.9.3 Statistical analyses
To determine if a difference exists between two groups (target vs control),
significance testing of difference using the 2-tailed Independent Student’s T-test was
performed using SPSS for Windows version 11.5 (SPSS Inc., Chicago, USA).
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Figure 2.4: Schematic overview of typical flow cytometry setup (see text for details).
Image was adapted from
http://www.bdbiosciences.com/instruments/facscalibur/features/index.jsp.
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3 - Identification of dysregulated pathways
and genes in AML
3.1 INTRODUCTION
AML is genetically heterogeneous with a unifying feature of inhibition of terminal
myeloid development arising from disordered gene expression and dysregulation of
developmental pathways. As well as somatic mutations (Rocquain et al, 2010),
chromosomal abnormalities and deletions (Ebert, 2010; Nagarajan, 2010), disordered gene
expression can arise from dysregulated non-coding RNA (Calin et al, 2007; Isken et al,
2008) and epigenetic regulation (Jiang et al, 2009; Martin et al, 2010). For example
constitutive activity within leukaemic cells can occur due to changes in expression of
transcriptional regulators such as STAT3 (Spiekermann et al, 2002), GATA2 (Wieser et al,
2000), DNMT3A (Mizuno et al, 2001; Hayette et al, 2012) or RUNX1 (Yan et al, 2009).
Pathway activation could also be due to epigenetic inactivation of important gene regulators
such as silencing of SFRP1 and PTEN (Reins et al, 2010; Yoshimi et al, 2011; Li et al,
2012). In the past decade, GEP using microarray technologies and sequencing technologies
have become popular tools for the discovery of dysregulated gene expression or
identification of high frequency gene mutations involved in cancer pathogenesis (Mi et al,
2007; Bacher et al, 2009; Welch & Link, 2011; Borate et al, 2012).  These abnormalities are
likely to act in a concerted manner to dysregulate the activity of a number of cellular
processes or pathways.  Given that most high frequency mutations have already been
detected, it is hoped that elucidation of changes in gene expression and pathway signalling
may generate a path to identifying viable therapeutic targets (Ricciardi et al, 2012;
Ungewickell & Medeiros, 2012).
This chapter uses GEP to identify commonly dysregulated genes in AML and to
characterise these changes with respect to aberrant pathway activation which may be linked
to the pathogenesis of this disease.  Analysis of gene expression associated with clinical
outcome data allowed the identification of gene targets with clinical relevance.  To this end,
this study describes a method used to compare microarray data from public repositories and
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inter-related platforms using batch effects removal.  Commonly dysregulated genes
associated with clinical importance were prioritised for subsequent analysis.
3.2 AIMS
The overall aim of this chapter is to discover aberrant gene expression and signalling
pathways that may contribute to the pathogenesis of AML.  The specific objectives of this
chapter were:-
 To identify aberrantly regulated pathways in AML. This will be achieved by
comparing the GEP of AML patient blasts to normal HPCs derived from CD34+ BM
using comprehensive genome wide microarray analysis.
 To establish the most dysregulated genes in AML within the most significantly
dysregulated pathway.
 To validate microarray expression data of significant genes using qRT-PCR.
 To determine the association of aberrant gene expression with AML patient clinical
outcome.
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3.3 MATERIALS AND METHODS
3.3.1 AML patient blast and normal CD34+ BM sample GEP datasets
A subset of BM or PB samples from AML patients who had enrolled in MRC-UK
NCRI AML clinical trial protocol were used in this study. Each AML patient sample was
taken at de novo presentation of the disease. The samples taken for this study were
approved by local and multicentre ethical committees in the UK.  Each patient sample was
taken at diagnosis before treatment in accordance with the 1964 Declaration of Helsinki.
Biological characteristics of AML patients that passed quality control (QC) and were
subsequently used for analysis (see 3.4.1) are shown in Table 3.1. The procedure for HG-
U133 Plus2.0 array refers to the customized Roche AmpliChip Leukaemia Custom
Microarray kit produced by Roche Molecular Systems, Pleasanton, USA to be used
specifically for the MiLE study in conjunction with the HG-U133 Plus2.0 Affymetrix
GeneChip®. The production of the Amplichip was developed independently for the MiLE
study stage II conducted between November 2006 until October 2007 (Kohlmann et al,
2008b).
RNA sample processing for HG-U133A array was performed using the GeneChip®
3’ IVT kit produced by Affymetrix® (High Wycombe, UK) according to manufacturer’s
recommendations:-
http://media.affymetrix.com/support/downloads/manuals/expression_analysis_technical_ma
nual.pdf. Both procedures were conducted previously by Amanda Gilkes from the
Department of Haematology, Cardiff University.
GEP data from healthy CD34+ BM samples (defined herein as Normal Controls)
were downloaded from ArrayExpress website available at http://www.ebi.ac.uk/microarray-
as/ae/at. A total of 10 raw .CEL files from HG-U133A were obtained from E-GEOD-13496
(n=8) and E-GEOD-12803 (n=2). A total of 13 raw .CEL files from HG-U133 Plus2.0 were
obtained from the following experiments: E-GEOD-12662 (n=3), E-GEOD-4619 (n=10).
Chapter 3: Identification of dysregulated pathways and genes in AML
__________________________________________________________________________
66
Table 3.1: Stratification of data of AML patients used in this study. Stratified AML
patient parameters obtained at diagnosis according to whether the samples were analysed in
the context of HG-U133 Plus2.0, HG-133A or DWD-merged GEP data. The DWD-merged
GEPs data set was created to increase statistical power for clinical outcome analysis (see
3.3.6).  The table shows the trial group (chemotherapy protocols for each group are detailed
in Supplementary 3.1 ) and cytogenetic prognostic classification according to (Grimwade et
al, 1998)detailed in Supplementary 3.2 .
Characteristic at diagnosis HG-U133 Plus2.0
(n=98)
HG-U133A
(n=160)
DWD (merged GEP)
(n= 246)
Trial group
AML10
AML11
AML12
AML14
AML15
AML16
Not determined
4
2
1
16
73
-
2
2
3
47
36
72
-
-
7
7
47
55
128
2
-
Sample type
Bone marrow
Peripheral blood
Not determined
66
31
1
3
-
157
70
16
160
Age
15-39
40-69
>70
26
64
8
50
95
15
65
158
23
WBC count (x109 /L)
<10
10-99
>100
Not determined
24
54
18
2
50
82
28
-
81
120
44
1
FAB subtype
M0
M1
M2
M3
M4
M5
M6
M7
Not determined
3
14
29
5
18
19
1
-
9
9
25
39
24
31
15
-
2
15
12
37
57
28
46
32
1
2
31
Gender
Male
Female
Not determined
49
47
2
88
72
-
131
115
-
Karyotype group
t(15 ;17)
t(8 ;21)
inv(16)
Complex (>5 chromosomal
abnormalities)
Normal karyotype
Other chromosomal abnormalities
Not determined
5
6
7
8
35
11
26
23
14
16
11
51
31
14
28
17
23
18
90
47
23
Cytogenetic prognostic classification
Favourable
Intermediate
Adverse
Not determined
34
50
11
3
53
85
17
5
68
135
28
15
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3.3.2 Data import and assessment of GeneChip® data quality
3.3.2.1 Visual inspection of GeneChip® raw data signal
Microarray 2-D raw images, .CEL and .CDF were initially imported into dChip
MFC Application (version 1.0.0.1) for background visual inspection. The application tool
for dChip was available from http://www.hsph.harvard.edu/cli/complab/dchip/ (Li, 2008).
Pseudo images will show artefacts not visible in the raw data image.  With the help of Dr
Anna Evans from the Haematology Trials Unit, Cardiff University,  pseudo GeneChip®
images were created from probe level model (PLM) weights and PLM residuals generated
using Bioconductor 2.11 packages written in R language for bioinformatics application
(Gentleman et al, 2004). The standard Bioconductor suite software was installed from
http://www.bioconductor.org/getBioC.R. Probe level investigation was carried out in
RScript1 2.6.1 that was created by Ihaka and Gentleman (Ihaka & Gentleman, 1996)
available for download at http://www.r-project.org.
3.3.2.2 Hybridisation and internal QC assessment
All .CEL files were imported into Partek® Genomics Suite version 6.5 (Partek Inc.,
St. Louis, USA). An overall QC analysis was performed for every GeneChip® to detect
GEP with lower or poor quality. The QC analysis was performed using customized versions
of the “affyQCReport packages” available from Partek® Genomics Suite.  The QC pipeline
analyses several internal control sequences as included in the array. The internal control
probe sets are the hybridisation controls with internal probe calls for “AFFX-r2-Ec-bioB”,
bioC, bioD and cre which are Escherichia coli genes that must always be present, also the
poly-A controls with the following probe sets “AFFX-r2-Bs-Dap”, Thr, Phe and Lys which
are the modied Bacillus subtilis genes and should be called present at a decreasing intensity.
Other QC probes analysed by the package include a normalisation control set (of 100 probe
sets) and housekeeping gene; Glyceraldehyde 3-phosphate dehydrogenase (GAPDH).  GEP
data are flagged if these probes have an unusually high variance, high RNA degradation
levels, overall low signal levels (poor hybridisation or labelling), or if the raw image of
array shows prominent spurious artefact.
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3.3.2.3 Multiple array signal pre-processing and normalisation
The main goal of normalisation is to remove systematic bias in the data as
completely as possible, while preserving the variation in gene expression that occurs due to
biologically-relevant changes in transcription. In short, the raw optical microarray image
files .DAT files and .CEL files were generated using default Affymetrix GeneChip®
Operating System (GCOS) parameters. The imported .CEL files are in text format and
contain intensity values for PM and MM features, and are converted from pixel-level .DAT
files. Only raw .CEL files were used for downstream expression analysis using Partek®.
For Partek® analyses, .CEL files were imported using Affymetrix annotation files (NetAffx,
Version na31. hg19). Robust multi-array averaging (GC-RMA) background correction
algorithms were used to normalise GEP data. GC-RMA is a method of converting .CEL
files into expression data with the help of probe sequence and with GC-content background
correction. The GC-RMA algorithm normalises and summarises probe level intensity of the
PM probes by quantile normalisation, Log2 transformation and median polishing for
summarisation. This will result in a set of expression measures. The algorithm for the
RMA model used is shown below (Bolstad et al, 2003; Irizarry et al, 2003b):
By using the method described as above, two GEP databases were created (i) HG-
U133 Plus2.0 and (ii) HG-U133A; each based on the GeneChip® to which the RNA was
hybridised (see 3.3.1). GEP data from each array type was analysed separately (3.3.3) or
was combined into a single database (see 3.3.6.1) for further batch correction using DWD
software to create a larger cohort of AML samples for clinical correlational study.
RMA Model
From a presentation by Ben Bolstad
http://bioinformatics.ca/workshop_pages/genomics/lectures2004/16
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3.3.2.4 Exploratory analysis using Principal Components Analysis (PCA)
PCA is a statistical technique used to select key variables for differences seen in
multidimentional data (eg: microarray gene expression) and helps to simplify visualisation
of complex data into 3 dimensions, based on the published method for discriminant analysis
(Krzanowski, 1980). PCA was applied to all GEPs hybridised to the HG-U133 Plus2.0
GeneChip® to provide insight into the underlying factors with most variability, to aid in QC
(i.e: identifying outliers) and sample grouping. The information gathered from PCA was
then used to find suitable factors to be included into the Analysis of Variance (ANOVA)
model (as shown in Figure 3.8) towards finding significant sources of variation across all
samples.
3.3.3 Calculating differentially expressed genes using Mixed-Model ANOVA
A total of 111 HG-U133 Plus2.0 .CEL files (representing 98 AML patients’ blasts
and 13 Normal Control GEPs) that had passed QC were used for this downstream analysis.
The HG-U133 Plus2.0 dataset was chosen because this array provides more comprehensive
coverage of probe sets compared to HG-U133A array. The specifications of both arrays are
described in Section 1.5. Initially, the common underlying gene changes associated
specifically with the more immature developmental subtypes of AML (M0 and M1)
together with the changes seen in other subtypes (M2 - M6) were analysed. This was
achieved by a two arm approach using either 1-way ANOVA or 4-way ANOVA (Figure
3.1).
The 1-way ANOVA was based on the following model: Yij = μ + FABi+ εij, where
Yij represents the jth observation on the ith FAB, μ is the common effect for the whole
experiment and εij represents the random error present in the jth observation on the ith FAB.
The errors εij are assumed to be normally and independently distributed with mean 0 and
standard deviation δ for all measurements. The contrast method using Fisher's Least
Significant Difference was performed to compare AML-M0 vs Normal Control and AML-
M1 vs Normal Control.
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The 4-way ANOVA is based on the following model: Yijklm = μ + Diseasei + Sample
type(Disease)ij + FAB(Disease)ik + Scan Date(Disease)il + εijklm, where Yijklm represents the
mth observation on the ith Disease, jth Sample type, kth FAB, lth Scan Date , μ is the common
effect for the whole experiment and εijklm represents the random error present in the mth
observation on the ith Disease, jth Sample type, kth FAB, lth Scan Date. The errors εijklm are
assumed to be normally and independently distributed with mean 0 and standard deviation δ
for all measurements and the Scan Date is a random effect.
The principles for both ANOVA models performed by Partek® were adapted from
Method of Moments (Eisennhart, 1947). Significant genes were then filtered to include
only changes of > 1.5 or < -1.5 fold changes between AML subtype(s) vs Normal Control.
Partek’s ANOVA uses Least Squares (LS) mean (Tamhane & Dunlop, 2000) to calculate
fold change. When the data is logged (such as by GC-RMA), the resulting LS means are
anti-logged, producing geometric means. Statistically significant genes were set to pass the
false discovery rate (FDR) threshold of P <0.05 based on the Benjamini–Hochberg test.
This filtering produced three genelists A, B and C (Figure 3.9A) based on comparisons
made as above.
Following pathway maps analysis in which WNT signalling was identified as a
significantly dysregulated pathway (see Table 3.3), the ANOVA test was repeated using the
above contrasts on a focused smaller subset of probe sets which were manually selected to
include 651 of the WNT signalling related probe sets (low probe density) (for ANOVA see
Figure 3.2). Following similar fold change and P–value filtering, an additional three
genelists D, E and F were generated (for results see Figure 3.9B).
The details of the 651 WNT related probe sets (the ‘WNT-ome’) are listed in
Supplementary 3.3 .  These probe sets were compiled based on the curated genes obtained
from the GeneGo MetacoreTM WNT signalling pathway map database and also based on
published WNT genes reviewed in other public pathway databases, primarily from the
Stanford University WNT homepage :http://www.stanford.edu/group/nusselab/cgi-
bin/wnt/main and Kyoto Encyclopedia of Genes and Genomes (KEGG) bioinformatics
resources for WNT pathway: http://www.genome.jp/kegg/kegg3a.html.  The accurate
Affymetrix® probe set code for each gene chosen was then retrieved from NetAffxTM
Analysis Centre, accessible from http://www.affymetrix.com/analysis/index.affx, in order to
match the HG-U133 Plus2.0 annotation on the GeneChip® used. The information about
alternative gene names, approved symbol abbreviation and aliases for each gene was
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manually compiled and obtained from http://www.genecards.org (Rebhan et al, 1997;
Safran et al, 2003). The approved gene symbol corresponding to each probe set was based
on the HUGO Gene Nomenclature Committee (HGNC) database.
Figure 3.1 : Flow diagram illustrating the ANOVA workflow to generate genelists A,
B and C. Two approaches (1-way and 4-way ANOVA) were used to search for
differentially expressed genes in AML blasts vs Normal Control samples from whole
genome probe sets.  Sample types and FAB subtypes are as characterised in Table 3.1.
Human Genome U133-Plus 2.0 Array
54,675 probe sets (approx. 38,500 genes)
Input : 111 CEL files
ANOVA- 4 way
Mixed Model
(factors : disease, FAB
types, scan date)
ANOVA-1 way
Linear Contrast
(factor : FAB subtype)
Fold change >1.5 or < -1.5
P <0.05
Fold change >1.5 or < -1.5
P <0.05
Viewing sources
of variation
between AML
vs normal
control
Creating
differentially
expressed
genelist
Genelist A
(AML M0
vs Normal Control
Genelist B
(AML M1
vs Normal Control
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Figure 3.2 : Flow diagram illustrating the ANOVA workflow to generate genelists D,
E and F containing differentially expressed genes in the ‘WNT-ome’. Two approaches
(1-way and 4-way ANOVA) were used to search for differentially expressed genes in AML
blasts vs Normal Control samples from ‘WNT-ome’ probe sets.  Sample types and FAB
subtypes are as characterised in Table 3.1. ‘WNT-ome’probe sets (n=651) are as
characterised in Supplementary 3.3 .
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3.3.4 Downstream analysis of significant genelists A-F
3.3.4.1 Pathway Maps analysis (genelists A-C)
Pathway analysis was generated through the use of specialised software provided by
Thomson Reuter (Thomson Reuters, New York, USA) called MetaCore™ from GeneGo
Inc. (GeneGo Inc., Michigan, USA) available at http://www.genego.com/faq.php. This is a
web application that generates Pathway Maps combined with functional ontology
enrichment analysis which can statistically rank the most relevant Pathways from the input
dataset. All maps were created by a team of experts and scientists from Thomson Reuters
by a high-quality manual curation process based on published peer-reviewed literature to
ensure its reliability. There are over 70,000 pathways within MetabaseTM which is the
internal knowledge base behind the MetacoreTM discovery tool.
For the input dataset, selected values from the three GEP genelists A, B and C were
imported into MetaCoreTM and the interconnectivity of each probe set was linked to its most
biologically relevant pathways. These genelists were derived from the whole genome
analysis thus allowing wider coverage of probe sets. In all three analyses, the following
values were selected for the input dataset: gene identifiers (in probe set format) and their
corresponding fold change characteristics and P-values obtained from the previous ANOVA
(3.3.3). These values were uploaded as an Excel file into the MetaCoreTM database.
Statistically significant pathway map sorting was applied. The pathways were ranked in a
format of table (and graphic) according to their newly calculated P-value of hypergeometric
intersection (further details about P-value algorithm in 3.3.4.2). The P-value of
hypergeometric intersection was set at <0.05 (no more than 5% false positives) and used to
estimate the probability of a random intersection between the input probe set IDs with
ontology gene IDs within the MetaCoreTM database.  The lower P -value means higher
relevance of the gene ontology IDs to the dataset, which shows as a higher rating for the
given probe sets of the corresponding pathway. The maps are arranged by hypergeometric
P-value and the sorting must pass the 1.5 fold change expression background threshold.
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3.3.4.2 Interactome and protein enrichment analysis (genelists D-F)
The Interactome tool provided by MetaCore™ allows estimation of
interconnectedness for the input dataset based on published literature, (e.g. a gene may
regulate another gene or they may bind with each other).  The tool will estimate statistically
significant interactions in the set, and enrichment of the dataset according to protein.
In order to identify statistically significant genes that regulate other genes (i.e by
direct binding, activate phosphorylation, transcription regulation etc), interactome analysis
using enrichment by protein function was applied. All probe sets within genelists D, E and
F that represent only WNT signalling genes were imported and uploaded as a tab-delimited
text file into the MetaCoreTM database. All three genelists were analysed for relative
enrichment with certain protein classes. The output data divided genes / proteins into seven
different functions (protein classes): transcription factors (TFs), receptors, ligands, kinases,
proteases, phosphatases and metabolic enzymes. The results were ranked by a P-value. The
P-values were calculated using the basic formula for a hypergeometric distribution similar
to the P-values for Pathway Maps, where r is the number of probe sets of a particular
protein class from the set of interest (input probe sets); R is the number of probe sets in the
set of interest; n is the number of probe sets of particular protein class in the whole GeneGo
global network; N is the number of probe sets in the GeneGo global network.
All probe sets for given genes were associated with their proteins and subsequently,
all protein lists were screened for the number of interactions with the GeneGo global
interactome network (interconnections) and within the individual protein lists
(intraconnections). The degree of over- and under-connectivity were evaluated by z-score.
The z-score signifies the difference between the obtained number of proteins and the
expected average number of proteins corresponding to genes expressed in units of standard
dispersion, where r = number of proteins derived from the current protein list that have
interactions with given protein; R = total number of proteins in the GeneGo global network
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that have interactions with the given protein; n = total number of proteins in given protein
list; and N = total number of proteins in the GeneGo global network.
All formulae used for scoring and prioritisation of genes and pathways according to
their relevance to input data were published by MetaCore™ from GeneGo Inc. Significant
data was considered to have P <0.05 with FDR applied.
3.3.5 Validation of TCF7L2 microarray expression using qRT-PCR
Based on the degree of over-expression, P-value significance, interactome analysis
and relevant literature reviews, the TCF7L2 gene was chosen for subsequent analysis
(results in 3.4.6).  This study first sought to validate mRNA normalised GEP data for this
gene by qRT-PCR. A small cohort (n=24) of randomly selected AML patients’ RNA
samples representing HG-U133A (n=15) and also HG-U133 Plus2.0 (n=9) were analysed
for TCF7L2 mRNA gene expression using qRT-PCR. The primer pair was designed to
amplify the region between exon 7/8 and exon 9 that was partially covered by the TCF7L2
Affymetrix probeset 212759_s_at  (illustrated in Figure 3.3). The forward primer spans the
boundary of exon 7 and 8 to increase specificity and to eliminate genomic amplification.
The RNA template was reverse transcribed (2.5.3) and the qRT-PCR assay is described in
2.5.4. The source of total RNA used for qRT-PCR validation was similar to the microarray
described in 3.3.1. For qRT-PCR data analysis, raw cycle threshold (Ct) values of TCF7L2
and ABL were collected from LightCycler LCS4 4.0.0.23 (Roche Diagnostics).  These raw
values were then imported into GeneSpring GX-11.0 (Agilent Technologies, Berkshire, UK)
and processed according to the baseline transformation option provided in GeneSpring GX
RealTime PCR analysis tools. In short, TCF7L2 averaged Ct values were normalised, in
which signal differences between averaged Ct of ABL and the target gene TCF7L2 within
each sample was calculated. Subsequently, for each gene, the median of the Log2
summarised values across all the samples was calculated in order to get the final `baseline
transformed’ normalised TCF7L2 expression.
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Statistical significance of the correlations was determined by comparing baseline
transformed values from qRT-PCR with the median polished Log2 values of the GC-RMA
normalised data of TCF7L2 after DWD adjustment (DWD data as described in 3.3.6.1).
Pearson’s correlation coefficient was used. Correlational statistical analyses utilized a 2-
tailed significance level of P <0.01 and were performed using SPSS for Windows version
11.5.0.
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Figure 3.3: Location of primers and probe pairs within the TCF7L2 probe set found to
be statistically significant by microarray analysis. (A) Location of primer pairs used for
TCF7L2 validation by qRT-PCR.  Schematic diagram of TCF7L2 gene and protein domains
encoded by the given exons, illustrating the position of the primer pair (forward and reverse
primers) used for validation of microarray using qRT-PCR. The green and red forward
primer denotes the exon-spanning primer.  (B) Location of eleven probe pairs within the
TCF7L2 probe set. The probe set number for TCF7L2 is 212759_s_at, and the sequence for
each probe pair as in Table 3.2.  NCBI RefSeq number for TCF7L2 is NM_001146274.1.
NM_001146274.1
Probe-set (212759_s_at)
Probe-pair (1-11)
B
A
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Probe pair (no.) Start
position
End
position
Exon no. (Perfect Match) Probe sequence 5’-3’
212759_s_at (no.1) 969 993 5 GAAATGGCCACTGCTTGATGTCCAG
212759_s_at (no.2) 984 1008 5 TGATGTCCAGGCAGGGAGCCTCCAG
212759_s_at (no.3) 998 1022 5 GGAGCCTCCAGAGTAGACAAGCCCT
212759_s_at (no.4) 1067 1091 7 AAGTGCCAGTGGTGCAGCACCCTCA
212759_s_at (no.5) 1108 1132 7 ACGCCTCTTATCACGTACAGCAATG
212759_s_at (no.6) 1242 1266 8a/8b ATCGCCTGGCACCGTAGGACAAATC
212759_s_at (no.7) 1301 1325 9 GTCAACCAGTGTACCCAATCACGAC
212759_s_at (no.8) 1323 1347 9 GACAGGAGGATTCAGACACCCCTAC
212759_s_at (no.9) 1406 1430 10a CACATCATACGCTACACACGACGGG
212759_s_at (no.10) 1444 1468 10a GCCATAGTCACACCAACAGTCAAAC
212759_s_at (no.11) 1470 1494 10a/b GGAATCGTCCCAGAGTGATGTCGGC
Table 3.2: Probe pair sequences of the TCF7L2 probe set 212759_s_at found to be
significant in HG-U133 Plus2.0 analysis. Probe pair sequences were adapted from
information published in the Annotation Database for Affymetrix Probesets and Transcripts
(ADAPT) (Leong et al, 2005). NCBI RefSeq number for TCF7L2 is NM_001146274.1
3.3.6 Measures to increase sample number for clinical outcome association studies
in the AML cohort
3.3.6.1 Merging of HG-U133 Plus2.0 and HG-U133A array datasets
In order to increase statistical power for the purpose of clinical outcome
analysis, it was necessary to merge the available GEP datasets from the two cohorts of AML
array platforms that were available. Combining both HG-U133A and HG-U133 Plus2.0
microarray datasets resulted in better utilisation of the existing AML clinical outcome data
available within Department of Haematology, Cardiff (n=246). The HG-U133 Plus2.0
contains 86 AML patients and the HG-U133A dataset provides an additional 160 AML
patients GEP data. Non-intensive AML patients who previously received low dose Ara-C
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treatment were excluded from analysis. The descriptions of the AML patients used for the
merged data are shown in Table 3.1.
A list of common probe sets IDs between the two arrays was created. This
resulted in a total of 22,277 probe-sets for downstream analysis. The .CEL files from the
array with greater density (HG-U133 Plus2.0) were imported first into Partek® software and
the probe-filtering option was applied to include only the common probe sets created earlier.
GC-RMA background correction and quantile normalisation was applied. Subsequently, the
second less dense probe GEP data was imported (HG-U133A) and similar settings were
applied throughout. The presence of significant variation in GEP before and after merging
was visualised by unsupervised hierarchical clustering. The GC-RMA normalised merged
GEP was saved in a separate Partek® spreadsheet for further use.
3.3.6.2 Removal of cross-experimental batch effect using the DWD algorithm due to
sample pooling
As described in 3.3.6.1, Partek® was able to merge and detect the presence of a
residual batch effect. However, in order to compensate for systematic technical differences
between different batches as detected, an additional approach (software) was required. This
study used a Distance Weighted Discrimination (DWD) method. A requirement of DWD is
that a large sample (batch) size is required for implementation due to the dependency on
batch mean and variance estimates in sample sizes, preferably more than 40 samples for
each batch. The software installation package for DWD ver1.0 was downloaded from
https://cabig.nci.nih.gov/community/tools/DWD, developed by University of North
Carolina Lineberger Comprehensive Cancer Center, USA. For the input dataset, the GC-
RMA normalised values from the merged array were uploaded as a single tab-delimited text
file into DWD software. The mean adjustment tool was applied to merge the two arrays
simultaneously. This approach finds the best DWD hyper-plane and the data were adjusted
by projecting different batches on the DWD plane (Benito et al, 2004; Hu et al, 2006).
Multivariate projection views were used to illustrate the adjustment process using the DWD
method. The final adjusted GEP generated by DWD was imported back into Partek® as a
single tab-delimited text file for further analysis. The quality of this adjusted GEP was
inspected using an exploratory tool (hierarchical clustering).
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3.3.7 Correlation of TCF7L2 expression with clinical outcome in AML patients
The statistical analysis described in this section was kindly assisted by Dr Robert
Hills from the Department of Haematology, Cardiff University. A total of 246 AML patient
data sets (Table 3.1) were utilised for clinical and microarray correlational studies. The
adjusted GEP generated by DWD for the expression of the TCF7L2 gene (212759_s_at)
obtained above (see 3.3.6) was selected as the input expression data.  Patients who were not
considered fit for intensive treatment and who had received non-intensive treatment, namely
low dose Ara-C versus one of two novel treatments, which are low dose Clofarabine or
Sapacitabine were removed from the dataset. This was done to remove noise and bias in the
clinical outcome. Clinical outcome data have been collected over a period of 8 years for
AML patients enrolled in the MRC AML studies.
Adjusted multivariate analysis of maximum likelihood estimates was performed to
look for an association of TCF7L2 as a prognostic independent factor.  The following
variables were included in the model: age, WBC count, cytogenetic prognostic groups,
gender, WHO performance and TCF7L2 gene expression. Proportional hazards Cox
regression models on time-to-event endpoints was performed. Significance was set at P <
0.05 for all tests for multivariable analysis. All analyses were performed using SAS version
9.1.3 software (SAS Institute Inc.). WHO performance scores are detailed in
Supplementary 3.4 (Oken et al, 1982).
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3.4 RESULTS
3.4.1 Quality Control analysis identifies high quality GEP data
In order to analyse only high quality GEP data, a number of QC steps were
performed. The initial RNA quality and integrity of AML blast samples were previously
analysed by Amanda Gilkes, Department of Haematology, Cardiff. All samples hybridised
to the GeneChips® were of high RNA quality as determined by Agilent Bioanalyser RNA
Integrity number (RIN>8). The RNA integrity data included 5 µg of total RNA yielding at
least 20 µg of biotinylated cRNA. Following fragmentation, the cRNA was electrophoresed
on the Agilent Bioanalyser: fragment sizes were between 50 and 200 bp. According to
MILE Working Group recommendations, samples that did not meet these criteria were
discarded (Kohlmann et al, 2008a). As part of this study, a number of bioinformatics
control steps were performed. Of the initial 155 GEP HG-U133 Plus2.0 GeneChip® data
files that were available from Department of Haematology (not listed here), a total of 111
(72%) files passed all QC criteria as listed in 3.3.2.2. The excluded data files either had
been deemed poor by visual inspection both by PLM weights and PLM residuals due to
prominent artefact spots or uneven hybridisation (Figure 3.4A - Figure 3.4C).
As for the internal probe set QC, hybridisation controls showed increasing
concentration as expected, with probe set ‘AFFX-r2-Ec-bioB-avg’ having the lowest
concentration (Figure 3.5A). Additionally, the signal intensity ratio of the 3’ probe set over
the 5’ probe set of the RNA-degradation control GAPDH transcript was less than 3
(indicative of good data) shown in Figure 3.5B, after removal of bad QC files. Most files
showed poly-A signals with acceptable linearity; where the signal for probe set ‘AFFX-r2-
Bs-dap-avg’ is present at a much higher concentration as expected than the other poly-A
probe sets (Figure 3.5C). This spiking test of internal probe sets verified that there was no
bias during the reverse-transcription between highly expressed genes and low expressed
genes during sample preparation. In summary, QC analysis has identified a final dataset
comprising of 98 GEPs of AML patients (Table 3.1) and 13 GEPs of Normal Control for
RNA hybridised to the HG-U133 Plus2.0 GeneChip®. Similarly, the QC of HG-U133A had
been previously validated in earlier studies using a similar AML cohort (Tonks et al, 2007a;
Tonks et al, 2007b; Liddiard et al, 2010) with only 68% passing QC from the total HG-
U133A samples available; the final 160 AML samples selected are also shown in Table 3.1.
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Figure 3.4 : Visual inspection of GEP data using 2-D pseudo-colour analysis. Each
GEP data set was visually analysed for artefacts. (A) AML GEP with acceptable QC. (B)
Poor AML GEP QC with uneven hybridisation and artefact ‘line’. (C) Poor AML GEP QC
with bright artefact spot. Note that the PLM residuals will allow a better view of the spurious
areas.
Raw default
background
PLM weights PLM residuals
A
B
C
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Figure 3.5 : Profiles of AFFX control probe sets before and after removal of poor quality GeneChips®. (A) Hybridisation controls showing
increasing concentration for good QC. (B) RNA degradation signal showing 3’/5’ ratio of GAPDH to be less than 3 for good QC. (C) Poly-A
signals showing doubling of amplification and ‘AFFX-r2-Bs-dap-avg’ probe set having highest signal for good QC.
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3.4.2 Exploratory data analysis discriminates AML from normal GEP
PCA mapping helps to reduce the dimensionality of the data set and to visualise
underlying similarities capturing most of the variance in the original GEP. The analysis is
based on all probe sets represented on the HG-U133 Plus2.0 microarray. As shown in
Figure 3.6, PCA was able to detect several AML samples that have quite a distinct
expression profile (dots outside the elipsoids), however this was a very small percentage of
the overall AML cases analysed (6.1%). No obvious outlier was detected within the Normal
Controls although they were derived from different donors taken from two different external
experiments.  The AML samples also clustered tightly regardless of the origin of sample
type taken during diagnosis, either BM or PB. PCA exploratory output indicates that the
disease factor (AML vs Normal Control) has a major effect on the data as expected and
should be a fundamental factor to be included in the subsequent ANOVA model along with
other factors described in the next section.
3.4.3 Finding differentially expressed gene changes between AML FAB subtypes
and normal controls
In order to detect biological changes in the GEP data, normalisation was first applied
to the raw intensity data followed by analysis of variance using ANOVA. Normalisation or
log transformation of the GEP using GC-RMA (3.3.2.3) produced normally distributed and
symmetrical GEP data as shown in Figure 3.7.  In order to find differentially expressed
genes, the normalised data was subjected to further variance analysis and this study
employed several strategies of ANOVA to find differentially expressed genes as detailed in
3.3.3.
From the ANOVA model output (Figure 3.8) and consistent with the PCA, the AML
vs Normal Control (or the “disease” factor) is still among the largest source of variation in
these data with a signal to noise ratio of 1.23 followed by FAB having a higher variation
signal of 1.82 above noise.  This means that the “disease” (AML vs Normal Controls) and
FAB subtypes are the factors that contributed to the variability in the gene changes
explained by the ANOVA model.  The scan date (signal to noise: 1.13) also contributed
some degree of variation in the GEP whilst the sample type (signal to noise: 0.70)
variability is not explained by the model used.  By taking into account all the different
factors, the heterogeneity in the GEP is highest between different FAB subtypes and
contributed significant gene expression changes. Thus subsequent genelists were derived
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based on FAB subtypes.  As previously illustrated in Figure 3.1, the 4-way ANOVA can
only compute one fold change value representing all FAB subtypes vs Normal Controls
(genelist C), therefore 1-way ANOVA was added for additional fold changes to be
computed separately for AML-M0 vs Normal Controls and AML-M1 vs Normal Controls
(genelists A and B).
In summary, grouping all AML FAB subtypes into one group may result in
obscuring gene changes due to the developmental status of the AML blasts.  Therefore
additional analyses were performed using FAB subtypes M0 and M1 since these are
developmentally closest to the CD34+ derived Normal Controls used. All three genelists A,
B, C generated from whole genome ANOVA analysis were utilised for further enrichment
analysis presented in 3.4.4.
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Sample Type :       BM         PB        BM (CD34+ )
Disease Type : AML             Normal Control
Figure 3.6 : Unsupervised PCA mapping of 98 AML samples and 13 Normal Controls
derived from CD34+ BM samples, showing 54,675 probe sets in a high-dimensional
gene space. Individual GEP (dots) are coloured based on the sample type taken at
diagnosis. Ellipsoids are drawn around each group and capture the underlying similarities
of the AML samples and of the Normal Control samples.
PC2 (35.5%)
PC1 (21.2%)PC3 (6.43%)
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Figure 3.7 : Box plots showing pre and post normalisation performance of 111 GEP
data. (A) Log Probe Cell intensity showing GEP distribution before normalisation (B) Log
expression signal after GC-RMA normalisation showing a more stable median.
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Figure 3.8 : Source of variation plot of the GC-RMA normalised HG-Plus2.0 dataset
using mixed model 4-way ANOVA. The height of each bar indicates the average signal
variance (mean square) for all 54,675 probe sets. The signal to noise ratio or mean F ratio
to error noise (1.00) is shown for each factor in the model. The nested factor is shown in
red. Signal to noise is variation contributed by each factor relative to error in the model.
Error is the amount of variability not explained by mixed model ANOVA.
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3.4.4 Enrichment analysis identifies WNT signalling as the most dysregulated
pathway in AML
The mixed model ANOVA resulted in three genelists for subsequent analysis. These
genelists contain GC-RMA expression value, fold change and P-value for each gene that
passed the threshold (see 3.3.3).  The three genelists and corresponding number of probe
sets passing the criteria are as follow; genelist A (2769 probe sets), genelist B (8136 probe
sets) and genelist C (4695 probe sets), illustrated in Figure 3.9A.  Given the challenges of
interpreting such large gene lists containing thousands of probe sets, it was necessary to
incorporate bioinformatics tools in the analysis to systematically extract biological themes
behind large gene lists produced by ANOVA.  One particular interest is to apply significant
gene list produced by ANOVA for pathway analysis to determine the relevance of gene
expression within a signalling pathway. Genelists A, B and C were uploaded into
MetaCoreTM analytical suite and analysed for significant deregulated pathways (see 3.3.4.1
for MetaCoreTM functional analysis; and results in Table 3.3). Although the different AML
subtypes might differ from each other, understanding how they share common pathway
characteristics should reveal fundamental information about AML pathogenesis.  The top
two significant pathways common to all three genelists were genes associated with
“cytoskeletal remodelling” (a GeneGo term to describe cancer cells progression) and
“WNT, TGF signalling”. The pathway associated with “WNT, TGF signalling” was found
to be highly significant in all comparisons and highest in AML-M0 vs Normal Control (P =
8.572 -16).  The P-value of the intersection between a gene of an experimental dataset (such
as from a genelist) and the same gene in a particular ontology is considered as a measure of
the relevance of pathway analysis.  In MetaCore™, P-value means the probability of a
random intersection of genes in two different sets. The lower the P-value, the higher the
"non-randomness" of finding such an intersection. In summary, global enrichment analysis
by using Pathway Maps has identified WNT signalling to be perturbed in AML compared to
Normal Control.
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Table 3.3 :  Statistically significant Pathway Maps generated from each genelist. Sorting was performed using FDR of < 0.05. The P -value
calculation is the number of probe sets in the list that hit a given pathway map as compared to pure random chance.
# AML-M0 vs Normal Control
(Genelist A)
AML-M1 vs Normal Control
(Genelist B)
Overall AML-M0:M6 vs Normal Control
(Genelist C)
Map title P-Value Map title P-Value Map title P-Value
1 Cytoskeleton remodeling_ WNT,TGF 8.57-16 Cytoskeleton remodeling 8.32-19 Cytoskeleton remodeling 1.42-16
2 Cytoskeleton remodeling 1.17-14 Cytoskeleton remodeling_WNT,TGF 6.25-17 Cytoskeleton remodeling_ WNT,TGF 2.94-15
3 Cell cycle_Influence of Ras and Rho
proteins on G1/S Transition
2.77-13 Transcription_Sin3 and NuRD in
transcription regulation
3.58-15 Apoptosis and survival_p53-dependent
apoptosis
2.68-12
4 Immune response_IL-2 activation and
signaling pathway
1.04-11 Cell cycle_Influence of Ras and Rho
proteins on G1/S Transition
3.85-13 DNA damage_ATM/ATR regulation of
G1/S checkpoint
5.59-12
5 Cell cycle_Chromosome condensation in
prometaphase
1.60-10 Apoptosis and survival_p53-dependent
apoptosis
5.32-10 Cell cycle_Influence of Ras and Rho
proteins on G1/S Transition
3.42-11
6 Immune response_Fc epsilon RI pathway 1.17-8 Transcription_P53 signaling pathway 2.04-11 DNA damage_Role of Brca1 and Brca2 in
DNA repair
1.07-10
7 Development_VEGF signaling via
VEGFR2 - generic cascades
8.60-8 Cell cycle_Chromosome condensation in
prometaphase
2.33-11 Cell cycle_Chromosome condensation in
prometaphase
1.47-10
8 Transcription_P53 signaling pathway 1.72-7 Development_VEGF signaling via
VEGFR2 - generic cascades
8.25-11 Cell cycle_The metaphase checkpoint 2.34-10
9 Cell cycle_The metaphase checkpoint 2.21-7 Cell cycle_The metaphase checkpoint 8.72-11 Cell adhesion_Chemokines and adhesion 3.19-10
10 DNA damage_ATM/ATR regulation of
G1/S checkpoint
1.05-6 Immune response_Fc epsilon RI pathway 9.09-11 Development_GM-CSF signaling 1.39-09
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3.4.5 Probe level filtering identifies dysregulated WNT signalling genes in AML
The data above (3.4.4) suggests WNT signalling is commonly dysregulated in AML.
By mapping and compiling all genes known to be associated with WNT signalling (i.e.
upstream and downstream regulatory genes and target genes) a more focused strategy was
followed to facilitate the selection of the most dysregulated WNT associated gene(s) within
AML. This was achieved by performing a cross validation analysis using an ANOVA
approach as described in 3.3.3 and also illustrated in Figure 3.2; from here a further three
genelists (D, E and F) were generated (Figure 3.9B). Two major observations were
obtained from this approach. Firstly, all genelists (A – F) shared 74% similarity in terms of
WNT genes that overlap, giving rise to the 14 common probe sets (Figure 3.9) and their
corresponding fold changes are listed in Table 3.4 - Table 3.6. This shows that the output
from the ANOVA model employed was reproducible even after reduction in the number of
input probe sets. Secondly, the production of WNT genelists (D, E and F) has made it
possible to search for significant interaction of different classes of genes (and proteins)
within WNT signalling that might be important in AML, as described below.
The Interactome analysis of this set of genes (from genelist D, E and F) was
conducted according to 3.3.4.2 using the “MetaCoreTM enrichment by protein function”
tool. This tool gives enrichment of gene expression changes based on different protein
classes. From this, a series of protein rankings (similar to probe sets) and their level of
interaction with other proteins present across all genelists were achieved. Table 3.7 lists 11
transcription factors, 2 receptors, 2 ligands, 8 kinases, 2 phosphatases, enzyme and other
proteins which were identified to be significantly ‘overconnected’. The protein (identified
by probe set) with common agreement across all genelists and the most connected with the
highest z-score was found to be a TF gene known as TCF7L2 (z-score of 19.87). A
representative image of a network showing direct interaction of TCF7L2 with other genes in
various cellular compartments is illustrated in Supplementary 3.5 (built using MetaCoreTM
Direct Interaction Map). Furthermore, TCF7L2 was consistently found to be over-
expressed in all other type of comparisons (Table 3.4 - Table 3.6), having the highest fold
differences in AML-M0 vs Normal Control (10-fold). Following this collective observation
and the potential role of a TF as a central nuclear regulator involved in transcriptional
dysregulation of WNT signalling, TCF7L2 was selected for further investigations.
Chapter 3: Identification of dysregulated pathways and genes in AML
__________________________________________________________________________
92
Figure 3.9 : Venn diagram showing significant genelists for both whole-genome and ‘WNT-ome’ comparisons (A) The intersection showing
1595 probe sets representing various genes from various pathways (B) The intersection showing 15 probe sets representing only WNT pathway
genes. The number of probe sets found to be significant in each of the genelist is shown in parentheses. All genelists passed the 1.5 fold change
threshold and P-value <0.05. Each genelist was generated by the Partek® List Manager tool.
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Table 3.4 : The common 14 dysregulated WNT probe sets identified in AML-M0 vs
Normal Controls built from genelist D. Genelist D contains a total of 27 probe sets and
shown here are the common 14 WNT probe sets overlapping between Genelist A-F. Each
probe set was arranged based on the fold change from lowest to highest. Genes are
significant at P < 0.05.
Probe set ID Gene Symbol P -value Fold-Change Description
203895_at PLCB4 2.81-14 -6.78 M1 down vs control
203896_s_at PLCB4 9.50-14 -3.93 M1 down vs control
212669_at CAMK2G 3.01-09 4.1 M1 up vs control
212759_s_at TCF7L2 4.50-06 4.23 M1 up vs control
204489_s_at CD44 1.81-11 5.27 M1 up vs control
1567458_s_at RAC1 1.06-10 6.4 M1 up vs control
1555814_a_at RHOA 4.23-08 7.62 M1 up vs control
1557905_s_at CD44 9.54-11 8.33 M1 up vs control
214083_at PPP2R5C 1.15-08 8.43 M1 up vs control
209835_x_at CD44 1.04-11 8.54 M1 up vs control
212014_x_at CD44 9.67-12 9.25 M1 up vs control
204490_s_at CD44 4.14-12 9.42 M1 up vs control
207993_s_at CHP 3.51-10 9.53 M1 up vs control
210916_s_at CD44 4.04-13 16.07 M1 up vs control
Table 3.5 :  The common 14 dysregulated WNT probe sets identified in AML-M1 vs
Normal Controls built from genelist E. Genelist E contains a total of 131  probe sets and
shown here are the common 14 WNT probe sets overlapping between Genelist A-F.   Each
probe set was arranged based on the fold change from lowest to highest. Genes are
significant at P < 0.05.
Probe set ID Gene  symbol P -value Fold change Description
203895_at PLCB4 6.19-07 -6.77 M0 down vs Normal Control
203896_s_at PLCB4 2.08-07 -4.35 M0 down vs Normal Control
212669_at CAMK2G 1.12-05 5.3 M0 up vs Normal Control
204489_s_at CD44 5.46-06 5.78 M0 up vs Normal Control
1567458_s_at RAC1 5.52-05 6.08 M0 up vs Normal Control
207993_s_at CHP 0.0003891 7.24 M0 up vs Normal Control
214083_at PPP2R5C 0.0005686 7.62 M0 up vs Normal Control
1557905_s_at CD44 8.15-06 9.93 M0 up vs Normal Control
204490_s_at CD44 4.71-06 9.93 M0 up vs Normal Control
209835_x_at CD44 3.03-06 9.96 M0 up vs Normal Control
212759_s_at TCF7L2 1.03-05 9.96 M0 up vs Normal Control
212014_x_at CD44 3.51-06 10.61 M0 up vs Normal Control
1555814_a_at RHOA 5.84-05 10.92 M0 up vs Normal Control
210916_s_at CD44 2.26-07 21.75 M0 up vs Normal Control
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Probe set ID Gene Symbol P -value Fold Change Description
203895_at PLCB4 3.94-06 -4.29 AML down vs normal
203896_s_at PLCB4 1.42-05 -2.74 AML down vs normal
212669_at CAMK2G 0.00059 2.75 AML up vs normal
212759_s_at TCF7L2 0.00348 3.18 AML up vs normal
204489_s_at CD44 1.43-05 3.72 AML up vs normal
1557905_s_at CD44 0.00029 4.48 AML up vs normal
1555814_a_at RHOA 0.00179 4.54 AML up vs normal
209835_x_at CD44 8.07-05 4.61 AML up vs normal
1567458_s_at RAC1 1.07-05 4.81 AML up vs normal
212014_x_at CD44 7.62-05 4.95 AML up vs normal
204490_s_at CD44 2.25-05 5.5 AML up vs normal
207993_s_at CHP 2.67-05 6.19 AML up vs normal
214083_at PPP2R5C 1.64-05 6.84 AML up vs normal
210916_s_at CD44 1.31-05 7.8 AML up vs normal
Table 3.6 : The common 14 dysregulated WNT probe sets identified in overall AML
(M0-M6) vs Normal Controls built from genelist F. Genelist F contains a total of 71
probe sets and shown here are the common 14 WNT probe sets overlapping between
Genelist A-F. Each probe set was arranged based on the fold change from lowest to highest.
Genes are significant at P < 0.05.
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Table 3.7 : Significant enrichment by protein functions in agreement with changes
seen in all three genelists D, E and F. A gene (probe set) is considered overconnected if
the corresponding z-score is more or equal to 0. P-value was calculated using the basic
formula for a hypergeometric distribution.  Fold change agreement shows upregulation or
downregulation of a gene in each genelist dataset.  Interactome agreement indicated by
“Yes” means the gene is significantly overconnected across all 3 genelists datasets
(interaction within < 3 datasets highlighted in black).
Gene type Network gene
name
P-value z-score Input  probe
set  IDs
Fold change
agreement
(D/E/F)
Interactome
agreement
(D/E/F)
Transcription factors TCF7L2 7.56-25 19.87 212759_s_at  Yes
Transcription factors JUN 1.64-20 13.97 201465_s_at 
Transcription factors LEF1 3.52-15 14.55 221558_s_at 
Transcription factors SMAD4 1.12-13 11.32 235725_at 
Transcription factors SMAD2 2.08-13 11.89 226563_at 
Transcription factors SNAIL1 4.42-12 13.74 219480_at 
Transcription factors NFATC4 1.39-08 12.65 213345_at 
Transcription factors TCF4/ITF2 9.66-08 12.23 212382_at 
Transcription factors TCF12 4.50-04 6.13 208986_at 
Transcription factors NFATC3 9.80-04 6.38 210555_s_at 
Transcription factors NFATC1 2.37-03 4.27 211105_s_at 
Receptors LRP6 4.63-10 14.42 225745_at 
Receptors CD44 2.53-08 10.20 204490_s_at;
212014_x_at
 Yes
Ligands CYR61 5.88-10 14.20 210764_s_at 
Ligands IL8 1.35-09 12.31 211506_s_at 
Kinases GSK3B 1.53-20 17.71 242336_at;
226183_at;
226191_at
 Yes
Kinases NLK 1.08-09 15.29 222589_at 
Kinases PRKCD 2.67-08 9.59 202545_at 
Kinases MAPK9 1.85-07 10.32 225781_at 
Kinases MAP3K7 6.36-06 7.61 206854_s_at 
Kinases CAMK2G 2.22-05 9.46 212669_at  Yes
Kinases PRKCE 4.86-04 5.07 226101_at 
Kinases ROCK1 2.28-02 3.67 230239_at 
Phosphatases PPP2R5C 3.38-08 11.81 214083_at  Yes
Phosphatases PPP2R5B 2.93-07 16.22 204611_s_at 
Enzymes EP300 1.62-24 16.18 202221_s_at 
Other DVL-1 1.21-22 26.50 203230_at 
Other CTBP2 1.98-09 12.02 201218_at 
Other ABCB1 2.09-08 12.26 209994_s_at 
Other RAC1 3.14-07 7.84 1567458_s_at  Yes
Other PPP2R1B 8.50-07 10.05 202883_s_at 
Other TBL1XR1 1.47-06 10.92 222634_s_at;
221428_s_at;
223013_at
 Yes
Other CUL1 3.09-06 8.13 207614_s_at 
Other CDKN2A 4.20-06 7.90 209644_x_at 
Other RHOA 5.95-06 7.19 1555814_a_at  Yes
Other DAAM1 7.62-06 10.89 232552_at  Yes
Other CCND2 7.82-06 8.10 200951_s_at 
Other TLE3 6.50-04 6.90 206472_s_at 
Other ABCB1 3.21-03 6.60 209993_at 
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3.4.6 Correlation of TCF7L2 expression using Affymetrix microarray profiling and
qRT-PCR
Microarray and Interactome analyses led to identification of TCF7L2 as a potential
key regulator in WNT signalling that may play important role in AML. Validation of
TCF7L2 mRNA expression obtained by microarray was necessary prior to any further
functional validation. To achieve this, qRT-PCR was performed according to the method
described in 3.3.5.  This study focused on the mRNA region of TCF7L2 represented on the
array by probe set (212759_s_at) that was found to be significantly expressed in AML
compared to Normal Controls. The expression of TCF7L2 by microarray and qRT-PCR
showed a significant degree of correlation (R=0.748, P <0.01). In conclusion, this study
suggests that the observed changes in TCF7L2 expression by microarray are reliable and
successfully validated by an independent method.
Normalised TCF7L2 expression by microarray
Figure 3.10 : Validation of TCF7L2 mRNA expression using qRT-PCR. Correlation was
shown between Log2 array (GC-RMA normalised) and Log2 qRT-PCR (deltaCt normalised)
expression data. Correlation is significant at the 0.01 level (2-tailed) using Pearson’s test.
RMA381
.50.0-.5-1.0-1.5-2.0
GS
DE
LT
CT
4
3
2
1
0
-1
-2
-3 Rsq = 0.5595
No
rm
ali
sed
 TC
F7
L2
 ex
pre
ssi
on
 by
 qR
T-P
CR
Chapter 3: Identification of dysregulated pathways and genes in AML
__________________________________________________________________________
97
3.4.7 Correlation of TCF7L2 expression and clinical outcome in a larger cohort of
AML
3.4.7.1 Exploratory analysis showed a significant reduction in the source of batch
effects after DWD adjustment in AML cohort
To increase the statistical power of the GEP dataset associated with clinical
outcome, this study combined GeneChip® GEP raw data from HG-U133 Plus2.0 and HG-
U133A into a single analysis. Due to the complexity in studying genes distributed in
different experiments, background signal corrections were performed as described in the
methods (3.3.6.1). Apart from signal normalisation, it is also possible to use other statistical
methods such as DWD to remove unwanted batch effects (that can’t be removed by
normalisation); in this case the batch effect is GeneChip® platforms (i.e. HG-U133 Plus2.0
and HG-U133A).  Prominent variation in GEP data was observed when the GeneChip®
platform (‘batch’) was taken into account within the AML datasets. By finding the most
fitted hyper-plane of the data, DWD was able to significantly reduce the variation between
platform batches and the adjustment step was visualised by multivariate view as in Figure
3.11. This was also supported by unsupervised hierarchical clustering (Figure 3.12) which
identified “batch’ as the factor influencing the distribution of data suggesting that GEP data
were initially clustered due to technical effects rather than biological effects even after
normalisation.
The ‘batch effect’ was successfully removed following DWD adjustment supported
by hierarchical clustering of DWD adjusted data. Figure 3.13 shows all AML samples from
both GeneChip® platforms (red bar) are now clustered together. In summary, DWD
adjustment helped to reduce substantial background noise and allowed creation of a single
GEP dataset from the two different platforms. The expression value of TCF7L2 gene
derived from DWD adjusted merged GEP dataset (n=246) was then used for further clinical
outcome analysis.
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Figure 3.11 : Multivariate projection view of the merged GC-RMA data showing
effective removal of platform bias using the DWD batch removal tool. The green line
connects all samples.   Red dots (Series 1 and Source 1) refer to GC-RMA normalised
samples from HG-U133A and blue dots (Series 2 and Source 2) refer to HG-U133 Plus2.0.
Kernel density estimations (KDE) show distribution of the values for the combined array
expression. Multimodalities are indicated in principal component (PC) 1 for the HG-U133
Plus2.0 and HG-U133A and in PC2 - PC4 for the combined arrays. (A – C) Scatter plots
with KDE are showing the distribution of the array expression means projected on the DWD
direction. (D) KDE of the pooled DWD distribution of HG-U133 Plus2.0 and HG-U133A is
shown in the scatter plot.
(A)
(B)
(C)
(D)
Chapter 3: Identification of dysregulated pathways and genes in AML
__________________________________________________________________________
99
GeneChip® Type:                     HG-U133 Plus2.0                                 HG-U133A
Samples:               AML                                                     Normal Control
Figure 3.12 : Hierarchical clustering of the combined samples from HG-U133A (green
dendrogram) and HG-U133 Plus2.0 (brown dendrogram) before batch effect
adjustment.
Chapter 3: Identification of dysregulated pathways and genes in AML
__________________________________________________________________________
100
GeneChip® Type:                          HG-U133 Plus2.0                                 HG-U133A
Samples:                   AML                                                     Normal Control
Figure 3.13 : Hierarchical clustering of the combined samples from HG-U133A (green
dendrogram) and HG-U133 Plus2.0 (brown dendrogram) after batch effect
adjustment.
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3.4.7.2 High TCF7L2 gene expression is associated with reduced complete remission
rate in patients with adverse cytogenetic AML
To gain further insights into the prognostic impact of TCF7L2 expression at
diagnosis in AML, a cohort of AML patients (n=246) for which both microarray and
clinical data were available were analysed. Among those, 55 patients didn’t achieve CR.
The prognostic impact of TCF7L2 expression in AML was assessed using multivariate
analysis described in 3.3.7.  This analysis took into account patient co-variables including
age, WBC count, cytogenetic prognostic group, gender and WHO performance. The
analysis revealed that TCF7L2 mRNA overexpression was found to be independently
prognostic for reduced CR rate after the adjustment for co-variables with an odds ratio (OR)
for CR: 5.19 (1.39-19.39) P = 0.0144. No statistically significant impacts were seen
between TCF7L2 gene overexpression and OS or relapse incidence. In summary, TCF7L2
mRNA expression is an independent prognostic marker for CR status in AML patients.
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3.5 DISCUSSION
3.5.1 Aspects of GEP processing and data integration
Analysis of microarray GEP data has increasingly become a common technique to
provide insights into biological processes. Global inter-laboratory studies have recognised
this tool for various clinical applications such as to predict patients’ outcome, to discover
cancer subclasses, and to identify new therapeutic targets (Bullinger & Valk, 2005;
Haferlach et al, 2005). Although in the analysis of microarray data, many statistical
methods exist for identification of relevant target genes, the choice of method used can
greatly affect the set of genes identified (Allison et al, 2006; Jeffery et al, 2006; Dupuy &
Simon, 2007; Ioannidis et al, 2009).
To identify important genes and pathways that were dysregulated in AML, the initial
approach taken relied on identifying common underlying gene changes associated
specifically with developmental subtypes of AML (M0 and M1) compared to Normal
Control; the changes observed were then extended to all subtypes (M0 - M6).
Unfortunately, CD34+ Normal Control GEP data was not derived as part of the original
experimental design at Cardiff. To circumvent this, this study downloaded pre-existing
GEP normal CD34+ data. Although these data were derived from a number of separate
experiments, their expression profiles clustered tightly together suggesting their intrinsic
gene expression was similar to each other but markedly different from the AML GEP (as
shown by multidimensional visualisation Figure 3.6). In addition to the limited availability
of Normal Control GEP data, there is some concern about what is the ideal control to
compare an AML sample to. Although limited, several studies have compared AML
patients’ GEPs with normal cells derived from the CD34+ cell population (Stirewalt et al,
2008; Majeti et al, 2009a).  Heterogeneity of the CD34+ cell subpopulation in leukaemia has
been reported (Bonnet & Dick, 1997; Gentles et al, 2010; Rockova et al, 2011), as well as
the heterogeneity of CD34+ cells in normal samples.  In contrast to AML, one study found
there was no significant difference in gene expression signatures between CD34+ cells
derived from PB and CD34+ data derived from BM in AML myeloblasts (Cheung et al,
2009).
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Combining multiple microarray GEP data sets across different experiments as part of
data pre-processing has always been challenging. Selecting a subset of discriminative genes
related to AML pathogenesis requires robust statistical methods and normally multiple
approaches would be used to derive a final genelist.  This includes different normalisation
and summarisation procedures. Because of this complexity in studying genes distributed in
different experiments processed through sequential hybridisations, background signal
corrections were performed based on the widely accepted algorithm GC-RMA that takes
into account PM signals. The PM-only methods such as RMA, GC-RMA and Probe
Logarithmic Intensity ERror (PLIER) prove particularly powerful in reducing false positives
(Seo & Hoffman, 2006) and have previously been shown to perform better in detection of
differential expression (Mieczkowski et al, 2010) as compared to the MAS5.0 algorithm.
Even though RMA based normalisation is more precise, it may hide real changes (due to
lower sensitivity), especially at low expression levels (Irizarry et al, 2003a; Millenaar et al,
2006).
To account for potential artefactual differences that may arise as a consequence of
combining multiple GEP data e.g. AML trial GEP data hybridised on different Affymetrix
GeneChips® (U133A and Plus2.0) a batch correction method was used.  Systematic biases
due to the two Affymetrix platforms were removed and GEPs were merged according to the
DWD algorithm (Benito et al, 2004; Qiao et al, 2010).  This approach has previously been
reported to be useful for validating cancer intrinsic subtype gene sets that are predictive of
survival outcome in breast cancer (Hu et al, 2006). DWD is flexible because it allows input
data to be pre-processed using any form of normalisation of interest (as RMA used above).
However with DWD, only two batches (i.e two sets of GEPs) can be applied at a time.
Other methods such as Empirical Bayes (Johnson et al, 2007) and Singular-Value
Decomposition (Alter et al, 2000) are among other options available that could remove
biases caused by non-biological conditions when sample numbers per batch are much
smaller (fewer than 25 arrays). Because the majority of microarray studies are conducted
using much smaller sample sizes (eg. fewer than 30 samples), existing batch correction
methods are not sufficient to remove the systematic biases in data, but this is not the case for
this study. As a result of merging two cohorts of AML trial patients that give rise to a total
of more than 200 samples, the adjusted GEP was then successfully utilised to assess
TCF7L2 expression as a prognostic marker in this study.
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This study applied integration of GEP data of Normal Controls from external sources
to be normalised with the existing AML GEPs. Through other meta analysis, researchers
have shown reliability of output obtained from integrating microarray repository data (Choi
et al, 2003; Rhodes et al, 2004; Warnat et al, 2005). This also promotes the discovery of
small but consistent expression changes with increased sensitivity. To facilitate this
process, a series of important checklists for conducting such a type of microarray analysis
have also been extensively reviewed by Ramasamy et al; one may remove arrays that are of
poor quality and check for batch effects before combining large data sets from multiple
sources (Ramasamy et al, 2008).
3.5.2 Networks of aberrantly expressed genes in AML
Due to the growing computational discovery programmes available (eg: Cytoscape,
GeneGo MetaCoreTM, Ingenuity Systems, Ariadne Pathway Studio etc) a much more
coordinated and data rich framework exists in which regulatory networks and pathway
analyses are among the advanced approaches applied to analysis of GEP data. For example,
these topological tools have discovered important unsuspected cross talk between different
haematopoietic pathways and have become the foundation for reconstructing a much more
up-to-date stem cell transcriptional network due to increased number of known TF binding
sites (Berger et al, 2006; Miranda-Saavedra & Gottgens, 2008; Philippakis et al, 2008). In
order to understand more of the biological interactions behind aberrant gene expression in
AML, this current study takes advantage of the Genego MetacoreTM Interactome and
pathway discovery tools. Using such approaches, this study has identified dysregulated
expression of a number genes in AML that belong to the “Cytoskeleton remodeling, WNT,
TGF” pathway.  This pathway name is given by GeneGo MetaCoreTM and consists mostly
of WNT components that cross-talk to a small subset of genes involved in TGF signalling
(eg: SMADs, RHOA, RAC).  Cytoskeletal remodelling is a simplified term used to describe
the role of WNT in cancer progression mechanisms such as microtubule stabilization, cell
polarity (via non canonical WNT), motility and adhesion as reviewed by (Lai et al, 2009).
WNT signalling is well known to regulate many cellular processes including cell
development and cell to cell interactions and is one of the most significantly affected
pathways in CLL (Lu et al, 2004), AML (Wang et al, 2010) and is well described in solid
tumours (Roman-Gomez et al, 2007; Liu et al, 2008).  However, the role of many key
proteins within WNT signalling is still not well described in the pathogenesis of AML in
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comparison to solid tumours.  Constitutive activation of canonical WNT / -catenin
expression has previously been shown in AML (Simon et al, 2005) including AML with
normal karyotype or low risk groups (Mikesch et al, 2007). Deregulation of non-canonical
WNT signalling (i.e independent of -catenin function) has also been observed in
haematologic malignancies. Hypermethylation of genes in the non-canonical WNT
pathway (eg. WNT5a) has been associated with reduced survival and high relapse in AML
patients (Roman-Gomez et al, 2007; Valencia et al, 2009; Martin et al, 2010), showing
involvement of non-canonical WNT in AML progression.
To date, there are at least 200 upstream proteins known to modulate WNT activity
including cell signalling ligands, receptors, phosphatases and transcription factors. In
addition, around 150 or more WNT target genes are transcribed as a result of direct binding
of TCF protein to relevant promoters and the list of WNT target genes continue to expand
throughout the years. This current study represents an effort to simultaneously compile the
growing number of WNT signalling target genes and other known WNT associated genes
from a wide variety of resources using both discovery tools (GeneGo MetaCoreTM, DAVID,
etc) and published literature. The resulting list of WNT genes and their corresponding
probe sets has become a primary reference in the process of searching for the most
dysregulated gene in WNT signalling. The analysis identified several common genes found
to be overexpressed in AML, for example TCF7L2, CD44 , RAC1, RHOA, PPP2R5C;
expression of these genes are highest in subtype M0 (Table 3.4).
TCF7L2 is of particular primary interest because it has been reported to be the
central regulator of canonical WNT signalling that interacts with -catenin acting in the
nucleus and mediates transactivation of other genes. -Catenin was also found to be
significantly overexpressed by one genelist but not observed by Interactome analysis.
Although not associated elsewhere with prognosis or any particular FAB subtype, TCF7L2
has been described in AML, in which FLT3-ITD AML has shown to induce TCF
transcriptional activity (Tickenbrock et al, 2005). Upregulation of TCF7L2 expression was
also documented during macrophage differentiation at the expense of granulocyte
differentiation (Baek et al, 2009; Brown et al, 2012) showing an important role in normal
haematopoiesis. Through DNA array-based genome-wide analysis of TCF7L2 chromatin
occupancy, others have identified with high confidence TCF7L2-binding sites in target
genes showing inappropriate activation of TCF7L2 in colorectal cancer progression (Hatzis
et al, 2008).
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This study further suggests involvement of other genes that are not part of
transcription factors in the dysregulation of AML. The upregulation of RAC1 and RHOA
seen in AML patients partly supports by the role of Rac GTPase signaling in myeloid-
associated disease that is well documented to be up-regulated in murine AML (Rozenveld-
Geugien et al, 2007). RAC1 and RHOA are shown to enhance -catenin accumulation in the
nucleus leading to activation of canonical WNT through TCF and activation of RAC1 has
been reported to control nuclear localisation of -catenin (Wu et al, 2008). Both RAC1 and
RHOA also play role in non-canonical WNT and this suggests involvement of non-canonical
WNT dysregulation in AML. Identification of CD44 overexpression in this study is in
keeping with other studies showing overexpression in both AML and CML stem cells
relative to normal HSC (Jin et al, 2006). Conversely, this current study also observed
overexpression of negative regulators of WNT signalling such as PPP2R5C. The
overexpression of PPP2R5C was reported to reduce the abundance of -catenin and to
inhibit the transcription of TCF / -catenin target genes by interacting with Axin / APC
(Seeling et al, 1999; Hsu et al, 1999).  Among the most commonly downregulated genes
seen in this study is PLCB4. PLCB4 had been reported to be one of the gene related to a
more primitive HSC stem cell and the expression is high in normal stem cells such as the
multipotent mesenchymal  stem cells (Tsai et al, 2007) and in the subpopulation of CD133+
derived CB cells that play important role in haematopoiesis (Toren et al, 2005). Little is
known about implication of PLCB4 in the context of AML but PLCB1 another key enzyme
in nuclear signal transduction has been reported to play a role in the progression of MDS to
AML (Cocco et al, 2005). However, inconsistencies were also observed where Majeti et al
found downregulation of RAC1 and did not find any significant changes of TCF7L2,
PLCB4, RHOA or PPP2R5C when comparing normal to leukaemic stem cells (Majeti et al,
2009).
Subsequent analysis using Interactome as a gene interaction model revealed
additional important genes in the dataset, which were missed by the direct fold change
analysis. Moreover, this provides evidence that TCF7L2 and other genes identified earlier
are also inter-connected to each other. Following Interactome, the same set of genes
TCF7L2, CD44, RAC1, RHOA and the PPP2R family once again appeared to be significant.
These findings proposed that these genes are overconnected in the AML dataset along with
several other genes from different protein classes. JUN, LEF1 and the SMAD family are
among important TF genes that were highly overconnected and also found to be
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dysregulated (Table 3.7). The NFAT family (NFATC1, NFATC3, NFATC4) also appear to
be among the overconnected TFs. NFAT is a key TF in non canonical WNT. Researchers
have shown that NFAT protected CML cells and was responsible for Imatinib resistance in
CML implying that NFAT plays important roles in leukaemia cell survival (Gregory et al,
2010). Transcription activation of NFAT is specifically enhanced by promyelocytic
leukaemia (PML) protein, showing specific binding of NFAT to PML.  PML also has a
wide spectrum of target genes (Lo et al, 2008).
Besides NFAT family genes and TCF7L2, another TF that also has a high z-score
(second most connected TF) is JUN. The upregulation of JUN has been documented in
leukaemia patients previously (Casas et al, 2003; Rangatia et al, 2003; Pise-Masison et al,
2009). One particular interest is the complex between TCF, JUN and DVL1.  DVL1 is
another WNT regulator that was found be overconnected as well as upregulated in this
study. It is well known that the formation of the TCF / -catenin transcriptional complex is
subjected to many forms of regulation of other genes. Both DVL1 and JUN stabilise the
nuclear transcription complex whilst reduction of DVL1 shown to suppress -catenin /
TCF7L2 association (Gan et al, 2008). The upregulation of both DVL1 and JUN could
therefore lead to aberrant activation of WNT that disrupt the balance of this mechanism
which is crucial for developmental processes. In the context of non-canonical WNT
signalling such as planar cell polarity, DVL1 interacts with the DAAM1 / RHOA axis, the
RAC1 axis and GSK-3 microtubule signalling (Habas et al, 2001) to regulate cytoskeleton
remodelling through a transcriptional-independent mechanism, indicating the ability of
DVL1 to mediate complex and versatile signal transduction.
Of the eleven most overconnected TF genes identified, a number of important
lineage-specific TF partners were also seen to be dysregulated. Among these are the
TCF7L2, SMAD and NFAT families. These three groups of genes have been reported to be
important for long term lineage decisions for T-regulatory cells and shared conserved
binding sites for FOXP3 locus controlling regulatory T cell development (Floess et al,
2007). Because TF genes are well known to play a significant role in cell lineage fate, it is
important to understand their function and the consequences of TF dysregulation in this
process. Normal haematopoiesis relies on lineage-specific transcription factors including
GATA2, RUNX1, TAL1, PU.1 that control cell differentiation; disruption of these factors in
normal  differentiation is a hallmark of AML blasts (Tenen, 2003; Pabst & Mueller, 2007).
Complementary to that, JUN (Oh et al, 2000) and TCF7L2 (Jaatinen et al, 2006) are among
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the TF genes that are highly expressed in HSC. Another observation is aberrant expression
and high connectivity of both TCF7L2 and SMAD (SMAD2, SMAD4) indicating an altered
activity of these ultimate effectors of BMP / WNT pathways. Both TCF7L2 / SMAD
proteins interact during developmental processes and co-occupy genomic sites with GATA1
/ GATA2 to regulate erythroid lineage (Trompouki et al, 2011). Disruption of either by
silencing or aberrant expression of TCF / SMAD complex might affect their established
roles in erythropoiesis.
Other genes such as CAMK2, NLK and NFAT that antagonise β-catenin-dependent
canonical WNT signalling were also found to be dysregulated in this AML GEP study
suggesting involvement of non-canonical pathway through either the CAMK2-TAK1-NLK
pathway or NFAT-mediated transcriptional regulation. Both NLK and NFAT were
previously reported to suppress β-catenin-dependent transcription (Ishitani et al, 1999;
Saneyoshi et al, 2002). The WNT dysregulated genes presented so far indicate the
possibility of involvement of non canonical WNT, in addition to the dysregulation in TCF /
-catenin activation in AML.
3.5.3 Aspects of gene selection
Affymetrix designed a certain number of probe sets to detect expression of each
gene (ranging from 1 until 13 probe sets per gene). With regards to the number of probe
sets found to be overexpressed or underexpressed in this study, there are several
inconsistencies seen between different probe sets per gene.  From Table 3.7, CD44, GSK-3B
and TBL1XRL are examples of genes that appeared to have more than one probe set
concomitantly significantly expressed, suggesting consistent signal detection of more than
one probe set that exists on the Affymetrix GeneChip® belonging to these genes. However
this is not the case for majority of other genes.  Considering TCF7L2, there are actually
seven probe sets engineered on the GeneChip® for hybridisation to occur. Nevertheless,
only the probe set located within the centre of the coding gene was found to be consistently
overexpressed (212759_s_at). For the other six probe sets that are located near to the 3’ end
of TCF7L2 mRNA, the detection was hampered after statistical tests and fold change
filtrations possibly due to weaker signals than the interior probe set. For CD44, there are 13
probe sets available to detect its expression on a single GeneChip® but only half are
efficiently detected after statistical filtrations. These types of discrepancies could be
explained partly by the location of probe sets that are close to the 3’ ends of genes tending
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to have a lower chance of coverage and to not be amplified as efficiently as the interior
probesets, whilst probe sets located closer to the 5’ end will have higher GC content with
less specific binding to the genes (Bemmo et al, 2008). Therefore the interior probe sets
could be the most reliable target for hybridisation. By taking CD44 and TCF7L2 as
examples in this study, there is also a wealth of evidence showing multiple splicing within
exonic regions of these two genes (Hsu et al, 1999; Shiina et al, 2003; Wang et al, 2009;
Weise et al, 2010; da Cunha et al, 2010; Banky et al, 2012; Zeilstra et al, 2013).  This
explained the inconsistencies of the 3’ IVT Affymetrix probe sets’ ability to detect all
signals with equal efficiency, particularly for highly spliced genes.
In summary, it is clear that AML is constrained by complex networks involving both
positive and negative regulatory interactions among substantial numbers of WNT genes and
that no single gene or TF is necessary and sufficient to cause AML progression. This study
not only identified TCF7L2 to be consistently upregulated across all datasets but is also the
first study to show its prognostic value in AML. Constitutive activation of TCF / -catenin
remains the most widely accepted mechanism for dysregulation of WNT signalling.
However, TCF7L2 expression has more complexity involving its gene structure, variants
and functions due to multiple splicing which require further investigation in AML. The
functional specificities of the different TCF7L2 isoforms remain incompletely understood in
AML.  The next chapter will attempt to distinguish the different variants of TCF7L2 mRNA
that might exist in AML (that cannot be distinguished by microarray) coupled with protein-
mRNA correlational studies adding further insights into validating TCF7L2 expression in
AML.
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4 - Validation of TCF7L2 as a dysregulated
WNT signalling transcription factor in
AML
4.1 INTRODUCTION
Data from gene expression analysis in the previous chapter established WNT
signalling to be the most significantly dysregulated pathway in AML. Extended
downstream analysis of differentially expressed WNT signalling genes using Interactome
(MetaCoreTM) identified TCF7L2 as the most overconnected TF to be aberrantly expressed
in AML. As previously described (see 1.4.1), TCF7L2 is a member of the TCF family in
the canonical WNT signalling pathway and affects a wide range of fundamental cellular
processes such as embryonic development (Korinek et al, 1998b), cell lineage regulation
(Trompouki et al, 2011), stem cell maintenance (Pinto & Clevers, 2005), tumour
suppression (Angus-Hill et al, 2011) and oncogenesis (van de Wetering et al, 2002; van &
Clevers, 2002). Misregulation of TCF / -catenin activities and involvement of TCF7L2 in
cancer formation have been reported in both myeloid and T-cell leukaemia (Chang et al,
2006; Pise-Masison et al, 2009) as well as solid tumours (van de Wetering et al, 2002;
Shiina et al, 2003; Valenta et al, 2003).
Besides being dysregulated at transcript expression level as described in Chapter 3,
previous studies in vertebrates and solid tumours have shown the presence of alternative
splicing within the coding region of TCF7L2 particularly at the exterior of the β-catenin and
HMG box domains (Arce et al, 2006; Weise et al, 2010). According to the NCBI database,
TCF7L2 is comprised of 18 exons, six of which are alternative exons (i.e. exon 4, 6 and 14 -
17), with additional complexities to exon 8 and exon 10 that have been reported to be
alternatively spliced into two distinct sequences; i.e. type-a and type-b (Pukrop et al, 2001;
Weise et al, 2010). To date, there are at least 13 types of TCF7L2 protein isoforms
published in public databases (NCBI and UniProt), and the longest isoform of the full length
TCF7L2 protein has been characterised to encode several functional domains that are
important for its transcriptional regulation including the β-catenin binding domain, NLS and
promoter-specific activation region (i.e. C-clamp) as illustrated in Figure 1.10. Through
mRNA splicing, TCF7L2 protein isoforms with differing properties are generated. Full
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length TCF7L2 cDNA with E-tail isoforms (hereafter known as C-tail E1 - E4) has
originally been reported to express unique cysteine rich sequence-specific DNA binding
motif known as C-clamp motifs (CRARF or CRALF) that recognise different groups of
TCF binding elements which are located in the promoter regions of TCF target genes (Hecht
& Stemmler, 2003; Wallmen et al, 2012). Several promoter genes such as Caudal Type
Homeobox Transcription Factor-1 (CDX1) and LEF1 specifically require a C-tail E2
TCF7L2 isoform for β-catenin activation (Atcha et al, 2003). As a nuclear mediator of
WNT signalling, TCF7L2 also associates with several other corepressors such as Groucho,
the MTG family and TLE to repress transcription in the absence of -catenin (Moore et al,
2008). In addition to the C-clamp, TCF7L2 with the C-tail E2 isoform also encode another
unique motif within exon 18 that has been reported to recognise a transcriptional
corepressor known as CtBP that could prevent -catenin from binding to TCF (Eastman &
Grosschedl, 1999; Fang et al, 2006).
However, further details of TCF7L2 alternative splicing have not been characterised
in AML. This chapter will therefore be focusing on detecting variations of TCF7L2 mRNA
transcript and protein expression, as well as in depth characterisation of each TCF7L2
protein isoform in both AML and normal cells.  Findings from this chapter will allow
functional studies to be performed on the predominantly overexpressed isoform found in
myeloid cells.
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4.2 AIMS
Affymetrix microarray data analysis has identified overexpression of TFC7L2 in
AML blasts compared to normal HPC. It is known from previous studies that this gene
generates multiple protein isoforms, each of which might have a different functional
significance. Therefore this chapter aims to:
 Characterise the TCF7L2 mRNA variants in AML patients and leukaemic cell lines
and to compare the expression to normal HPC and total BM cells. This will
determine the exon composition of the different mRNA variants seen and their
predicted protein molecular weight.
 Determine which TCF7L2 isoforms are overexpressed at the protein level in AML.
Characterise the TFC7L2 variants (again in comparison with normal HPC), their
subcellular localisation and whether expression of mRNA correlates with protein
TCF7L2 levels in AML.
 Compare how TCF7L2 isoform expression in AML differs from that seen in normal
haematopoietic development.
4.3 MATERIALS AND METHODS
4.3.1 Source of primary AML blasts, myeloid cell lines, normal BM and normal
CD34+ HPC from CB.
Primary AML blasts (mononuclear fractions) were collected from the MRC / NCRI
AML Trial bank.  All samples had ethical permission and material transfer agreement
(MTA) with Cardiff University. RNA was extracted using the protocol described in 2.5.1.
The RNA samples were used for variant PCR analysis as detailed in Table 4.1. Thirty RNA
samples from this cohort were already available and previously processed for the MILE
study (Kohlmann et al, 2008a). Additional AML samples were obtained prospectively from
MRC trials AML16 (n=5) and AML17 (n=5) that were not part of the MILE study but were
processed similarly. From this cohort, a total of 19 AML samples (refer to Table 4.1) had
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their proteins extracted using the method previously described in section 2.8.  These were
used for western blotting.
Normal BM cells (n=4) were derived from healthy donors purchased from AllCells®
(Alameda, U.S.A.). Normal human HPC were derived from neonatal umbilical CB that was
collected from the Maternity Unit, UHW, Cardiff following informed consent.
Mononuclear cells were originally isolated from CB and the CD34+ population was
enriched according to a similar method to 2.4.2 – 2.4.3. RNA and protein samples from
normal CD34+HPC  (n=4) were provided courtesy of Dr Alex Tonks and Dr Richard Darley
(Tonks et al, 2007b). (Tonks et al, 2007)
Myeloid cell lines were cultured as described in 2.3.1 and passaged at least twice
before use in the experiments described below. A total of five myeloid cell lines were
tested for alternative splicing using PCR namely K562, U937, THP-1, NB-4 and Kasumi-1.
RNA from normal BM and myeloid cell lines was extracted using the method described in
2.5.1.  Nuclear and cytosolic fractions were extracted as described in section 2.8.
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Characteristic at diagnosis
Patients for variant
analysis
Patients for protein
analysis
Trial group
AML14
AML15
AML16
AML17
9
21
5
5
4
5
5
5
Diagnostic sample type
Bone marrow
Peripheral blood
Not determined / unknown
4
13
23
-
11
8
FAB subtype
M0
M1
M2
M3
M4
M5
M6
RAEB
Not determined
5
11
7
0
8
2
0
1
6
2
7
1
0
2
1
0
1
5
Karyotype group
t(15;17)
t(8;21)
inv(16)
Complex (>5 chromosomal abnormalities)
Normal karyotype
Other chromosomal abnormalities
Not determined / unknown
0
2
4
4
7
6
17
0
0
0
1
2
2
14
Total 40 19
Table 4.1: Details of AML patients included in the variant and protein analysis of
TCF7L2.
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4.3.2 Determination of TCF7L2 mRNA splice variants by PCR
The total RNA yield was determined for each sample using a Nanodrop
spectrophotometer with a purity between 1.7 to 2.0 as determined by A260/A280. For the
cDNA synthesis, 500 ng of total RNA was reversed transcribed (see 2.5.3). Two sets of
primers were used to amplify TCF7L2 mRNA. The primer sequences and their respective
Tm are shown in Table 4.2. The PCR reactions were performed using 5 l of the RT
product, 0.5 µM each of the forward and reverse primer (Eurofins MWG Operon,
Ebersberg, Germany), 200 µM of dNTP mix (Applied Biosystems®, Paisley, UK) , 1X PCR
buffer II (Applied Biosystems®, Paisley, UK), 1 mM of MgCl2 (Applied Biosystems®,
Paisley, UK) for N-terminus primer pair (or 0.9 mM for C-terminus primer pair), 0.5 units
of AmpliTaq® Gold DNA Polymerase (Applied Biosystems®, Paisley, UK) and made up to
a final volume of 25 l with sterile molecular grade water. The PCR reaction was carried
out in an Applied Biosystem thermal cycler. The sample reaction mix was then subjected to
Touch-down (TD) PCR cycling parameters as detailed in Table 4.3. PCR products or
amplicons from the N-terminus primer pair amplification were separated on a 2% (w/v)
agarose gel in 1X TBE buffer (Tris (89 mmol/L), boric acid (89 mmol/L) and EDTA (2
mmol/L), pH 8.3) at 120 V for 50 minutes. The PCR products amplified by the C-terminus
primer pair were separated on 3% (w/v) agarose gel for better resolution due to the shorter
amplicons generated.  DNA ladders (New England Biolabs, Hertfordshire, UK) of either 50
bp or 100 bp sizes were included in every electrophoretic run. The agarose gel was
visualised using ethidium bromide staining and ultraviolet (UV) light and digitised using a
Fujifilm LAS3000 imaging system.
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Table 4.2: Primer combinations used for variant screening and sequencing. Calculated
PCR size shown is based on TCF7L2 gene exon sequences published for NM_001146274.1.
Primer sequences were adapted from (Shiina et al, 2003).
N-terminus
5’ end
3 54 6 7 8 9 10 11 12 13 14 15 16 17 1821
forward forward
reverse reverse
C-terminus
3’ end
Figure 4.1: Schematic diagram illustrating the positions of both primer sets within the
TCF7L2 gene. The length shown for each exon in the diagram is approximate.
Type of
primer pair
Exons
coverage
Calculated size of full
PCR product without
exon skipping
(bp)
Primer sequences (5’ – 3’) Tm
°C
Forward ex1: AAT TGC TGC TGG
TGG GTG A 56.7N-terminus
(5’-Primary) exon 1 toexon 12
1213 bp product from
linear template
gi|226371763|ref|
NM_001146274.1
Reverse ex12:  TGC TCT TCT CTG
GAC AGT GC 59.4
Forward ex13: CAA GCA GCC GGG
AGA GAC 60.5
C-terminus
(3’-Tail)
exon 13 to
exon 18
151 bp product from
linear template
gi|226371763|ref|
NM_001146274.1
Reverse ex18: TGG GCT GAG GCA
GCT GCC TT 63.5
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Cycle parameters Temperature (C) Duration Cycle
Pre-incubation: 94 10 min (1 step x 1 cycle)
94 30 sec
70
(reduce 2ºC every 2
cycles)
30 sec
Touch-down PCR:-
(Part 1)
Melt:
Anneal:
Extension: 72 1 min
94 30 sec
70
(reduce 2ºC every 2
cycles)
30 sec
(Part 2: additional cycles
to stabilise the reaction
in Part 1)
Melt:
Anneal:
Extension: 72 1 min
(6 steps x 5 cycles)
94 30sec
60 30sec
Melt :
Anneal :
Extension : 72 1min
(3 steps x 35 cycles)
Final extension: 72 5min (1 step x 1cycle)
Hold: 4 - -
Table 4.3: TD PCR parameters used for PCR screening. TD protocol was characterised
by Part 1 and Part 2 that were added to the standard PCR cycling parameters. The annealing
temperature of the TD reaction was decreased by 2C every 2 cycles from 70C to a final
touchdown at 65C after 5 cycles. This helps to reduce the formation of heterodimers and
to increase the binding affinities of primers to the template DNA, particularly for long
sequences. The TD cycles were followed by standard PCR cycling of 35 cycles.
Chapter 4: Validation of TCF7L2 as a dysregulated WNT Signalling transcription factor in AML
__________________________________________________________________________
118
4.3.3 Sequencing of PCR products
4.3.3.1 PCR products above 100 bp
Selected samples were sequenced using either the N-terminus primer pair (exon 1
and exon 12) or the C-terminus primer pair (exon 13 and exon 18) depending on the PCR
product. In order to sequence a single band from a mixture of PCR products (indicated by
multiple bands on the gel), each band was excised (see 2.6.2). After gel purification, the TD
PCR step was repeated (see 4.3.2) using the gel purified DNA, to ensure specificity of each
excised band. The resulting single PCR product was then purified again using the
QIAquick PCR Purification Columns protocol (Qiagen®, West Sussex, UK) and sequenced.
PCR products that contained a single band on a gel were directly purified using the
QIAquick PCR Purification Columns protocol (Qiagen®, West Sussex, UK) described in
2.5.5 and sequenced according to steps described in 2.5.6.
4.3.3.2 PCR products below 100 bp
PCR products that contain a DNA amplicon of less than 100 bp were excised from
the gel according to methods described in 2.6.2 and cloned into the appropriate plasmid
vector (see 4.3.4). Plasmid DNA from at least two clones was selected for sequencing using
universal M13 forward and reverse primers (see 2.5.6). The pDrive cloning vector map
showing the position of the M13 primer pair site is available in Supplementary 4.1 material.
4.3.4 PCR cloning
PCR cloning allows small products (< 100 bp) to be sequenced more efficiently.
PCR products of less than 100 bp were excised from the gel and cloned into pDrive vector
using the Qiagen PCR Cloning Kit (Qiagen®, West Sussex, UK) in accordance with the
manufacturer’s instructions.  In brief, after PCR reaction, a single band was purified from
3% (w/v) agarose gel according to 2.6.2. For ligation, 13 ng of gel purified PCR products
were mixed with 50 ng pDrive plasmid vector, 5 µl ligation master mix (2X) and sterile
water to a final volume of 10 µl. The ligation reaction mixture was gently mixed and then
incubated at 4°C for 30 minutes before proceeding to transformation and plasmid
purification (see 4.3.4.1 - 4.3.4.2).
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4.3.4.1 Transformation using EZ Competent Cells
Following ligation incubation, 2 µl of the ligation reaction mixture was added into
one vial of Qiagen® EZ Competent Cells, mixed gently and incubated on ice for 5 minutes.
The cells were then heat shocked for 30 seconds in a 42C water bath without shaking and
returned on ice for 2 minutes. Following that, 250 µl of SOC medium was immediately
added to the transformation mixtures and directly plated. Between 50 µl and 100 µl of
transformation mixture was spread onto pre-warmed LB agar plates containing 100 µg/ml
ampicillin, 80 µg/ml X-gal and 50 µM IPTG. The plates were incubated in a 37C
incubator for 16 hours. Plasmid incorporating the PCR products in the correct orientation
produced white recombinant colonies instead of blue colonies.
4.3.4.2 Small scale plasmid purification
Colonies of interest were picked from LB agar plates and inoculated into 5 ml of LB
broth containing 100 µg/ml ampicillin and incubated at 37C overnight with a shaking
speed of 220 rpm. After overnight incubation, the bacterial pellet was harvested from 3 ml
culture by centrifugation at 10,000 x g for 10 minutes at RT. Plasmids were purified
according to the QIAprep Spin Miniprep Kit (Qiagen®) protocol. In brief, the pellet was
resuspended in 250 µl of chilled Buffer P1 and transferred to a fresh microcentrifuge tube.
After cell clumps and pellets were completely resuspended by vortexing, 250 µl of Buffer
P2 was immediately added and the tube was gently inverted for mixing. Subsequently, 350
µl of Buffer N3 was added, gently mixed and the tube was centrifuged for 10 minutes at
10,000 x g. A clear supernatant containing plasmid DNA was transferred on to the QIAprep
spin column by pipetting and centrifuged at 10,000 x g for 1 minute. The QIAprep spin
column was washed by adding 0.5 ml Buffer PB followed by 1 minute of centrifugation.
Plasmid DNA was precipitated by the addition of 0.75 ml Buffer PE and centrifugation at
10,000 x g for 1 minute. The tube was spun twice to remove residual ethanol from Buffer
PE. Plasmid DNA was eluted from the column by adding 50 µl Buffer EB (10 mM Tris-
HCl, pH 8.5) to the centre of each QIAprep spin column followed by a final 1 minute
centrifugation.
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4.3.5 Analysis of nucleotide and protein sequences
The formal scientiﬁc name for TCF7L2 transcript and protein was used according to
HGNC guidelines and the National Centre for Biotechnology Information (NCBI)
nucleotide database at http://www.ncbi.nlm.nih.gov/nuccore. The length of each exon, exon
numbering, and exon sequences were obtained from NCBI and summarised in
Supplementary 4.2. Base calling quality checks of DNA sequences obtained from
sequencing were processed and assembled using the BioEdit Sequence Alignment Editor
version 7.0.9.0. DNA sequence multiple alignment, similarity search, translation and
identification of open reading frames (ORFs) were conducted using both pDRAW32 1.0
revision 1.1.114 by AcaClone software (www.acaclone.com) and the Clustal Omega
Multiple Sequence Alignment programme available at
http://www.ebi.ac.uk/Tools/msa/clustalo/ (Larkin et al, 2007).  The search for regions of
similarity using Protein BLAST was performed in http://www.uniprot.org/blast/uniprot/ and
the nucleotide BLAST search was performed in http://blast.ncbi.nlm.nih.gov/. The protein
sequences properties (eg: MW,  residues, charge, isoelectric point) were retrieved from
http://www.bi.up.ac.za/cgi-bin/emboss.pl?_action=input&_app=pepstats.
4.3.6 Determination of TCF7L2 protein expression
In order to assess cellular localisation and to detect different isoforms of TCF7L2
protein, nuclear and cytosolic proteins were extracted from each sample using the method
described in 2.8 and employed for western blotting. Details of AML patients used for
protein analysis are listed in Table 4.1. The sources of normal BM and normal CD34+ HPC
were previously described in 4.3.1.  The different type of myeloid cell lines fractionated for
nuclear and cytosolic proteins were previously cultured and are described in Table 2.1. The
monoclonal antibodies used to detect TCF7L2 proteins and housekeeping genes Histone H1
and GAPDH by immuno-blotting are described in Table 2.3.
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4.3.7 Total  protein extraction using TEAB lysis buffer
Cell pellet derived from 20 x 106 cells were thawed and 2 µl of Benzonase (5 units
per 10 x 106 cells) was added directly to each pellet and mixed thoroughly. Tubes were
incubated on ice for 30 minutes and 100 µl of TEAB buffer (0.5 M TEAB, 0.05% (v/v)
SDS, protease inhibitor cocktail, phosphatase inhibitor cocktail) was added. The mixture
was incubated for another 30 minutes on ice and vortexed every 10 minutes. The cell
lysates were then centrifuged at 4°C for 10 minutes at 10,000 x g. Potein supernatants were
aspirated into fresh tube and stored at -80°C.
4.3.8 Quantitation of TCF7L2 protein expression in AML vs normal samples
The amount of TCF7L2 protein expressed in AML was compared to normal samples
(BM and CD34+ HPC). For this purpose, TCF7L2 protein expression in both cytosolic and
nuclear fractions were quantified using western blotting and densitometry as described (see
2.8.2). All values for the raw protein signals were corrected from the background integral
of the peak (Integral-Bkg signal unit), as determined by densitometry using the Advanced
Image Data Analyzer software v4.5 (Raytek Scientific, Sheffield, UK). In order to
compensate for variation between different transfers and different primary antibody
detections, a control protein extract derived from Jurkat cells was selected as a standard for
inter-blot calibration. The Jurkat unfractionated lysate produced a strong signal at 72 kDa
and 58 kDa when probed with TCF7L2 antibody, both anti exon 11 and exon 1 TCF7L2.  In
each sample, densitometric signal values obtained from each protein band were first
normalised to the Jurkat signal; this was performed separately for 72 kDa and 58 kDa bands.
Normalised values were further standardised to the amount of total protein loaded (in µg)
for each sample. Normalised total protein was defined by the sum of 72 kDa and 58 kDa
isoforms detected in both subcellular fractions per sample.
4.3.9 Correlation of TCF7L2 mRNA and protein expression
A total of 19 AML patient samples (as in Table 4.1) were chosen for this correlative
analysis.  The protein samples were processed and quantified as described (4.3.8). The
RNA samples from this cohort of AML patients were processed as described in 4.3.1. The
qRT-PCR protocol and data analysis were performed similarly to the method described
previously in 3.3.5. Due to the small number of samples, the normalised total protein data
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didn’t meet the assumptions required for parametric test and was positively skewed to the
right (data not shown).  Therefore, the normalised total protein values were log transformed
and compared to the Log2 normalised qRT-PCR data. The SPSS compute commands and
guidelines were used when transforming data (Tabachnick & Fidell, 2007):-
Substantially positive skewness : use Logarithmic (Log 10)
SPSS commands: NEWX = LG10(X)
4.3.10 Statistical data analysis
The degree of correlation between paired variables (normalised total TCF7L2
protein vs normalised mRNA) was assessed using Spearman’s coefficient (R).  Test of
significance were obtained through Fisher’s Z transformation. The significance of
differences when comparing two unpaired groups was calculated using the Mann-Whitney
Test, and a value of P <0.05 (two-sided) was considered statistically significant. Analyses
were performed in SPSS for Windows version 11.5 (SPSS Inc., Chicago, USA).
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4.4 RESULTS
4.4.1 Expression of TCF7L2 mRNA 5’ variants in AML and normal haematopoietic
cells
Exon skipping of TCF7L2 has previously been shown to generate multiple mRNA
TCF7L2 transcripts in normal murine neonates (Weise et al, 2010), in adult mice (Nagalski
et al, 2012) and in several solid tumours (Shiina et al, 2003; Tsedensodnom et al, 2011). To
investigate whether this is also the case in AML and normal HPC, this study examined 40
AML patients, five myeloid cell lines and compared with these normal HPC. TCF7L2
mRNA variants were examined by amplifying cDNA using two sets of primers (N-terminal
and C-terminal primer sets), inherent exon complexity being too intractable to be resolved
by just a single primer set. Exons located near to the 3’ tail (or C-terminus) are mostly
alternatively spliced with high GC content sequences that hamper perfect amplification of
the whole gene using a single primer set. The N-terminus primer set amplified exon 1
through to exon 12 and thus was able to detect splicing within the 5’region sequence or the
primary sequence (refer to Figure 4.1). In addition to complete loss of an exon through
splicing, alternative types of exonic variants (namely type-a or -b) were also investigated for
the presence of exon 8 and exon 10.
Results of the N-terminus amplification show that multiple TCF7L2 transcripts were
detected in mRNA isolated from both leukaemic and normal haematopoietic samples.
Representatives of the PCR product banding patterns are shown in Figure 4.2. Nineteen
(47.5%) AML patients produced PCR products of 1128 bp, 15 (37.5%) AML patients
generated shorter products (ranging from 350bp – 600 bp), and six (15%) AML patients
generated a combination of 1128 bp with the shorter products. Four (80%) out of five
myeloid cell lines produced 1128 bp product and only one cell line generated a product of
approximately 350 bp in length. For normal CD34+ HPC, 50% of the samples produced
product of 1128 bp whilst the remaining had a combination of 1128 bp with the shorter
variants. Normal BM produced only the 1128 bp with the exception of one sample which
had a slightly longer product of 1197 bp. To confirm the identity of these PCR products
which covered only from exon 1 until exon 12 (i.e. primer set N-terminus) as mentioned
earlier, DNA sequencing was carried out. PCR product that contained DNA sequences with
complete open reading frame (ORF) were given a code (eg: P1), and PCR products
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containing premature intervening stop codons were excluded from this analysis.
Sequencing of the 1128 bp PCR product confirmed its homology with the published
TCF7L2 transcript variant 2, mRNA (NM_030756.4) from NCBI for the region covered by
the primer pair; hereafter referred to as type P1 as shown in Table 4.4. Protein translation of
this 1128 bp product sequence (or type P1) consistently generated a complete ORF (without
intervening stop codons between exons). The one normal BM sample with the longest bp
detected so far (1197 bp) was shown to retain a full exon 4 as detected by sequencing.  The
variable presence of exon 4 doesn’t cause any changes in the downstream ORF apart from
the local codon insertion. BLAST search showed that the region from exon 1 to exon 12 of
this variant had 100% similarity to TCF7L2 transcript variant 1 (NM_001146274.1) and
variant 13 (NM_001198531.1), hereafter referred to as type P2.  Sequencing of all samples
confirmed the presence of exon 8 variant type-b which is longer than variant type-a.
Similarly, all samples also harbour exon 10 variant type-b which is shorter than variant
type-a, as defined by NCBI.
For the shorter PCR products (350 bp – 600 bp), sequencing data show that,
irrespective of combination of exons, only one product actually had a complete ORF
however this sequence has not been published in NCBI.  This transcript (369 nucleotides)
was referred to as type P3. The exonic identities of all these sequences are shown in Table
4.4.
To conclude, the most frequently detected transcript for the 5’-primary region of
TCF7L2 seen in AML blasts and in normal samples contains 1128 nucleotides. Sequencing
of this transcript has confirmed the inclusion of exons 1 - 12 with a consistent loss of exons
4 and 6. All samples showed the presence of exon 8 variant type-b and exon 10 variant
type-b. The next section will further characterise the splicing at the 3’-end of TCF7L2 gene.
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Figure 4.2: Representative PCR products showing variants of TCF7L2 amplified by
the N-terminus primer set. (A) Gel showing presence of the 1128 bp product. (B) Gel
showing combination of the 1128 bp product and shorter products. (C) Gel showing AML
and cell line sample (THP-1) with shorter PCR products. Ladders indicate product size in
bp and all gels were electrophoresed using 2% (w/v) agarose.
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Table 4.4: Comparison of 5’- primary sequence exon combinations that give rise to
complete ORF. Exons shown were based on sequencing data. The predicted MW (kDa)
was calculated from the start codon `ATG’ in exon 1 until the last codon encoding exon 12.
For type P3, the sequences within exon 1 and 10 were truncated, indicated by dashed line
(red).
Exons combination of TCF7L2 5’- primary sequence confirmed by sequencing Type ofvariant
PCR
product
length in
bp
Present
in
AML?
Present
in
Normal?
P1 1128 Yes Yes
P2 1197 No Yes
* exon 1 and exon 10 were truncated (shown above)
P3 369 Yes No121110a/b1
4 952 31 1110b 128b7
95 1110b732 128b1
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4.4.2 Complex exon combinations were detected at the C-terminus region of
TCF7L2
Previous reports have shown that splicing of various exon combinations could occur
between exons 14 and exon 18 of the C-terminus resulting in a shift within the ORF,
therefore the proteins will utilize different stop codons within exon 18 (Shiina et al, 2003;
Arce et al, 2006; Weise et al, 2010). To further verify the molecular diversity of variants
expressed in the C-terminus region in AML blasts, PCR amplification and sequencing was
performed and the identity of each sequence was compared to the published nomenclature
of the C-tail TCF7L2 variants (Weise et al, 2010). The highly diverging C-termini of
TCF7L2 had been reported to generate alternative splicing exons known as C-tail-E (E1-
E4), C-tail-M (M1-M3) and C-tail-S (S1-S8).
Results from C-terminus PCR  show that, in contrast to the multiple patterns of PCR
banding produced at the N-terminus, all samples amplified using the C-terminus primer
produced only one pattern of PCR banding (consisting of four bands) as detected by gel
electrophoresis (Figure 4.3A). To independently characterise each PCR band, gel excision
followed by a second round of TD PCR (as described in 4.3.2) was performed for each PCR
band prior to sequencing. Gel electrophoresis following the second round of TD PCR
reproduced similar PCR products, now as individual bands of the following sizes: 200, 150,
125 and 80 bp (Figure 4.3B). These individual bands were successfully purified and
sequenced. Together, this suggests that the four PCR products were genuine variants.
However, due to the identical sizes of exons 15 and 16 (i.e. 73 bp), the identity of variants
carrying either one of these two exons could not be determined by size alone.
Following DNA sequencing, splicing patterns were compared between leukaemic
and normal samples. Results as summarised in Table 4.5 illustrate the exon composition for
all four bands found in leukaemic and normal samples. The 125 bp and 80 bp PCR products
were similar between AML, cell lines and normal samples. However, sequencing data for
the other bands (200 bp and 150 bp) showed that exon 15 and 16 are mutually exclusive and
inclusion of exon 15 was observed only in the leukaemic cells. The presence of exon 17
was not detected in all samples analysed. In terms of the nomenclature, the 80 bp band was
confirmed to be the correct tail for the variant carrying the C-tail-M1 as published
previously, whilst the 125 bp was confirmed as a correct tail belonging to the variant
carrying the C-tail-M2.  The 150 bp band was confirmed to be either the C-tail-E1 or E3 and
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finally, the 200 bp was found to be the correct sequence for either C-tail-E2 or E4.  This was
done by combining BLAST search with previous literature on nomenclature.
Data obtained from DNA sequencing were subjected to further analyses. The
prediction of MW is made based on the DNA sequences. The protein coding region of the
aforementioned six variants (C-tail E1-E4, M1 and M2) were compared as illustrated by
multiple alignments in Figure 4.4. The C-tail-E1 and E3 induce in-frame deletion of the
protein sequence after exon 13 and give rise to an exon 18 that harbours a stop codon at a
position similar to type E2 and E4. The C-tail-M1 and M2 will induce out-of-frame protein
sequence after exon 13 and exon 14 respectively, therefore creating a stop codon within
exon 18 at earlier position.
The combined data obtained from both primer sets (section 4.4.1 and section 4.4.2)
generate the full length TCF7L2 sequences, as presented in Figure 4.5. Because the 5’-
primary sequence type P1 was detected in both AML and normal samples, this transcript
was further analysed to determine sequences of the full length TCF7L2. The relationship
between 5’-primary sequence type P1 joined to different 3’- tails (or C-tails) is predicted to
generate six different protein isoforms with MW varying from 56 kDa to 72 kDa.
In terms of functional roles, only C-tail-E1, E2, E3 and E4 preserve the cysteines
within the C-clamp region identified by CRARF or CRALF motifs within exon 15 or exon
16 respectively. However only C-clamp with the CRARF motif (i.e. with exon 15) was
reported to cooperate with -catenin and the p300 complex for activation of downstream
target genes (Hecht & Stemmler, 2003).  No functional relevance has been reported for the
CRALF motif so far. Among the group of TCF7L2 C-tail variants detected, the inclusion of
exon 15 that gives rise to E1 and E2 was not detected in normal BM or normal CD34+HPC.
Even though the leukaemic samples produced all types of variants, the variants
incorporating exon 16 were more commonly detected among the cohort of AML samples
tested.
In summary, there are initially four bands detected by amplifying the 3’-tail region
using the C-terminus primer set. These four bands were shown to represent the C-termini of
six types of variants that, in turn, were predicted to generate six protein isoforms. The next
section will determine whether these predicted transcripts are being translated.
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Figure 4.3: TD PCR of TCF7L2 as amplified by the C-terminus primer set from a
representative AML sample. (A) Gel electrophoresis using 3% (w/v) agarose gel showing
presence of four PCR products (a-d) after initial TD PCR in the AML (and in all other
samples) (B) Gel electrophoresis after a repeat TD PCR confirmed the identity of each PCR
product a-d isolated from the agarose gel. Each product showed correct bp as seen by the
first round TD PC (200, 150 , 125 and 80 bp). The ladder shown here is a 50 bp ladder.
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Exon combination of TCF7L2 3’tail sequence confirmed by
sequencing
Type of
variant
PCR
product
length in
bp
Present
in
AML?
Present
in
normal
?
E2 200 Yes No
E4 200 Yes Yes
M2 125 Yes Yes
E1 150 Yes No
E3 150 Yes Yes
M1 80 Yes Yes
Table 4.5: Comparison of 3’ tail (or C-tail) exon combinations seen in AML,
leukaemic cell lines and normal samples (BM and CD34+ HPC).  Exons shown were
based on sequencing data.  The NLS motif is shown in purple, the cysteine rich C-clamp
motifs are shown in green (CRARF) and yellow (CRALF) , the RKKKC motif at the start of
exon 18 is shown in grey, Ctbp binding motif is shown in blue and stop codon is shown by
the symbol “S”. The nomenclature for E1-E4 and M1-M2 is from(Weise et al, 2010)
13 14 18
13 15 18
13 14     18
13 14 15 18
13
13 18
18
16
16
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C-tail-E2 GKKKKRKRDKQPGETNEHSECFLNPCLSLPPITDLSAPKKCRARFGLDQQNNWCGPCRRKKKCVRYIQGEGSCLSPPSSDGSLL////QPQPLSLVTKSLE.STOP
C-tail-E4 GKKKKRKRDKQPGETNEHSECFLNPCLSLPPITDANTPKKCRALFGLDRQTLWCKPCRRKKKCVRYIQGEGSCLSPPSSDGSLL/////QPQPLSLVTKSLE.STOP
C-tail-E1 GKKKKRKRDKQPGETN---------------------------- -DLSAPKKCRARFGLDQQNNWCGPCRRKKKCVRYIQGEGSCLSPPSSDGSLL/////QPQPLSLVTKSLE.STOP
C-tail-E3 GKKKKRKRDKQPGETN------------------------------DANTPKKCRALFGLDRQTLWCKPCRRKKKCVRYIQGEGSCLSPPSSDGSLL/////QPQPLSLVTKSLE.STOP
C-tail-M2 GKKKKRKRDKQPGETNEHSECFLNPCLSLPPIT--------------------------------------------------GEKKSAFATYKVKA AASAHPLQMEAY.STOP
C-tail-M1 GKKKKRKRDKQPGETN--------------------------------------------------------------------------------.GEKKSAFATYKVKA AASAHPLQMEAY.STOP
Figure 4.4: Multiple sequence alignments showing predicted amino acid sequence diversity starting from exon 13 until exon 18. Shown are
the four types of 3’-tails (or C-tail-E) that encoded motifs for the C-clamp region and other target binding regions (C-tail E1 – E4).  The cysteine
motifs are highlighted in green and yellow, the NLS motif is highlighted in grey and the CtBP binding motif is highlighted in blue.  The alternate
exons are boxed. The amino acids encoding exon 18 of C-tail E1 - E4 were cropped to fit in the illustration.  The position of each stop codon is
highlighted in red.
Cysteines - clamp region
EXON 13                  EXON 14                          EXON 15 / 16                                           EXON 18
Chapter 4: Validation of TCF7L2 as a dysregulated WNT Signalling transcription factor in AML
__________________________________________________________________________
132
4.4.3 Investigation at the protein level identifies 72 kDa, 58 kDa and 56 kDa
TCF7L2 protein isoforms in AML patients
The data above suggest that six protein isoforms are predicted to be expressed in
AML, illustrated in Figure 4.5B.  To determine whether these were expressed at the protein
level, western blotting was performed (see 4.3.6) and nuclear / cytosolic lysates were probed
with a TCF7L2 monoclonal antibody raised to an epitope surrounding Leu330 in exon 11.
A predominant 58 kDa protein band was detected in 19 AML blast nuclear fractions
but not in the cytosol following probing with exon 11 antibody. A 72 kDa protein was also
expressed but only found in the cytosolic fraction (Figure 4.6A).  Doublets of protein bands
at approximately 56 kDa and 58 kDa were also seen in several AML samples, suggesting
co-expression of different isoforms (see below). Several AML samples also expressed both
72 kDa and 58 kDa proteins in the nucleus, depicted by AML samples in lanes 6 – 7 in
Figure 4.6B. There was no consistent banding detected at lower than 56 kDa, suggesting
that any shorter isoform of less than 56 kDa (if any) is not being translated efficiently (see
Figure 4.6B).
The data above demonstrate that all bands detected by SDS-PAGE were
approximately 7 kDa larger in size than the predicted MW. The heaviest TCF7L2 protein
observed was 72 kDa and could possibly match the predicted 65.3 kDa (or 65.4 kDa)
isoform. Detection of similar isoforms by other studies has also shown the presence of 72 –
75 kDa (instead of 65 kDa) in nuclear but not cytosolic fractions (Weise et al, 2010).
Likewise, there is only 72 kDa in whole protein lysates (Struewing et al, 2010;
Tsedensodnom et al, 2011). The MW seen in the western blot is also 7 kDa higher than the
size indicated in UniProt (eg: TCF7L2 Isoform 8, Q9NQB0-8).  Possibly, this protein
migrated slower than predicted when electrophoresed under SDS-PAGE, due its highly
charged nature. As for 56 – 58 kDa isoforms, other studies (Vacik et al, 2011; Le et al,
2011a) had indicated presence of TCF7L2 bands at around this same region when probed
with TCF7L2 antibodies.
In summary, the distribution of TCF7L2 protein isoforms found in AML
encompassing exons 1 – 18  of the full length gene follow the PCR variant exon
composition data where it generates the 72 kDa, 58 kDa and 56 kDa isoforms seen in
western blot.
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Figure 4.5: Schematic diagram showing a summary of TCF7L2 expression. (A)
Established exons of TCF7L2 are represented as white rectangles, commonly absent exons
are shown in yellow and alternative exons as blue shaded rectangles. Protein domains are
indicated below the corresponding exons. Exon numbers in red font indicates the presence
of dual variants. (B) Exon combinations used to predict the ORF for each TCF7L2 isoform
with corresponding protein MW. Predicted MW (italic) was calculated from the first
“ATG” in exon 1 until the stop codon in exon 18. The apparent MW (in parentheses) at
which these protein run on SDS PAGE (and western blotting probed with exon 11
antibody). Only full combinations of 5’-primary sequence (or type P1) joined to different
type of 3’- tails (or C-tail) detected by sequencing are shown.
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Figure 4.6: Distribution of nuclear and cytosolic TCF7L2 protein isoforms detected by
western blotting in AML. Protein extracts were prepared from indicated patients and the
blots were probed with a monoclonal TCF7L2 antibody (exon11 epitope). Loading controls
used to show the purity of each fraction were probed with GAPDH and Histone H1. (A)
Cytosolic and nuclear protein extracts were prepared from primary AML samples with
different FAB subtypes (M0-M5). (B) Seven nuclear extracts of AML samples of FAB M1
(not listed in Table 4.1) and protein lysates were extracted using the TEAB buffer method
(see 4.3.7), 20 µg protein was loaded and probed with TCF7L2 antibody (exon11 epitope).
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4.4.4 Expression of the 72 kDa and 58 kDa TCF7L2 isoforms correlates with
TCF7L2 mRNA expression.
The previous chapter correlated TCF7L2 microarray expression (spanning exon 5 –
10) with qRT-PCR data derived from a similar region. Here, mRNA expression was
correlated with expression at the protein level (as described in 4.3.9). These data (Figure
4.7) show a positive correlation between normalised mRNA (analysed by qRT-PCR) and
protein expression (sum of 58 kDa and 72 kDa) in AML patient blasts (R=0.498, P= 0.042
using Spearman correlation coefficient). These findings suggest that expression of TCF7L2
protein is regulated at the transcriptional level.
Figure 4.7: Correlation between TCF7L2 protein and mRNA expression. Correlation
was done using normalised Log10 total protein expression of TCF7L2 72 kDa and 58 kDa
(detected by exon 11 / Leu330 epitope) and normalised Log2 mRNA expression using
matched AML patients (n=19). Spearman correlation, R=0.498; P < 0.05.
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4.4.5 Expression of TCF7L2 protein isoforms in normal haematopoietic cells
In order to determine whether TCF7L2 protein isoforms are aberrantly expressed in
AML, it was necessary to analyse expression in normal haematopoietic cells. A total of
four normal BM and four CD34+ HPC were included in the analysis. Due to the different
localisation of protein, expression of isoforms was measured separately for nuclear and
cytoplasmic protein fractions.
As seen in Figure 4.8, normal cells express the similar predominant 56 or 58 kDa
nuclear protein as seen in AML, thus being consistently detected when probed with TCF7L2
exon 11 antibody. The normal cells also expressed the 72 kDa protein in their cytosolic
fractions.
Each band detected in the cytoplasmic and nuclear fraction was quantified (see
4.3.8) and analysed separately. When comparing the relative level of TCF7L2 protein
expression between AML and normal samples, the mean protein expression in AML is
lower than in normals (both total BM and CD34+ HPC).  However, AML subtype M0 was
found to be expressing higher levels of TCF7L2 protein than normals (denoted by outlier
values), whereas other subtypes of AML generally produced lower mean protein expression
for both isoforms (Figure 4.9 - Figure 4.10). The mean protein expression of normal CD34+
HPC was apparently high as compared with AML and total BM. Work performed since
these experiments were completed show this unexpected conclusion is likely to be
erroneous (see Discussion section 4.5); additionally this could result from the use of
cultured normal controls for western blotting. There were insufficient cells and samples to
perform nuclear extraction from fresh normal CD34+ HPC derived from CB. Similarly,
total BM is not a perfect match for blasts AML as it contains only a small proportion of
blasts.
In summary, protein isoforms detected in normal cells are similar to those in AML.
Due to sampling limitations, the relative expression of these isoforms between AML and
normal is inconclusive at the protein level (see Discussion).
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Figure 4.8: Distribution of nuclear and cytosolic TCF7L2 protein isoforms detected by
western blotting in normal BM and CD34+ HPC. (A) Normal BM sample with cytosolic
and nuclear protein extracts, probed with exon 11 TCF7L2 monoclonal antibody. (B)
Normal CD34+ HPC day 5 culture sample with cytosolic and nuclear protein extracts,
probed with exon 11 TCF7L2 monoclonal antibody. Loading controls used to show the
purity of each fraction were probed with GAPDH and Histone H1.
72 kDa
56/58 kDa
Chapter 4: Validation of TCF7L2 as a dysregulated WNT Signalling transcription factor in AML
__________________________________________________________________________
138
4419N =
VAR00002
cbbmaml
VA
R0
00
01
700
600
500
400
300
200
100
0
-100
AML normal BM normal CD34+ HPC
Figure 4.9: Relative expression of 56/58 kDa nuclear TCF7L2 probed with exon 11
antibody. Statistical significance was calculated using the Mann-Whitney Test compared
to AML. • denotes data outlier. There is no significant difference in levels.
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Figure 4.10: Relative expression of 72 kDa cytosolic TCF7L2 probed with exon 11
antibody. Statistical significance was calculated using the Mann-Whitney Test compared to
AML, with *P <0.05. • denotes extreme value.
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4.4.6 Identification  of 56 kDa and 58 kDa isoforms as the dominant proteins
expressed in myeloid lines
The data presented so far show that endogenous TCF7L2 proteins are readily
detected in primary samples with different TCF7L2 isoforms being translated in both AML
and normal samples. In the nucleus, the two dominant TCF7L2 proteins (56 / 58 kDa) are
detected; however the functional consequences at the cellular level of these proteins are still
poorly understood.
Eight different myeloid cell lines were assessed by western blotting, in which
nuclear and cytosolic fractionation was performed similarly to 4.3.6. Either the 56 or 58
kDa isoform was found to be the most dominant isoform seen in the nuclear fraction of all
cell lines (see Figure 4.11). In this figure, a doublet band of 56 and 58 kDa was also visible
in NB-4 cells. Towards the end of this study, a number of improvements were made to the
nuclear and cytosolic protein extraction. The improved extraction procedure was able to
resolve the doublet much better than the old method and has helped to elucidate the banding
of 56 kDa and 58 kDa and also the absence of any TCF7L2 protein at lower molecular
weights, illustrated in the K562 cell line (Figure 4.12).
In summary, two TCF7L2 isoforms were expressed in the nuclear fraction and
TCF7L2 was absent from the cytosolic fraction in all myeloid cell lines tested. This finding
has given a clear picture of the overall expression of TCF7L2 in myeloid cell lines which
will assist further TCF7L2 functional studies in the next chapter.
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Figure 4.11: Distribution of nuclear and cytosolic TCF7L2 protein isoforms in myeloid
cell lines. Protein extracts were prepared from indicated cells and western blot analysis was
performed. The blots were probed with TCF7L2 antibody (exon11 / Leu330 epitope).
Loading controls used were anti-GAPDH and anti-Histone H1.
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Figure 4.12: Improved detection of TCF7L2 protein isoforms in the K562 myeloid cell
line. The blot was probed with TCF7L2 antibody (exon11/Leu330 epitope), and extracted
using improved TEAB buffer protocol (see 4.3.7). Image is courtesy of Dr Richard Darley.
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       Ladder        K562
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4.5 DISCUSSION
4.5.1 Comparison of TCF7L2 alternative splicing in AML and normal samples.
The study here revealed that within normal HPC and AML samples, a number of
TCF7L2 variants are generated as a result of splicing at both the N-terminus (or 5’-primary)
and the C-terminus (or 3’-tail). At the region near to the N-terminus, the complete length of
cDNA amplified by the method used is 1128 bp (5’-primary type P1 as illustrated in Table
4.4) representing exon 1 – exon 12 with consistent absence of exons 4 and 6 confirmed by
sequencing in both normal HPC and AML.  Using the same primer pair, Shiina et al
reported there was no splicing variant across exons 1 – exon 12 in other renal cancer cell
lines; A498, Caki-1, and Caki-2 (Shiina et al, 2003), showing differential variant expression
in different cancer types.
Comparative studies of haematopoietic cells have not been published.  In this study,
both exon 4 and exon 6 are found to be commonly absent in normal samples and also in
AML blasts. With the exception of one normal BM sample where exon 4 was detected;
however, the protein sequence encoded by exon 4 does not comprise any known functional
domain as revealed by a BLAST search. Other types of tissue exhibited only the loss of
exon 4 but not exon 6, such as in hepatocellular carcinoma and in zebrafish (Young et al,
2002). The presence of exon 4 and absence of exon 6 has been reported in murine intestinal
eplithelia (Nazwar et al, 2009) and in human pancreatic islets with pro-apoptotic phenotype
(Le et al, 2011b). In addition, differential expression of exon 4 and exon 6 has been
implicated during developmental stages in which exon 4 is lowest in foetal endothelial cells
and highest in adult endothelial cells (Struewing et al, 2010).
Apart from the identification of 5’-primary type P1 and P2 (see Table 4.4),
electrophoreses data also revealed an abundance of shorter DNA bands. Sequencing had
confirmed only one PCR product of 369 bp to be informative, given the name ‘type P3’ (i.e.
with a correct ORF without intervening stop codons). This transcript showed loss of exon 2
through to exon 9 and was only detected in leukaemic cells not in the normal samples
tested. The functional significance of this variant is unknown, although co-repressor
proteins Groucho and TLE have been reported to interact with TCF within this missing
region and in the HMG domain within exon 12 (Daniels & Weis, 2005); however, one
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functional study conducted in epidermal cells suggested that the absence of the Groucho
domain did not affect transcriptional activity (Nguyen et al, 2009).
Depending upon the exon combinations near to the C-terminus, different ORFs are
used for translation of exons 15, 16 and 17. Previous reports have used this distinction to
classify TCF7L2 transcripts into three groups giving rise to TCF7L2 with C-tail-E, TCF7L2
with C-tail-M and TCF7L2 with C-tail-S protein isoforms (Tang et al, 2008; Weise et al,
2010). Normal HPC and AML also differ by their C-terminus (or 3’-tail) exon
combinations. Sequencing data from the C-terminus primer revealed that there are two
variants with complete C-clamp found in both AML and cell lines but not in normal
samples.  These are the C-tail-E2 and C-tail-E1 that harbour a CRARF motif.  The other
variants, namely C-tail-E3 and –E4 that display a CRALF motif were detected in AML, cell
lines and normal samples.  CRALF harbours an incomplete C-clamp and its function has not
been extensively studied.
TCF7L2 with C-tail-M variant which lack both CRARF or CRALF motifs was also
detected by PCR and sequencing in both AML and normal samples. This short C-terminus
isoform lacks a functional C-clamp and was not able to bind to the coactivators, p300, and
has also been reported to produce decreased activation of WNT/β-catenin target gene
promoters (Hecht & Stemmler, 2003). Taken together, the existence of function-specific
variants of TCF7L2 could produce distinct effects affecting promoter-specific
transactivation and cell phenotype.
4.5.2 Predicted and observed TCF7L2 protein isoforms.
Western blot analysis was performed to confirm TCF7L2 protein expression in
AML and normal samples. As presented in Figure 4.5, the combination of C-tail-E2 or C-
tail-E4 with the N-primary type-P1 (the most prevalent N-terminus variant confirmed by
sequencing) was predicted to produce a protein of 65 kDa. The heaviest protein detected by
western blotting migrated at 72 kDa. This isoform was found to be expressed in all normal
HPC and BM, but only in 61% of AML samples analysed. The significance of the 72 kDa
protein in AML is still unknown but CtBP has been described to interact with the domain in
the C-tail-E of this isoform to repress expression of certain target genes (e.g. NKD) in the
absence of WNT stimulation in parallel with Groucho (Fang et al, 2006).  In addition to
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repression, the nuclear coactivator also binds to the C-tail-E to promote CDX1 promoter
activation showing coupling effects of this protein.
In relation to the published variants, there are at least 13 transcripts of TCF7L2
published in NCBI, and the UniProt entry describes 12 predicted protein isoforms produced
by TCF7L2 alternative splicing. The closest match to the longest variant carrying C-tail-E2
(seen as 72 kDa by western blotting) shows 100% similarity to the transcript variant 2,
mRNA (NM_030756.4), as supported by BLAST search. A protein sequence similarity
search in Uniprot also showed 100% homology to TCF7L2  Q9NQB0-8 isoform 8, a fully
reviewed protein, suggesting that the 72 kDa isoform described in this study is the full
length transcript, and C-tail-E2 is the most described E-tail for full length TCF7L2.  At
transcript level, sequencing revealed that C-tail-E2 (containing exon 15) was only found in
AML and cell lines but not in normal samples. This suggests the presence of a domain
which may be of regulatory significance in leukaemia.
Very limited studies were performed using C-tail-E4, although this isoform could
also be equally expressed. The 72 kDa C-tail-E4 protein (with exon 16) had only 99%
similarity to transcript variant 2, mRNA (NM_030756.4) and no perfect match was found in
NCBI database. The closest match is 99% similarity to TCF7L2 Q9NQB0-8 isoform 8,
with variation of amino acid between position 435 until 455. Whilst this C-tail-E4 isoform
has not been fully reviewed, it is impossible to distinguish the 72 kDa isoform derived from
C-tail-E2 or C-tail-E4 by migration alone.
The combination of alternative exons in the C-terminus (or 3’-tail) produced
different ORFs which modified the reading frame in exon 18 and lead to another shorter
group of proteins identified as C-tail-M. For AML, 67% samples expressed this protein at
nuclear level identified as 56 kDa or 58 kDa isoforms by western blotting. In some AML
cases (~15%), doublets of protein bands were seen to migrate between 56 and 58kDa
suggesting the expression of C-tail-M1 and C-tail-M2 respectively in combination with the
common N-primary type-P1. The detection of this doublet is consistent with previous
reports that have shown to be near identical MW to the variants within the TCF7L2 with C-
tail-M group, and which was resolvable by SDS-PAGE (Tsedensodnom et al, 2011). This
protein was found to be strongly expressed in both cell lines and normal cells. In line with
other studies, C-tail-M was expressed in U937 cells (Baek et al, 2009) and detected only in
nuclear fractions (Golan et al, 2004; Shitashige et al, 2007).
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Similarity search showed that the putative 56 kDa transcript is 100% similar to
variant 6 (NM_001146286.1), with 100% homology to T-cell factor-4 variant B
(B4DRJ8_HUMAN) which is an unreviewed protein, published in UniProtKB/TrEMBL,
whereas the 58 kD transcript has a 100% similarity to transcript variant 11, mRNA
(NM_001198529), and the closest match in Uniprot is TCF7L2  Q9NQB0-10 isoform 10, a
fully reviewed protein but only with 99% homology.  The amino acid variation starts from
position 233 until 236. In the context of AML, it is still unclear which isoforms might play
the critical role in predisposition to TCF activation instead of repression.
4.5.3 Differential expression of TCF7L2 protein
TCF7L2 has been reported to be differentially expressed in colon and neural cells
and different splicing events were detected during development. In normal HPC, high
expression levels of both 72 kDa and 56 / 58 kDa TCF7L2 were detected in early CD34+
culture (day 5), owing to the growth factor enriched culture condition, where the cells were
actually harvested for western blotting. Day 13 cultures (and later) derived from CD34+
cells are devoid of TCF7L2 expression that may equate to more differentiated status
(Supplementary 4.3).  Differential TCF7L2 expression with development has been observed
in other tissue types.  The intestinal epithelium is an example of tissue showing a highly
restricted expression pattern related to the developmental stage. Strong TCF7L2 expression
was present within the crypts of early human foetal small intestine (Barker et al, 1999;
Barker et al, 2000), with the villi showing barely detectable TCF7L2 protein levels.
Conversely, TCF7L2 expression levels increased in the more developed villi suggesting
presence of differential TCF7L2 expression.
Electrophoretic mobility on SDS-PAGE indicated a MW 7 kDa higher than the
predicted value. For example, the longest isoform was predicted to be 65 kDa in
accordance to the value published for TCF7L2  Q9NQB0-8 idsoform 8 but migrated at 72
kDa in SDS-PAGE.  This behaviour on SDS-PAGE appeared to be due to the large positive
charge of this protein counteracting the negative swamping charge of the SDS and hence
slowing migration.  Studies have also suggested low electrophoretic mobility of some
proteins due to disordered N- and C-terminal domains (Iakoucheva et al, 2001). Incomplete
unfolding of proteins in SDS and poor binding of the detergent rather than to an unusual
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shape of the SDS-protein complex can also be the cause of the abnormal protein
migration (Matagne et al, 1991).
Subcellular localisation of TCF7L2 was not specifically examined in vertebrate
studies but TCF is abundant in nuclear extracts from NLK activated cells (Ishitani et al,
2003).  Consistent with findings from other studies, the shorter isoforms that migrated at 56
-58 kDa were also found to be expressed in the nucleus, however there is no literature to
support localisation of TCF7L2 protein in the cytosol. The presence of the 72 kDa band in
the cytosol is therefore contentious and subsequent work following completion of these
experiments has shown that this cytosolic banding is a likely artefact.  Hence the relative
expression analysis of TCF7L2 in AML and normals is probably incorrect given the much
higher levels of the “72 kDa isoform” detected in the cytosol of normal samples.  This
would suggest that the levels of TCF7L2 are in fact higher in AML than in normal samples
which would be consistent with the transcript analysis.
In summary, this chapter identified combinations of splicing events in the N- and C-
terminus region of TCF7L2 producing several variants and proteins which have been
reported to display differential DNA binding specificity and regulatory potentials. The
potential functional differences of these isoforms will be examined in the next chapter.
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5 - Functional Roles of TCF7L2 Isoforms
in Haematopoietic Cells
5.1 INTRODUCTION
Chapters 3 and 4 characterised the mRNA and protein expression of TCF7L2 in AML
and normal haematopoietic cells.  The identification of TCF7L2 isoform sequences
responsible for the observed protein expression in AML (Section 4.4.3) has led to the
investigation of its function as presented in this chapter.
Several reports in the literature support the role of TCF7L2 protein as a downstream
nuclear effector of WNT signalling in association with -catenin.  TCF reporters, containing
multiple TCF binding sites have shown activity specifically in response to -catenin
stabilisation (Korinek et al, 1997; DasGupta & Fuchs, 1999). This study employs a
lentiviral -catenin activated reporter (BAR) which stably integrates multiple TCF binding
sites coupled to a GFP reporter (Biechele & Moon, 2008; Biechele et al, 2009).
The rationale for studying TCF reporter activity is supported by the constitutive TCF
or LEF transactivation seen in carcinogenesis and in AML (Simon et al, 2005). WNT
signalling was reported to be activated by AML fusion proteins (RUNX1-ETO, PML-
RAR or PLZF-RAR) (Zheng et al, 2004) and also during blast crisis in BCR-ABL.
Whether activation of WNT is important for all types of AML or only feature in AML with
balanced translocations has not been established (Muller-Tidow et al, 2004).  In addition,
different isoforms of TCF7L2 have been shown to have different effects on TCF-dependent
transcription depending on the differential promoter binding properties of the C-terminal
sequence with different sets of target genes (Eastman & Grosschedl, 1999; Atcha et al,
2003).  The functional relevance of the different TCF7L2 isoforms identified in AML will
therefore be verified in this chapter.
There is compelling evidence that the TCF7L2 / -catenin complex is an important
factor that determines the balance between cell proliferation and differentiation of normal
haematopoiesis (Kirstetter et al, 2006; Luis et al, 2012); however it is not currently known
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how the expression of TCF7L2 isoforms will influence the development of normal human
CD34+ haematopoietic cells. These studies will promote the understanding of the role of
TCF7L2 overexpression in AML.
5.2 AIMS
The isoforms of TCF7L2 identified in Chapter 4 were assessed for their functional
effects in leukaemic and normal haematopoietic cells. To achieve this objective, this
chapter aims:-
 To measure the effect of TCF7L2 knockdown in myeloid cell lines on TCF-
dependent transcription using a TCF-reporter system.
 To examine effect of TCF7L2 knockdown on proliferative and survival capacity of
myeloid cell lines.
 To establish the effect of TCF7L2 isoform overexpression (72 kDa, 58 kDa and 56
kDa) on TCF-dependent transcription in myeloid cell lines.
 To investigate the consequences of TCF7L2 72 kDa and 56 kDa isoform
overexpression on the differentiation of normal human haematopoietic cells.
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5.3 MATERIALS AND METHODS
5.3.1 Generation of TCF-reporter stable cell lines
To investigate the activity of TCF7L2 upon activation of WNT signalling, stable
reporter lines using the BAR platform were generated in myeloid and epithelial cell lines.
These reporter lines were created and supplied by Dr. Richard Darley.
In brief, K562, U937 and HeLa cells were engineered to express a TCF-venus GFP
reporter which enabled analysis of TCF-dependent transcription. Cells were transduced
with BAR lentiviral packaging plasmids (plasmid no. 200 or 186) (Table 5.1) supplied by
Randy Moon (Biechele & Moon, 2008). The BAR reporter contains a concatemer of 12
TCF response elements to improve TCF binding that were inserted between the long
terminal repeats (LTR) of a lentivirus plasmid (Figure 5.1).
For the generation of stable reporter lines, the pBAR-VubiR (plasmid no. 200) or
pBAR-VS (plasmid no. 186) lentiviral constructs were initially transfected into producer
cells and the lentiviral particles were harvested (courtesy of Dr Richard Darley).
Subsequently, parental K562 and U937 cells were infected with pBAR-VubiR lentivirus and
HeLa cells were infected with pBAR-VS lentivirus in order to create stable reporter cell
lines. Both BAR reporters (plasmid no. 200 and 186) drive the transcription of venus GFP
to report the WNT signalling activation upon TCF binding. A second promoter known as
Phosphoglycerate Kinase (PGK) drives the puromycin resistance gene (of vector pBAR-VS)
to allow selection of the transduced HeLa cells and in the case of pBAR-VubiR, the
ubiquitin promoter (instead of PGK) drives DsRed expression for selection of transduced
K562 or U937 cells. The schematic diagrams of these promoters are shown in Figure 5.1.
Transduced reporter cell lines were selected based on DsRed positivity (K562 and
U937) and puromycin resistance for HeLa cells. Following selection, a reporter clone of
K562 and U937 cells was obtained by a limiting dilution method in a 96 well plate. Dr.
Richard Darley kindly created and supplied these stable reporter BAR clones (refer Table
5.2).
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Name of
plasmid
vector
Plasmid
Code No.
Coding
sequence
Type of
plasmid
Antibiotic
resistant
Selectable
marker
Source
pBAR-VubiR 200 Venus GFP Lentiviral
Reporter
Ampicillin DsRed (Biechele &
Moon, 2008)
pBAR-VS 186 Venus GFP Lentiviral
Reporter
Ampicillin Puromycin (Biechele &
Moon, 2008)
pHR 179 TCF7L2-
72kDa with
MYC tag
Mammalian
expression
vector
Kanamycin Neomycin Addgene,
Cambridge,
USA
pBSII-SK+ 311 TCF7L2-
56kDa
Bacterial
expression
vector
Ampicillin lacZ Eurofins
MWG
Operon,
Ebersberg,
Germany
pEX-A 209 TCF7L2-
24kDa
Bacterial
expression
vector
Ampicillin lac Eurofins
MWG
Operon,
Ebersberg,
Germany
pLKO.1-puro 214 Non
mammalian
-shRNA
Lentiviral
vector
expressing
shRNA
Ampicillin Puromycin Sigma-
Aldrich®,
Poole, UK
pLKO.1-puro 235 – 239 TCF7L2
-shRNAs
Lentiviral
vector
expressing
shRNA
Ampicillin Puromycin Sigma-
Aldrich®,
Poole, UK
PINCO-
DsRed
206
262
216
TCF7L2-
72kDa
TCF7L2-
58kDa
TCF7L2-
56kDa
Retroviral
vector
expressing
TCF7L2
insert cDNA
Ampicillin DsRed (Grignani et
al, 1998)
Table 5.1: Details of plasmids and expression vectors used in this study.  Plasmid
numbers are those used in the laboratory plasmid catalogue.
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(A)
(B)
Legend:-
LTR: Lentiviral long terminal repeat
12 X TRE: 12 TCF response elements
minP: Promega minimal promoter
-Globin: -Globin gene intronic sequences
Venus: GFP from eYFP variant gene
Ubi: Ubiquitin promoter
PGK: Phosphoglycerate Kinase promoter
DsRed: DsRed gene
PuroR: Puromycin resistance gene
Figure 5.1: Schematic illustration showing components of the BAR reporter system
used to create stable reporter lines. (A) pBAR-VS expression plasmid vector (B) pBAR-
VubiR expression plasmid vector. Images were adapted from (Biechele & Moon, 2008).
minP -Globin Venus DsRed12 X TRE LTRUbi
-Globin Venus PGK Puro R LTR12 X TRE minPLTR
LTR
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Reporter
cell line
Type Source Culture
conditions
K562-
pBAR-
VUbiR
Subline of
K562-myeloid
leukaemia
Created by lentiviral transduction of
K562 parental cells with BAR reporter
plasmid no. 200. The DsRed positive
clones were subsequently screened for
BIO-induced activity. The clone with the
highest fold induction was selected and
expanded to produce this stable cell
RPMI-1640,
10% FBS,
20µg/ml
Gentamicin,
2mM L-
glutamine
U937-
pBAR-
VUbiR
Subline of
U937-myeloid
leukaemia
Created by lentiviral transduction of
U937 parental cells with BAR reporter
plasmid no. 200. The DsRed positive
clones were subsequently screened for
BIO-induced activity. The clone with the
highest fold induction was selected and
expanded to produce this stable cell
RPMI-1640,
10% FBS,
20µg/ml
Gentamicin,
2mM L-
glutamine
HeLa-
pBAR-VS
Subline of
HeLa-cervical
carcinoma
Created by lentiviral transduction of
HeLa parental cells with BAR reporter
plasmid no. 186. Cells were selected in
0.5 µg/ml puromycin for 9 days. The
puromycin resistant clones were
subsequently screened for BIO-induced
activity and expanded to produce this
stable cell
DMEM, 10%
FBS, 20µg/ml
Gentamicin,
2mM L-
glutamine
Table 5.2: List of stable TCF-reporter cell lines used in this study. Conditions for
induction with the WNT agonist BIO are described in 5.3.4.
5.3.2 The effects of TCF7L2 knockdown in cell lines using lentiviral shRNA
5.3.2.1 Design of TCF7L2 shRNA plasmids
In order to specifically knock down the expression of the TCF7L2 gene; MISSION®
shRNA Lentiviral plasmid based RNA interference was used. This lentiviral system
permits efficient and stable expression of shRNA using the pLKO.1-puro vector (Zufferey
et al, 1998). The shRNA contains 21 sense bases that are identical to the TCF7L2 target
gene, a loop and 21 antisense bases (see Figure 5.2).
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A total of six shRNA clones were obtained from MISSION® shRNA, supplied in
glycerol stocks. The pLKO.1-puro non-mammalian shRNA control (plasmid no. 214)
supplied by the manufacturer contains a sequence that should not target any known human
or mouse gene and serves as a non-targeted control for interpretation of knockdown results.
The target sequences to be silenced within the TCF7L2 gene were selected based on
predicted sequences of shRNA clones accessible from The RNAi Consortium (TRC)
database;
http://www.broadinstitute.org/rnai/public/trans/candidates?transId=TRCT0000020432. The
list of shRNA targets are shown in Table 5.3.
Figure 5.2: Schematic diagram of the shRNA insert cloned into the pLKO.1 puro
vector. Hairpin sequences are comprised of a 21 base stem and a 6 base loop. The human
U6 promoter (a pol III promoter) is used to drive expression of the shRNA hairpin.
Expression using pol III promoter is optimal for producing shRNAs due to precise initiation
and termination of transcription by the polyT termination sequence.  This image was
obtained from http://www.sigmaaldrich.com/life-science/functional-genomics-and-
rnai/shrna/library-information/vector-map.html
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Type of shRNA Exon
target
shRNA target sequence (21 bp)
TCF7L2-exon1 MISSION® shRNA 1 GCGCCAACGACGAACTGATTT
TCF7L2-exon2 MISSION® shRNA 2 CCGAAAGTTTCCGAGACAAAT
TCF7L2-exon11 MISSION® shRNA 11 TAGCTGAGTGCACGTTGAAAG
TCF7L2-exon13 MISSION® shRNA 13 CCTTTCACTTCCTCCGATTAC
TCF7L2-exon18 MISSION® shRNA 18 CGTCACCAAGTCTTTAGAATA
Non-target control MISSION® shRNA Control CAACAAGATGAAGAGCACCAA
Table 5.3: List of TCF7L2 shRNAs used in this study.
5.3.2.2 Production of TCF7L2 shRNA lentiviruses
The MISSION® shRNA bacterial glycerol stock (25-50µl) was streaked onto LB
agar plates and plasmid DNA was purified from bacterial culture as described in sections
2.6.4. and 2.6.5.
Lentiviral particles of each TCF7L2 shRNA including the control were produced in
packaging cells HEK293T by co-transfection with compatible packaging plasmids and
harvested as described in sections 2.7.2 and 2.7.3.
5.3.2.3 TCF7L2 shRNA lentiviral transduction
The shRNA lentiviruses were used to transduce the stable reporter cell line K562-
pBAR-VubiR according to section 2.7.4.
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5.3.2.4 Puromycin selection of shRNA transduced cells
Following lentiviral transduction, cells expressing stable gene knockdown were
selected using puromycin as follows. Cells (2 x 105) in fresh medium were transferred to a
new TC treated 24-well plate and treated with 1 µg/ml puromycin and cultured at 37oC and
5% CO2. Selection was carried out in the presence of puromycin until all uninfected control
cells were killed (~1 week).  Growth medium containing puromycin were replaced every 3
days during the period of selection.
5.3.2.5 Validation of shRNA knockdown by Western Blotting and qRT-PCR
Cell pellets were harvested from shRNA transduced K562-pBAR-VubiR cells at day
14 after transduction. Nuclear protein samples were extracted from 2 x 106 cells as
described in 2.8.1. To complement protein validation, gene knockdown was also validated
at the mRNA level. For this purpose, total RNA was prepared from 2 x 106 cells derived
from shRNA transduced K562-pBAR-VubiR cells harvested at day 14 using Trizol as
described in 2.5.1 – 2.5.2. Reverse transcription was carried out using 500 ng of RNA as
described in 2.5.3. Expression of TCF7L2 was assessed by amplifying two sets of primer
pairs using the SYBR-Green protocol. The first primer pair set amplified the region
between exons 7/8 and exon 9. The second set of primers amplified the exon 18 region of
the TCF7L2 gene. The primer design, primer sequences for TCF7L2 and ABL, cycling
parameters and protocol used for the qRT-PCR assay are described in 2.5.4. Raw data were
imported into DataAssistTM v2.0 software (Applied Biosystems). The mRNA expression of
TCF7L2 level in the target shRNA sample relative to the pLKO.1-puro control sample was
calculated by the comparative cycle threshold (Ct) method. Once the control sample was
selected as a reference, the results were calculated by the DataAssistTM v2.0 software
algorithm as below:-
Relative Fold change =  2 (–ΔCt target) / 2 (–ΔCt control)
Average Ct  = mean of the technical replicates
ΔCt= Average Ct – Normalisation Factor
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5.3.2.6 Cell growth and viability assessment
To determine whether TCF7L2 knockdown affects cell growth, cells were counted
using a haemocytometer under a microscope (see 2.3.3).
To assay cell viability and apoptosis, 7-Amino-actinomycin D (7-AAD) was used.
The 7-AAD dye intercalates cytosine and guanine bases of DNA; apoptotic and non-viable
cells can be characterised and identified (Philpott et al, 1996). Viable cells retain their
membranous integrity and are impermeable to 7-AAD (Schmid et al, 1992).  Briefly, 1 x
105 cells were washed with 1 ml of 1 X PBS by centrifugation at 180 x g for 5 minutes.
Cells were incubated with 1 µg/ml of 7-AAD for 20 min protected from direct light and
analysed by flow cytometry as described in 2.9.1.
5.3.3 The effects of TCF7L2 overexpression in cell lines using a retroviral system
5.3.3.1 Creation of TCF7L2 clones and expression plasmids
Standard cloning methods including restriction enzymes used to construct TCF7L2
coding PINCO-DsRed plasmids (no. 206, no. 262 and no. 216 (see Table 5.1) are described
in 2.6.1.
The TCF7L2-58kDa and TCF7L2-56kDa constructs contain the 5’ Kozak sequence
(GCCACC) at the start of the ORF. The sequence encoding TCF7L2-56kDa isoform was
generated by creating a BamHI/EcoR1 fragment to ‘drop’ the 56kDa insert from the source
pBSII-SK+ plasmid (no. 311) (Eurofins MWG Operon, Ebersberg, Germany). The PINCO-
DsRed plasmid vector was also digested using a similar RE for directional cloning. The
TCF7L2-56kDa insert (1.7 kb) was purified from agarose gel (2.6.2) and sub cloned into the
BamH1/EcoR1 sites of PINCO-DsRed yielding the expression plasmid no. 216.
The sequence encoding the TCF7L2-58kDa isoform was generated by introducing
different alternative C-terminal “tail sequences” (containing exon 14) into the existing
TCF7L2-56kDa isoform expression plasmid vector no. 216 created as above. The tail
sequence was derived from expression plasmid no. 209 (Eurofins MWG Operon, Ebersberg,
Germany) containing exon 13, 14 and 18. This tail region was excised using Xho1/EcoR1
digestion and the predicted 200 bp product was gel purified and was ligated into plasmid
TCF7L2-56kDa isoform (plasmid no. 216). This modified plasmid then became the
TCF7L2-58kDa isoform (plasmid no. 262).
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The sequence encoding TCF7L2-72kDa was generated by creating a BglII/Xba1
insert fragment of 72kDa sequence from the pHR-TCF7L2 plasmid no. 179 (Addgene,
Cambridge, USA). Klenow was used to blunt the Xba1 end site.  The resulting 2.4 kb insert
sequence contains a 5’ MYC tag within the ORF. The insert fragment was purified and
subcloned into the BamH1/ blunt end sites of the PINCO-DsRed expression plasmid vector
to create expression plasmid no. 206. DNA sequence verification of each construct DNA
was checked by direct sequencing using PINCO vector primer pairs around the cloning
sites.
5.3.3.2 TCF7L2 retroviral transduction and western blotting
The amphotropic packaging cell line Phoenix was transfected with 45 µg of each
TCF7L2 plasmid DNA (as created in 5.3.3.1) using calcium phosphate as described in
section 2.7.1. Retroviral constructs were packaged and used to infect myeloid cell lines and
HeLa cells as previously described (2.7.4 - 2.7.3).
The HeLa-pBAR-VS reporter line was seeded at approximately 30% confluency
prior to infection. In order to infect the adherent HeLa cells, 1ml of retrovirus (PINCO-
DsRed empty vector (EV), 72kDa and 56kDa TCF7L2 virus) was added directly to each
culture in a 5mL flask and incubated overnight at 37C with 5% CO2. On the following
day, virus containing medium was replaced with fresh medium.
In order to verify the success of retroviral transduction at the protein level, western
blotting was performed to assay TCF7L2 isoform expression using protocols described in
section 2.8. To isolate discrete subpopulation of transduced cells from the K562-pBAR-
VubiR reporter line, DsRed expressing cells were enriched by fluorescent activated cell
sorting. Specifically, 5 x 106 cells were aliquoted and centrifuged at 300 x g for 5 minutes.
The growth medium was discarded and the cell pellet was resuspended in 1X PBS buffer
containing 1% BSA and passed through a 40 µM cell strainer. Cells were then flow sorted
with the help of Dr Chris Pepper, Cardiff University, using FACSDiva™ version 6.1.3 (BD
Biosciences, Oxford, UK).  DsRed positive cells (2 x 105) were recovered post cell sorting;
each condition with more than 70% DsRed positivity. Sorted cells were expanded and
harvested for TCF7L2 protein expression by western blotting.
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5.3.4 Assay for TCF reporter activity
To observe the effect of TCF7L2 on WNT signalling, cell lines (K562-pBAR-VubiR
and HeLa-pBAR-VS) overexpressing TCF7L2 isoforms and shRNA transduced cell line
(K562-pBAR-VubiR) were assayed for TCF reporter activity. The assay was performed on
days 5 and 7 post transduction. Cell lines expressing the BAR reporter system that co-
expressed the PINCO-DsRed EV construct or non-targeted shRNA served as controls for
TCF reporter activity. All cells were treated for 24 hours with 2.5 μM of the GSK3
inhibitor BIO (2'Z,3'E)-6-Bromoindirubin-3'-oxime) (Tocris, Bristol, UK) prior to analysis.
BIO is a potent ATP-competitive GSK3 inhibitor that stabilizes -catenin levels by
preventing its degradation. At the same time, a separate set of cells were treated with 1
µg/ml recombinant WNT3A (R&D Systems, Abingdon, UK) using similar conditions.
WNT3A is a physiological agonist of WNT ligands that activates -catenin via WNT
signalling. In each case, cells were seeded at a density of 2 x 10 5 cells/ml in a 48 well plate
and cultured in appropriate growth medium (see Table 5.2) and incubated for 24 hours at
37C with 5% CO2. The following day, 250 µl of culture was washed with 1X PBS buffer
containing 1% BSA, and centrifuged at 300 x g for 5 minutes. Cell pellets were
resuspended in 100 µl staining buffer and analysed for reporter expression using the
Accuri® C6 flow cytometer (Accuri Cytometers, Ann Arbor, USA). Histogram data analysis
was performed as described in 2.9.2.1.
5.3.5 The effects of TCF7L2 overexpression in normal haematopoietic cell
development using a retroviral system
5.3.5.1 Transduction of normal CD34+HPC with TCF7L2 expression plasmid
CD34+ cells were purified from mononuclear cells from neonatal CB using
MiniMACS (Miltenyi Biotec, Camberley, UK) and infected with retrovirus encoding for
TCF7L2 (5.3.3.1) as described in 2.4.3 and 2.7.4. Transduced CD34+ HPC were seeded at
0.5 x 105 /ml in supplemented IMDM containing the following growth factors; 50 ng/ml IL-
3, SCF, FLT-3 and 25 ng/ml IL-6, G-CSF and GM-CSF at 37C with 5% CO2. After three
days of culture, transduced CD34+ HPC in logarithmic growth phase were seeded at 2 x 105
/ml and sub-cultured in supplemented IMDM containing 5 ng/ml IL-3, G-CSF, GM-CSF,
and 20 ng/ml SCF. The optimal concentration of growth factors used was adapted from
previous experiments (Darley et al, 1997; Darley et al, 2002).
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5.3.5.2 Immunophenotypic analysis of transduced cells
To assess cell differentiation, immunostaining was carried out using lineage
discriminator antibodies (CD13 and CD36) as well as specific differentiation antibodies
(CD14, CD15, CD34) as listed in Table 5.4. Immunophenotyping was performed in a 96-V
well plate using a minimum of 5 x 104 cells taken from each culture. Appropriate cell
numbers were aliquoted into each well and centrifuged at 300 x g for 3 minutes and growth
medium was discarded. Cells were then washed with 150 µl flow cytometry staining buffer.
Following centrifugation as above, the supernatant was discarded and cell pellets were
resuspended in 15 µl of staining buffer. Between 2.5 µl – 5 µl of primary antibodies were
added (according to manufacturer’s recommendations). The plate was securely covered
with a plate sealer and briefly vortexed prior to incubation at 4C for 30 minutes. Following
incubation, cells were washed with 150 µl staining buffer as above. Supernatant was
aspirated and replaced with 15 µl of staining buffer. The diluted secondary antibody
streptavidin (SA) - peridinin chlorophyll protein (PerCP) Cy5.5 (diluted 1:20 in flow
cytometry staining buffer) (BD Pharmingen™, Oxford, UK) was added to each well (5µl),
vortexed and incubated at 4C for 30 minutes. Finally, cells were washed with 150 µl
staining buffer, centrifuged as above for 3 minutes and resuspended with 100 µl staining
buffer for analysis using an Accuri® C6 flow cytometer. Data analysis was performed using
FCS Express as described in 2.9.2.2.
Antibody
reagent
Fluorescent
conjugate
Ig type Manufacturer Target cell receptor
CD13 APC IgG BioLegend, London,
UK
Myeloid lineage
CD36 Biotin IgM Ancell, Bayport, UK Myeloid/erythroid
lineage
CD34 FITC IgG BD Pharmingen™,
Oxford, UK
Progenitor cells
CD14 FITC IgG DAKO, Ely, UK Monocytes
CD15 FITC IgG BioLegend, London,
UK
Granulocytes
IgG FITC 1gG1 DAKO, Ely, UK Isotype control (non-
specific binding)
Table 5.4: List of antibodies used for immunophenotyping of transduced
haematopoietic cells. Biotinylated CD36 was subsequently labelled with SA-PerCp Cy5.5.
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5.4 RESULTS
5.4.1 TCF7L2 knockdown in myeloid leukaemia cell lines
To evaluate the physiological relevance of TCF7L2 overexpression in leukaemia
cells, five shRNA clones were assayed for suppression of endogenous TCF7L2 expression
in the K562 cell line. Each shRNA lentiviral construct (Table 5.3) was transduced into the
K562 pBARVubiR reporter line and stable gene knockdowns were achieved by puromycin
selection (see 5.3.2.1- 5.3.2.4). The effects of gene knockdown was assessed by qRT-PCR
and western blotting as described in 5.3.2.5.
As shown in Figure 5.3, all but one of the shRNA constructs were able to bring
about TCF7L2 mRNA gene knockdown by more than 50% compared to control. Gene
knockdown was not achieved by targeting exon 2, as validated by two sets of primers.
Downregulation of TCF7L2 mRNA expression by shRNAs targeting exon 1, 11, 13 and 18
also led to reduced protein levels as seen in the nuclear extracts (Figure 5.4). Consistent
with the qRT-PCR data, inhibition was not achieved at the protein level by shRNA targeting
exon 2. Therefore the shRNA clone targeting exon 2 of TCF7L2 was omitted from further
analysis.
These results provide evidence that stable production of shRNA in K562-pBAR-
VubiR cell allows efficient knockdown for most exons targeted.
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Legend:-
RQ primer exon 7/9
RQ primer exon 18
Figure 5.3: Validation of shRNA knockdown by quantitation of TCF7L2 mRNA
expression detected by qRT-PCR. Fold change plot showing mRNA expression levels of
TCF7L2 in K562-pBAR-VubiR cells transduced with shRNA clones targeting TCF7L2 at
day 14 post transduction. TCF7L2 mRNA was amplified using exon 7/9 and exon 18
primer pairs. The fold expression level shown for each shRNA target is relative to the
control. Data represent the mean ± SD from duplicate samples.
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Figure 5.4: Validation of shRNA knockdown by protein expression as detected by
western blotting. Blot showing nuclear TFC7L2 protein expression levels of shRNA
transduced K562-pBAR-VubiR at day 14 post transduction. Nuclear protein extracts were
prepared from indicated samples and the blot was probed with monoclonal TCF7L2
antibody (exon 1 epitope). Loading control used was Histone H1.
20kda ladder
TCF7L2 (ex1)
control        exon 18      exon 11 exon 1 exon 2  exon 13
Histone H1
  58 kDa
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5.4.2 TCF7L2 knockdown represses TCF-dependent reporter activity in myeloid
leukaemia cells
To investigate the effect of TCF7L2 knockdown on WNT signalling, TCF-
dependent transcriptional activity using BAR reporter constructs was measured. As above,
the K562-pBAR-VubiR cells expressing BAR reporter were transduced with TCF7L2
shRNA constructs (see 5.4.1) and stimulated with either BIO or WNT3A agonists (agents
which stabilise the levels of -catenin and thereby promote TCF-dependent-transcription).
The differences between GFP signals were measured by histogram subtraction as described
in section 2.9.2.
As shown in Figure 5.5 (and summarised in Figure 5.6) BIO induced TCF-
dependent transcriptional activity was suppressed by up to 60% relative to control activity.
Unexpectedly, shRNA targeting exon 18 exhibited little effect on TCF transcriptional
activity.
The effect of the natural WNT agonist, WNT3A was next examined. These findings
suggested that all shRNA clones suppressed the baseline reporter activity in this cell,
yielding more than 60% transcriptional reduction relative to the control (see Figure 5.7). In
contrast to the effect seen in BIO stimulation, exon 18 exhibited strongest inhibition on
reporter activity after WNT3A stimulation.
In summary, transcription induced by -catenin stabilisation was inhibited by the
loss of TCF7L2 gene expression in leukaemic cells, suggesting that canonical WNT
signalling is at least partially dependent on TCF7L2 expression in these cells.
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Figure 5.5: Histogram analysis of shRNA transduced K562-pBAR-VubiR reporter cell
lines in response to BIO treatment. Cells were seeded on a 48-well plate treated with 2.5
µM BIO for 24 hours. The positive difference of GFP fluorescence signal was calculated
for each construct by subtracting the fluorescence of non-stimulated cells from that of BIO
stimulated cells. Histograms overlay and values for positive differences are shown for (A)
Control only (B) Control vs shRNA exon 1 (C) Control vs shRNA exon 11 (D) Control vs
shRNA exon 13 (E) Control vs shRNA exon 18. Data derived from cells harvested at day
10 post transduction.
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Figure 5.6: TCF-reporter activity of shRNA transduced K562-pBAR-VubiR reporter
cell lines in response to BIO treatment.  Transduced cells were seeded on a 48-well plate
treated with 2.5 µM BIO for 24 hours. The positive difference of GFP fluorescence signal
was calculated for each construct by subtracting non-stimulated cells from BIO stimulated
cells (see 5.3.4). The fold GFP fluorescence (positive difference) shown for each shRNA
target is relative to the Control. Data represent the mean ± SD from two independent
experiments at day 10. Statistical significance was calculated using Student’s T-test. * P <
0.05.
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Figure 5.7: TCF-reporter activity of shRNA transduced K562-pBAR-VubiR reporter
cell lines in response to WNT3A treatment. Transduced cells were seeded in a 48-well
plate treated with 1 µg/ml WNT3A for 24 hours. The positive difference of GFP
fluorescence signal was calculated for each construct by subtracting non-stimulated cells
from WNT3A stimulated cells (see 5.3.4). The fold GFP fluorescence (positive difference)
shown for each shRNA target is relative to the control. Data represent the mean ± SD from
two independent experiments at day 10. Statistical significance was calculated using
Student’s T-test. * P < 0.05, **P < 0.01.
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5.4.3 TCF7L2 knockdown inhibits growth and survival of myeloid leukaemia cell
lines
Previous reports have shown that mice deficient in TCF7L2 develop normally, but
die shortly after birth due to the absence of cycling epithelial progenitor cells of the small
intestine (Korinek et al, 1998a). Similarly, TCF7L2 -/- mutant zebrafish also display a
defect of proliferation in the intestine leading to death (Muncan et al, 2007a).  This section
therefore investigated whether depletion of TCF7L2 would impair growth and survival of
leukaemic cells. Viability was assessed by flow cytometry using 7-AAD (method in 5.3.2.6)
and cell counts were assessed as in 2.3.3.
As shown in Figure 5.8, TCF7L2 knockdown by shRNA exon 1 and 13 induced a
stronger inhibition of cell growth as compared to shRNA exon 11 and 18 knockdown in
K562-pBAR-VubiR cells. Impaired growth was also prominent for U937-pBAR-VubiR
(Supplementary 5.1).
To examine whether TCF7L2 shRNA-mediated growth inhibition is associated with
apoptosis, cells were stained with 7-AAD. TCF7L2 shRNA reduced the number of living
cells as compared to control shRNA. Consistent with the growth data, TCF7L2 shRNA
targeting exon 1 and 13 were more effective at inducing apoptosis as compared to exon 11
and 18 (see Figure 5.9).
In summary, TCF7L2 knockdown was found to inhibit proliferation and promote
apoptosis indicating the involvement of TCF7L2 in maintaining the survival of myeloid
leukaemia cells.
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Figure 5.8: Proliferative activity of shRNA transduced K562-pBAR-VubiR reporter
cell lines. Proliferation was counted as cell number /ml (x105). Relative proliferation
shown for each shRNA target is relative to the control. Data represent the mean ± SD from
seven time points. Statistical significance was calculated using Student’s T-test.  **P <
0.01
shRNA target
Figure 5.9: Effect of TFC7L2 shRNA on cell viability. The gated live cells shown for
each shRNA transduced K562-pBAR-VubiR cell line is shown relative to control. Data
represent the mean ± SD from three time points. Statistical significance was calculated
using the Student’s T-test.  * P < 0.05, **P < 0.01.
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5.4.4 Over-expression of TCF7L2 isoforms repress TCF-reporter activity in myeloid
cells
Chapter 4 (4.4.3) identified the protein isoforms that are expressed in AML patients.
To explore the role of TCF7L2 over-expression, the sequences of the three TCF7L2
isoforms (78kD, 58kD and 56kD) were generated and retroviral expression constructs were
created by subcloning into the PINCO-DsRed vector (detailed in section 5.3.3). Transduced
K562-pBAR-VubiR and HeLa-pBAR-VS cells were derived and exogeneous protein
expression was determined as described in 5.3.3.2. Western blotting data (Figure 5.10)
shows that the TCF7L2-72kDa construct produced a protein with much higher MW of
approximately 78kDa, probably due to the in-frame MYC tag coding sequence. The
TCF7L2-58kDa construct produced the predicted overexpression at 58kDa compared to the
parental control. The shortest construct, TCF7L2-56kDa, generated overexpression at
56kDa MW but also at the 72kDa and 58kDa MW levels, which could be due to stabilising
effects on the expression of the other isoforms. This protein expression data shows that it is
possible to stably overexpress TCF7L2 protein isoforms in K562-pBAR-VubiR cells.
In the previous section (as described in 5.4.2), TCF7L2 knockdown was shown to
cause repression of TCF transcriptional reporter activity. To establish the effect on
transcriptional activity of overexpression of TCF7L2, K562-pBAR-VubiR and HeLa-
pBAR-VS cells were transfected with retroviral expression constructs encoding three
TCF7L2 isoforms; 72kDa, 58kDa and 56kDa and EV as control. Transduced cells were
then treated with the WNT agonists, BIO and WNT3A (described in 5.3.4).
No change in constitutive reporter activity was seen for any of the three isoforms
analysed (data not shown).  Surprisingly overexpression suppressed the response to WNT
agonists for TCF7L2 72kDa, 58kDa and 56kDa in myeloid cells (Figure 5.11A-B). To
examine if this response might be restricted to the context of myeloid cells, an epithelial cell
reporter line, HeLa-pBAR-VS, was transduced with TCF7L2-72kDa and 56kDa constructs
and assayed for reporter activity similarly to K562-pBARV-UbiR. Again, in this case, no
significant changes of relative reporter activity were seen between the control and TFC7L2
transduced HeLa reporter cells (see Figure 5.11C). Though the effect on reporter activity in
myeloid cells was similar to that observed with TFC7L2 knockdown, in contrast to the
effect of knockdown, no significant difference was observed in terms of cell growth and
survival due to TCF7L2 overexpression (data not shown). In conclusion overexpression of
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all TCF7L2 isoforms tested suppressed WNT agonist responses in myeloid cells but not in
epithelial cells.
Figure 5.10: Validation of retroviral overexpression of TCF7L2 protein as detected by
western blotting. Blot shows nuclear TCF7L2 expression levels in retrovirally transduced
K562-pBAR-VubiR at day 28 post transduction. The blot was probed with monoclonal
TCF7L2 antibody (exon11 epitope). The loading control used was Histone H1. EV (empty
vector): PINCO-DsRed vector backbone plasmid, no.206: PINCO-DsRed TCF7L2-72kDa
plasmid, no.262: PINCO-DsRed TCF7L2-58kDa, no.216: PINCO-DsRed TCF7L2-56kDa.
Control   72kDa 58kDa 56kDa
(EV)  (no. 206) (no. 262)  (no. 216)
TCF7L2
Histone H1
78kDa
72kDa
58kDa
56kDa
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Figure 5.11: Effect of TCF7L2 overexpression on TCF-reporter activity in response to BIO and WNT3A treatment. TCF7L2-72kDa, 58kDa
and 56kDa isoforms were overexpressed in stable TCF reporter cell lines. (A) K562-pBAR-VubiR treated with 2.5 µM BIO for 24 hours (B)
K562-pBAR-VubiR treated with 1 µg/ml WNT3A for 24 hours (C) HeLa-pBAR-VS cells treated with 2.5µM BIO for 24 hours. Positive
differences of GFP fluorescence were calculated for each construct by subtracting non-stimulated cells from BIO-stimulated cells (see 5.3.4). The
fold GFP fluorescence (positive difference) for each TCF7L2 isoform overexpressing cell is relative to EV Control. Data represent the mean ± SD
from two time points. Statistical significance was calculated using Student’s T-test. ** P < 0.01.
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5.4.5 Overexpression of TCF7L2 induces differentiation of monocytic lineage in
normal haematopoietic cells
To assess whether TCF7L2 overexpression affects normal haematopoietic
development, normal human CD34+ HPC were transduced with 72kDa and 56kDa TCF7L2
isoforms and their subsequent development was assessed by immunophenotypic assay.
Normal CD34+ HPC were purified from neonatal CB and transduced with the
retroviral expression vectors as detailed in 5.3.5.1. Verification of transduction efficiency
was determined by flow cytometric detection of the DsRed marker starting on day 3 until
day 20 of culture. Transduction frequencies at day 6 are shown in Figure 5.12.  Though the
transduction frequencies of the TCF7L2 overexpressing cultures were relatively low
compared to that achieved with EV, it was sufficient to carry out immunophenotypic
analysis and was consistent with the relative titre of the virus used for transduction.
Following infection (from day 3), the three sub-populations of lineage committed
haematopoietic cells (monocytes, granulocytes and erythrocytes) were identified using the
lineage discriminators, CD13 and CD36. By day 9, it was evident by 4-colour flow
cytometric analysis that the TCF7L2 transduced cultures consisted predominantly of
monocytes of which > 50% were of monocytic phenotype (CD13+CD36+) as shown by dot
plot (Figure 5.13) and lineage frequency (Figure 5.14). The fluorescence intensity of
lineage marker expression shows not only that there is a higher frequency of monocytic
cells but there are also higher levels of CD14 implying accelerated monocytic development
(Figure 5.15); whereas the frequency of granulocytic lineage cells was reduced as was the
level of differentiation marker expression (CD15) implying retarded development (Figure
5.16).
Taken together, these results demonstrate that overexpression of TCF7L2 isoforms
via WNT signalling is sufficient to promote monocytic differentiation.
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Figure 5.12: Bivariate dot plots showing typical DsRed positivity of TCF7L2
transduced CD34+ cells (A) A scatter gate has been drawn to exclude debris high forward
scatter events (cell clumps). This scatter region was then used to gate cells based on DsRed
fluorescence (B) The gate has been set to define the DsRed positive cells. Similar gating
was applied to determine DsRed positive regions for (C) EV Control (D) TCF7L2-56kDa
transduced CD34+ (E) TCF7L2-72kDa transduced CD34+. The data represent cultures
harvested on day 6.
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Figure 5.13: Representative dot plot and histograms showing immunophenotypic
analysis of lineage differentiation of TCF7L2 transduced CD34+ cells. (A) CD13 and
CD36 discriminate monocyte, granulocyte and erythroid lineages within DsRed positive
gated cells. Each subpopulation has been further examined for cell surface marker
expression. (B) Example data for the granulocyte subpopulation showing expression the
granulocytic marker, CD15, and (C) for the monocytic marker using CD14 on the
monocytic subpopulation.  Isotype staining: filled histogram; marker staining: open
histogram. Data represent cultures harvested at day 9.
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Figure 5.14: Relative frequency of erythroid, monocytic and granulocytic lineage cells
in transduced CD34+ HPC. Comparison of relative lineage frequency over 13 days post
transduction as detected by CD13 and CD36 expression in CD34+ HPC transduced with (A)
EV (B) TCF7L2-72kDa (C) TCF7L2-56kDa.
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Figure 5.15: Intensity of specific lineage marker expression in CD34+HPC transduced
with TCF7L2-72kDa. The levels of marker expression over 13 days post transduction are
shown for (A) monocytic lineage (CD14+) and (B) granulocytic lineage (CD15+). Data
represent the mean ± SD from two experiments. MFI = Mean Fluorescence Intensity.
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Figure 5.16: Intensity of specific lineage marker expression in CD34+HPC transduced
with TCF7L2-56kDa. The levels of marker expression over 13 days post transduction are
shown for (A) monocytic lineage (CD14+) and (B)  granulocytic lineage (CD15+). Data
represent the mean ± SD from two experiments.  MFI = Mean Fluorescence Intensity.
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5.5 DISCUSSION
5.5.1 TCF7L2 is required for leukaemia cell survival and growth
The importance of TCF7L2 expression on the growth and survival of myeloid cells
was established using shRNA.  Downregulation of endogenously expressed TCF7L2
mRNA and protein were shown to suppress both the growth of myeloid cells and thus
transcriptional activity in response to -catenin stabilisation.  This data is in line with
previous reports which suggest that TCF7L2 might be a key factor in WNT signalling
involved in cancer cell proliferation.  TCF7L2 is known to be normally expressed in
intestinal stem cells.  Transgenic mice lacking this protein (TCF7L2-/-) have a significantly
reduced proliferative activity in the intervillus regions along with reduced numbers of
epithelial cells which die within 24 hours of birth (Korinek et al, 1998b). Conditional
murine models (TCF7L2LoxP/LoxP knockout embryos) also demonstrated a phenotype similar
to that of the classical TCF7L2-/- knockout mice, indicated by the total absence of
proliferative cells in the small intestinal crypt (van Es et al, 2012).  Further, a defect of cell
proliferation was also reported in TCF7L2-/- zebrafish intestine (Muncan et al, 2007).  In
colon carcinoma, expression of dominant-negative TCF7L2 caused severe growth arrest (as
measured by colony-forming assay and viable cell counting of HCT116 cells) due to cell
cycle arrest in G1. The growth of these cells was reported to be strongly dependent on -
catenin / TCF7L2 mediated expression of cyclin D1 (Tetsu & McCormick, 1999a).
Loss of -catenin / TCF7L2 interaction and the reduced expression of cyclin D1 as
seen in colon carcinoma, causing cell cycle arrest, could also be relevant to myeloid cells.
Cyclin D1 is one of the direct TCF7L2 target genes known to have a TCF response element
within its promoter region.  Indeed, inhibition of WNT signalling using small molecule -
catenin / LEF1 inhibitors ( eg: CGP049090 and PFK115-584 ) selectively induced cell death
in AML cell lines and primary AML blasts within 24 hours and led to decreased protein
expression of cyclin D1 and c-MYC contributing to a loss of proliferative activity (Minke et
al, 2009). The induction of apoptosis promoted by TCF7L2 shRNA in this study is in
accord with the induced apoptosis and cell cycle arrest effect of antagonists of the β-catenin
/ TCF7L2 complex in HepG2 and Huh7 hepatocellular carcinoma cells. All antagonists also
suppressed in vivo tumour growth in a HepG2 xenograft model, associated with reduced C-
MYC, cyclin D1 and survivin expression (Wei et al, 2010). The impact of induced apoptosis
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in colorectal cancer cells has been reported to be even stronger due to loss of TCF7L2 as
compared to -catenin (Xie et al, 2012), supporting a role for TCF7L2 in the survival of
cancer cells. Nevertheless in this study, the role of individual isoforms is unknown because
there has been no attempt to knockdown individual isoforms in any context. Most of the
work on TCF7L2 in proliferation and survival has been carried out in the colorectal cells
and there has been no other investigation of its role in the context of haematopoietic cells
except where its role is inferred from the use of WNT signalling inhibitors which may also
inhibit the activity of other TCF family members (Leung et al, 2002; Bao et al, 2012).
In contrast to the tumour promoting ability, previous studies have shown that
knockdown of TCF7L2 in colorectal cell lines using TCF7L2 RNAi (Tang et al, 2008)
could actually produce an increase in cell growth. Heterozygous TCF7L2
haploinsufficiency resulted in increased tumour formation in the colon of APC mutant mice
suggesting that TCF7L2 may also function as a tumour suppressor (Angus-Hill et al, 2011).
Angus-Hill et al hypothesised that TCF / LEF family members may function in distinct and
opposing roles rather than overlapping roles and are essential for maintaining normal
epithelial cell turnover.  This was supported by the increased expression of LEF1 and TCF7
in TCF7L2 haploinsufficiency mutant APC colon tumours mentioned above. Additionally,
TCF7L2 and LEF1 are also differentially regulated during colon tumour progression (Kriegl
et al, 2010) and melanoma phenotype switch (Eichhoff et al, 2011) showing both are
phenotype-specific and inversely correlated, with a function opposing each other. Another
possible explanation for the tumour phenotype is the synergy between its homolog TCF7
and APC. TCF7 can act as a feedback transcriptional repressor of β-catenin / TCF7L2
target genes and disruption of this negative feedback loop would allow the formation of
epithelial tumours similar to that seen with the loss of APC. Transcriptional activation of
target genes such as c-MYC and cyclin D1 by β-catenin / TCF7L2 is thus counteracted by
TCF7 as repressor (Roose et al, 1999). The knock-down data obtained from this study
supports a role for TCF7L2 in proliferation of haematopoietic cells (rather than as a tumour
suppressor).
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5.5.2 Effect of TCF7L2 overexpression on canonical WNT signalling
Overexpression of TCF7L2 either in combination with -catenin or singly elicits
enhancement of a transactivation response in several cancer cell lines (Korinek et al, 1997;
Tsedensodnom et al, 2011).  From this study, no activation was produced by TCF7L2
isoform overexpression (72kDa, 58kDa and 56kDa).  Stable reporter lines expressing the
lentiviral BAR reporter were generated and the effects on TCF reporter activity of
overexpression of different TFC7L2 isoforms were assayed on this background.  In this
study, -catenin was stabilised by the action of the GSK3 inhibitor (BIO) or by WNT3A
ligand binding. Stimulation of the WNT pathway by both agonists along with TCF7L2
overexpression showed attenuated promoter activities in the BAR reporter lines (as
described in 5.4.4).  A plausible explanation for this effect is that there might be insufficient
-catenin being translocated into the nucleus to bind with the excess TFC7L2 resulting in
the blunted response as measured by the BAR reporter.  Previously, Morgan et al has
reported similar findings in which overexpression of catenins alone is insufficient to
promote their transcriptional activity, which requires their translocation and retention in the
nucleus (Morgan et al, 2013).  Alternatively, nuclear translocation of TCF7L2 could have
been impaired.  However, in this study, western blotting analysis confirmed the nuclear
translocation of TCF7L2 in the cell lines tested.  Ectopic expression of TCF7L2 seems to
overload the nucleus with TCF7L2 that potentially might bind free nuclear -catenin
promoting a loss of function effect. These data imply that there is an optimal level of
TCF7L2 and that by overexpressing on a background of already high expression, the ability
of these cells to respond to WNT agonists may be compromised.
TCF7L2 has a known role as a transcriptional repressor. A repression effect as seen
with TCF7L2-72kDa has also been documented in colon cancer with mutated APC; DLD1
cells (Tang et al, 2008). Tang et al expressed the TCF7L2-72kDa in colorectal cancer and
concluded that the C-clamp sequence of TCF7L2 contributes to its repressor function and
that CtBP may regulate a tumour suppressive function by contributing to the transcriptional
repression of TCF7L2 as well as by antagonising the activity of the β-catenin complex
(Chinnadurai, 2002; Hamada & Bienz, 2004). In contrast, constructs expressing shorter
TCF7L2 isoforms (58kDa and 56kDa) have shown augmentation of the reporter signal, as
compared to the 72kDa isoform, upon -catenin stabilisation in the context of colorectal and
hepatocarcinoma tumours (Tang et al, 2008; Tsedensodnom et al, 2011). However, in this
study, the overexpression of all three TCF7L2 isoforms suppressed WNT agonist responses
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in myeloid cells.  Whereas in the epithelial cell line, HeLa, overexpression of TCF7L2-
72kDa had little effect and other studies have suggested that this is because HeLa cells
already express sufficient levels of TCF to support -catenin-dependent activation and their
findings show that full-length TCF7L2-72kDa increased activation only slightly (Tetsu &
McCormick, 1999b).   Taken together these data suggest that the effects of TCF7L2
overexpression are highly context dependent.
Another factor that could impair TCF transactivation is post-translational
modifications that include association of TCF / LEF with acetyltransferases and
deacetylases. Acetylation of TCF7L2-72kDa by cAMP-response-element binding protein
(CREB)-binding protein (CBP) protein has been reported to inhibit transcriptional activation
as seen in HEK293 cells. Furthermore, the shorter TCF7L2-56kDa or TCF7L2-58kDa
isoforms are not acetylated by CBP (Elfert et al, 2013). Genetically, the CBP acetylase
behaves as a repressor of WNT signalling preferentially by inducing acetylation of the
TCF7L2-72kDa isoform (Waltzer & Bienz, 1998). Consistent with this, CBP acetylates the
catenin-binding domain in TCF, thereby weakening its interaction with -catenin and its
DNA binding ability as compared to the shorter isoforms therefore giving a repression
effect. These observations add to the notion that different TCF7L2 isoforms may have
different roles as transcriptional repressors or activators, also depending on its binding
partner proteins.  The uniform effect of the different isoforms in this study suggests that in
this context acetylation is not a factor in inhibiting transcriptional responses.
One caveat to the TCF reporter data is that most TCF reporters incorporate only
minimal promoters (as for the pBAR series) and that in fact, most cellular promoters are not
exclusively dependent on TCF activation, therefore reporter activity may not necessarily be
predictive of effects on WNT responsive genes because it may be co-regulated by a variety
of other factors.  More significantly, natural TCF activated enhancers require additional
activators such as CBP and p300 that may either link activator proteins to the basal
transcription machinery or alter chromatin structure through their intrinsic activities for
proper expression (Carlsson et al, 1993; Hecht & Kemler, 2000; Darken & Wilson, 2001).
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5.5.3 TCF7L2 in haematopoietic development
Few studies have addressed the role of TCF7L2 in haematopoietic development
although a number of studies have described roles of various other components of WNT
signalling in erythroid and myeloid differentiation, as reviewed previously (Staal & Luis,
2010). Findings from this study indicated that an increase in TCF7L2 (in the absence of
WNT agonists) is sufficient to promote the relative expansion of the monocytic lineage.  At
the same time it promoted the expression of monocyte differentiation antigen expression on
the monocyte subpopulation.  It is possible that high TCF7L2 expression alters monocyte
differentiation through its transactivation of target genes such as PU.1 that have been shown
previously to regulate different stages of monocytes differentiation as reviewed by
(Valledor et al, 1998; Auffray et al, 2009).
Monocytes themselves are heterogeneous, with variable nuclear morphology,
granularity and differential expression of CD14 and CD16 surface markers (Gordon &
Taylor, 2005).  Monocytes can differentiate into macrophages or dendritic cells, however it
is still not known whether TCF7L2 regulates monocyte commitment or monocyte
differentiation.  Yet, studies have shown that TCF7L2 expression is consistently up-
regulated in primary macrophages (Lehtonen et al, 2007), and its protein expression is
induced upon macrophage differentiation in myeloid cell lines (Baek et al, 2009).  This is
consistent with high TCF7L2 being sufficient to promote monocyte differentiation or
suppress granulocyte differentiation during GM-CSF directed bi-lineage terminal
differentiation of FDB1 cells (Brown et al, 2012).
Following acute injury of HSC, TCF7L2 has been shown to be involved in the
regeneration of cells by its combined action with SMAD1 to regulate erythroid
differentiation (Trompouki et al, 2011) indicating further functional diversity of TCF7L2.
Additionally, genome studies using ChIP sequencing analysis in several types of solid
tumour cells revealed significant TCF7L2 binding site enrichment for other TFs, including
HNF4, FOXA2 and the GATA3 (Frietze et al, 2012), indicating an important relationship
between TCF7L2 and other TFs in lineage regulation.
Enforced WNT signalling activation could also led to loss of myeloid lineage
commitment and disruption of repopulating stem cell activity (Kirstetter et al, 2006),
indicating the presence of WNT dosage-dependent effects. This notion is supported by
work done in APC mutant mice that demonstrated the intermediate amounts of WNT
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signals are sufficient to enhance myeloid differentiation while only low level of WNT
signals are required to sustain normal haematopoiesis (Luis et al, 2011).
In summary, overexpression of TCF7L2 does not necessarily promote transcription
in myeloid cell lines in the context of the minimal reporter system used. Endogeneous
TCF7L2 expression is required for myeloid cell line survival supporting its role as a tumour
promoting gene.  In the case of normal cells, enforced expression of TCF7L2, potentiates
monocytic differentiation compared to other lineages suggesting a role in regulating cell
fate.
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6 - General Discussion
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Genome-wide expression analysis directly comparing the expression profile of
normal HPC and from patients with AML in this study has identified 1595 differentially
expressed genes common to different subtypes of AML (Figure 3.9). Using further
downstream analysis, several pathways, including WNT signalling were identified to be
dysregulated in AML; WNT is well known for its role in cancer development and stem cell
biology. Furthermore, by using protein enrichment bioinformatic tools to compare the
WNT genes corresponding to up and downregulated expression, a list of putative common
TFs which are connected to other WNT genes were identified.
Transcriptome microarray GEP has become a frontline standard approach to identify
changes in gene expression involved in both physiological and pathophysiological
processes. Chapter 3 initially identified WNT as a pathway associated with dysregulated
gene expression in AML blasts.  As part of this pathway, the study showed for the first time
that TCF7L2 was the most dysregulated TF in AML. The TCF7L2 gene as discussed
previously is known to be susceptible to alternative splicing. This study also examined the
mRNA splice products and the protein expression of these isoforms in AML. Although it is
noteworthy that this pan-genome 3’IVT microarray is often described as being able to scan
the whole transcriptome, they are not well suited to detect expression of isoforms generated
by alternative mRNA splicing produced by TCF7L2. Novel strategies are now available to
detect splicing based on the expression of known or predicted splice variants at the RNA
level and microarrays are evolving towards the inclusion of splice-related content of the
gene. The combination of exon and junction specific probe-sets will provide a robust
approach to monitor known splice events. More recently, several groups have reported the
used of more extensively designed probes around splicing events on a genome-wide scale
(Castle et al, 2003; Le et al, 2004; Fehlbaum et al, 2005).  This approach provided a
comprehensive profile of alternatively spliced apoptotic genes in Imatinib-treated K562
cells (Liu et al, 2012).
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In addition to the TCF7L2 isoforms identified and presented in Chapter 4, a previous
study utilising embryonic cells has identified a further splice event within TCF7L2 (Vacik
et al, 2011). Vacik et al discovered that a dnTCF7L2 transcript can be generated from an
alternative first exon that lies hidden inside the fifth intron of the gene encoding TCF7L2,
yielding a new 35 kDa isoform. Functionally, dnTCF7L2 can displace TCF7L2 in the
nucleus and because this protein lacks a β-catenin binding site, it remains a transcriptional
repressor even in the presence of a WNT signal and the availability of β-catenin.  This
isoform would not have been amplified by the PCR strategy used in this study but a
TCF7L2 isoform of this molecular weight was not detected at the protein level.
TCF7L2 activity can also be influenced by alternative splicing giving rise to proteins
that have different susceptibilities to post translational modification. Acetylation of TCF7L2
has been reported to be restricted to C-tail-E splice variants and requires the simultaneous
presence of β-catenin. The fact that acetylation affects only a subset of TCF7L2 splice
variants and is mediated preferentially by CBP suggests that the conditional acetylation of
TCF7L2 is a novel regulatory mechanism that diversifies the transcriptional output of TCF /
β-catenin signalling in response to changing intracellular signalling (Elfert et al, 2013).
TCF7L2 activity can also be influenced by sumoylation which leads to its activation and
possibly also affects its stability (Yamamoto et al, 2003). Sumoylation of TCF7L2 has
however not been studied in haematopoietic cells.
Data from Chapter 5 suggests that TCF7L2 could serve a role in normal
haematopoietic lineage fate; its overexpression potentiated monocytic development in
haematopoietic progenitor cells. From GEP analysis done in AML however, the highest
mRNA expression of TCF7L2 was found mostly within the undifferentiated AML (M0/M1)
rather than AML with monocytic features (M4, M5) (Supplementary 6.1).  Validation of
this finding was not performed at the protein level in M1 patients.  However, data from
Chapter 4 demonstrates a correlation between the levels of TCF7L2 protein and mRNA in
primary human AML blasts, thereby supporting the Affymetrix GEP data.
The function of TCF7L2 in cancer is widely determined from studies in colon
carcinoma but very few have been tested in AML.  This current study found that
knockdown of TCF7L2 suppressed myeloid cancer growth.  However, previous studies
found that in colorectal cancer where TCF7L2 is inactivated, the cells grew more rapidly in
culture, and TCF7L2 is therefore thought to function as a tumour suppressor instead of
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promoting cancer (Tang et al, 2008; Angus-Hill et al, 2011).  This strongly suggests dual
roles of TCF7L2 that remain uninvestigated in the context of haematological malignancies.
It also remains unknown whether different isoforms of TCF7L2 differentially
regulate target genes in haematopoietic cells. In further studies, it would be important to
demonstrate evidence of direct regulation of WNT target gene expression by TCF7L2 in the
context of myeloid cells.  The search for TCF7L2 target genes has not been extensively
studied in the context of haematopoiesis and a combination of different approaches are
required to achieve this; e.g. the assessment of gene expression changes in HPCs with or
without WNT pathway stimulation combined with chromatin immunoprecipitation binding
assay (Trompouki et al, 2011). The regulatory region through which TCF7L2 expression is
activated is among the most conserved DNA sequences across vertebrates. Through in
silico analysis (Park et al, 2013) and DNA arrays (Hatzis et al, 2008), putative TCF7L2
binding elements have been identified in the promoter regions of several direct TCF7L2
target genes (eg: c-MYC, ABCD1) that might be useful to monitor the downstream output of
TCF7L2 / -catenin activation or repression; this needs to be established in the context of
myeloid haematopoiesis. It will be important to evaluate the promoter activity under
multiple criteria such as how do the target promoters respond to WNT agonist or β-catenin
mediated signals and whether there are cooperative interactions with other TCF homologs
(e.g. TCF7 and TCF7L1).
If activation of WNT signalling due to high TCF7L2 expression can be confirmed in
a larger cohort of primary AML cells then this protein may represent a potential therapeutic
target. Previous studies have found ways to block WNT signalling, both upstream and
downstream of APC as reviewed previously (Anastas & Moon, 2013).  However, WNT
signalling effectors within the nucleus have been difficult to target. Improved drug
discovery platforms have helped to discover new molecules that can alter the WNT pathway
including small molecule compounds that target specifically the TCF7L2 / -catenin
complex (eg:  iCRT3, iCRT5, BC21, NC043, PKF118-310) (Tian et al, 2012) and
compounds that target TCF / -catenin-dependent transcription (eg: OSU030123, 6-
dihydroxyflavone) (Baryawno et al, 2010; Ewan et al, 2010).  These have been
demonstrated to inhibit growth of mainly colorectal cancer cells and other solid tumours
(eg: medulloblastoma, breast cancer). Their efficacy in leukaemia still needs to be
addressed.
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8 – Supplementary
Trial Regime Treatment
AML10
C1 DAT 3+10 Daunorubicin 50 mg/m2 d1,3,5;
Cytarabine 100 mg/m2 d1-10 every 12h
Thioguanine 100 mg/m2 d-10 every 12h
C2 DAT 3+8 Daunorubicin 50 mg/m2 d1,3,5
Cytarabine 100 mg/m2 d1-8 every 12h
Thioguanine 100 mg/m2 d-8 every 12h
C1 ADE 10+3+5 Daunorubicin 50 mg/m2 d1,3,5
Cytarabine 100 mg/m2 d1-10 every 12h
Etoposide 100 mg/m2 d1-5
C2 ADE 8+3+5 Daunorubicin 50 mg/m2 d1,3,5
Cytarabine 100 mg/m2 d1-8 every 12h
Etoposide 100 mg/m2 d1-5
AML11
C1 DAT 3+10 Daunorubicin 50 mg/m2 d1,3,5
Cytarabine 100 mg/m2 d1-10 every 12h
Thioguanine 100 mg/m2 d1-10 every 12h
C2 DAT 2+5 Daunorubicin 50 mg/m2 d1,3
Cytarabine 100 mg/m2 d1-5 every 12h
Thioguanine 100 mg/m2 d-5 every 12h
C1 ADE 10+3+5 Daunorubicin 50 mg/m2 d1,3,5
Cytarabine 100 mg/m2 d1-10 every 12h
Etoposide 100 mg/m2 d1-5
C2 ADE 5+2+5 Daunorubicin 50 mg/m2 d1,3
Cytarabine 100 mg/m2 d1-5 every 12h
Etoposide 100 mg/m2 d1-5
C1 MAC 3+5 Mitozantrone 12mg/m2 d1-3
Cytarabine 100 mg/m2 bd, d1-5
C2 MAC 2+5 Mitozantrone 12mg/m2 d1,3
Cytarabine 100 mg/m2 bd, d1-5
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AML12:
Pre-amendment
C1 ADE 10+3+5 Daunorubicin 50 mg/m2 d1,3,5
Cytarabine 100 mg/m2 d1-10 every 12h
Etoposide 100 mg/m2 d1-5
C2 ADE 8+3+5 Daunorubicin 50 mg/m2 d1,3,5
Cytarabine 100 mg/m2 d1-8 every 12h
Etoposide 100 mg/m2 d1-5
C1 MAE 10+3+5 Mitoxantrone 12 mg/m2 d1,3,5
Cytarabine 100 mg/m2 d1-10 every 12h
Etoposide 100 mg/m2 d1-5
C2 MAE 8+3+5 Mitoxantrone 12 mg/m2 d1,3,5
Cytarabine 100 mg/m2 d1-8 every 12h
Etoposide 100 mg/m2 d1-5
Post-amendment
C1 H-DAT 3+10 Daunorubicin 50 mg/m2 d1,3,5
Cytarabine 200 mg/m2 d1-10 every 12h
Thioguanine 100 mg/m2 d-10 every 12h
C2 H-DAT 3+8 Daunorubicin 50 mg/m2 d1,3,5
Cytarabine 200 mg/m2 d1-8 every 12h
Thioguanine 100 mg/m2 d-8 every 12h
C1 S-DAT 3+10 Daunorubicin 50 mg/m2 d1,3,5
Cytarabine 100 mg/m2 d1-10 every 12h
Thioguanine 100 mg/m2 d-10 every 12h
C2 S-DAT 3+8 Daunorubicin 50 mg/m2 d1,3,5
Cytarabine 100 mg/m2 d1-8 every 12h
Thioguanine 100 mg/m2 d-8 every 12h
AML14:
C1 S-DAT 3+10 Daunorubicin 35/50 mg/m2 d1-3
Cytarabine 100/200 mg/m2 d1-10 every 12h
Thioguanine 100 mg/m2 d-10 every 12h
C1 S-DAT 3+8 Daunorubicin 35/50 mg/m2 d1-3
Cytarabine 100/200 mg/m2 d1-8 every 12h
Thioguanine 100 mg/m2 d-8 every 12h
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AML15:
C1 DA 3+10 Daunorubicin 50 mg/m2 d1,3,5
Cytarabine 100 mg/m2 d1-10 every 12h
C2 DA 3+8 Daunorubicin 50 mg/m2 d1,3,5
Cytarabine 100 mg/m2 d1-8 every 12h
C1ADE 10+3+5 Daunorubicin 50 mg/m2 d1,3,5
Cytarabine 100 mg/m2 d1-10 every 12h
Etoposide 100 mg/m2 d1-5
C2 ADE 8+3+5 Daunorubicin 50 mg/m2 d1,3,5
Cytarabine 100 mg/m2 d1-8 every 12h
Etoposide 100 mg/m2 d1-5
C1,2 FLAG-Ida Fludarabine 30mg/m2 iv days 2-6 inclusive,
Cytosine Arabinoside 2g/m2 over 4 hours
starting 4 hours after Fludarabine on days 2-6,
G-CSF [Lenograstim 263µg (1 vial)] SC daily
days 1-7]
Supplementary 3.1: The specific intensive chemotherapy regimens used in UK MRC-NCRI
AML Trials 10-15 relevant to patient samples used in this study are detailed.
Supplementary 3.2: Cytogenetic prognostic classification based on established guidelines
published by (Grimwade et al, 1998).
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(Please refer electronic document on CD)
Supplementary 3.3: List of 651 WNT related probe-sets for HG-U133 Plus2.0
Score WHO /ECOG  Performance Status
0 Fully active, able to carry on all pre-disease performance without
restriction
1 Restricted in physically strenuous activity but ambulatory and able to
carry out work of a light or sedentary nature, e.g. light house work,
office work
2 Ambulatory and capable of all selfcare but unable to carry out any work
activities.  Up and about more than 50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair more than
50% of waking hours
4 Completely disabled.  Cannot carry on any selfcare.  Totally confined to
bed or chair
Supplementary 3.4: WHO or the Eastern Cooperative Oncology Group (ECOG)  performance
score. Published by Oken et al,1982.
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Supplementary 3.5: Representative diagram showing Direct Interaction Network built for
WNT Signalling genes taken from genelist F. All proteins shown are differentially expressed
in AML (M0-M6) vs Normal Controls. Blue for underexpression and red for overexpression of
corresponding gene. Localisation of each gene/protein and the hubs of its interconnection to
other genes/proteins are shown. The full legend explaining identity of each protein and objects
are listed in Supplementary 3.6 .
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Supplementary 3.6:  Legend showing identity of each objects mapped in Direct Interaction
Network. Provided by GeneGo Metcore™.
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Supplementary 4.1: pDrive cloning vector map. The unique restriction endonuclease
recognition sites on either side of the cloning site are listed. The positions of the T7 and SP6
promoter sites and the M13 forward and reverse sequencing primer binding sites are provided.
Adapted from QIAGEN PCR Cloning Handbook.
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Exon
number
Sequences 5’ to 3’
Exon 1 AATAATCTCCGCTCCCAGACTACTCCGTTCCTCCGGATTTCGATCCCCCTTTTTCTATCTGTCAATCAGC
GCCGCCTTTGAACTGAAAAGCTCTCAGTCTAACTTCAACTCACTCAAATCCGAGCGGCACGAGCACCTCC
TGTATCTTCGGCTTCCCCCCCCCTTTGCTCTTTATATCTGACTTCTTGTTGTTGTTGGTGTTTTTTTTTT
TTTTACCCCCCTTTTTTATTTATTATTTTTTTGCACATTGATCGGATCCTTGGGAACGAGAGAAAAAAGA
AACCCAAACTCACGCGTGCAGAAGATCTCCCCCCCCTTCCCCTCCCCTCCTCCCTCTTTTCCCCTCCCCA
GGAGAAAAAGACCCCCAAGCAGAAAAAAGTTCACCTTGGACTCGTCTTTTTCTTGCAATATTTTTTGGGG
GGGCAAAACTTTTTGGGGGTGATTTTTTTTGGCTTTTCTTCCTCCTTCATTTTTCTTCCAAAATTGCTGC
TGGTGGGTGAAAAAAAAATGCCGCAGCTGAACGGCGGTGGAGGGGATGACCTAGGCGCCAACGACGAACT
GATTTCCTTCAAAGACGAGGGCGAACAGGAGGAGAAGAGCTCCGAAAACTCCTCGGCAGAGAGGGATTTA
GCTGATGTCAAATCGTCTCTAGTCAATGAATCAGAAACGAATCAAAACAGCTCCTCCGATTCCGAG
Exon 2 GCGGAAAGACGGCCTCCGCCTCGCTCCGAAAGTTTCCGAGACAAATCCCGGGAAAGTTTGGAAGAAG
Exon 3 CGGCCAAGAGGCAAGATGGAGGGCTCTTTAAGGGGCCACCGTATCCCGGCTACCCCTTCATCATGATCCC
CGACCTGACGAGCCCCTACCTCCCCAACGGATCGCTCTCGCCCACCGCCCGAACC
Exon 4 CTCCATTTTCAGTCCGGCAGCACACATTACTCTGCGTACAAAACGATTGAACACCAGATTGCAGTTCAG
Exon 5 TATCTCCAGATGAAATGGCCACTGCTTGATGTCCAGGCAGGGAGCCTCCAGAGTAGACAAGCCCTCAAGG
ATGCCCGGTCCCCATCACCGGCACACATTGTC
Exon 6 AGCCCCCTCCCTTGCTGCACTCAGGGACATGACTGTCAGCACTTCTACCCCCCCTCAGACTTCACTGTCA
GCACTCAAGTCTTCAGGGACATGAAAAGGAGCCACTCCTTACAAAAAGTTGGGGAGCCCTGGTGTATTGAG
Exon 7 TCTAACAAAGTGCCAGTGGTGCAGCACCCTCACCATGTCCACCCCCTCACGCCTCTTATCACGTACAGCA
ATGAACACTTCACGCCGGGAAACCCACCTCCACACTTACCAGCCGACGTAGACCCCAAAACAG
Exon
8 b
GAATCCCACGGCCTCCGCACCCTCCAGATATATCCCCGTATTACCCACTATCGCCTGGCACCGTAGGACA
AATCCCCCATCCGCTAGGATGGTTAGTACCACA
Exon
8 a
GAATCCCACGGCCTCCGCACCCTCCAGATATATCCCCGTATTACCCACTATCGCCTGGCACCGTAGGACA
AATCCCCCATCCGCTAGGATG
Exon 9 GCAAGGTCAACCAGTGTACCCAATCACGACAGGAGGATTCAGACACCCCTACCCCACAGCTCTGACCGTC
AATGCTTCCATGTCCAG
Exon
10 a
CTTTCTGTCTTCTAGGTTCCCTCCCCATATGGTCCCACCACATCATACGCTACACACGACGGGCATTCCG
CATCCGGCCATAGTCACACCAACAGTCAAACAGGAATCGTCCCAGAGTGATGTCGGCTCACTCCATAGTT
C
Exon
10 b
GTTCCCTCCCCATATGGTCCCACCACATCATACGCTACACACGACGGGCATTCCGCATCCGGCCATAGTC
ACACCAACAGTCAAACAGGAATCGTCCCAGAGTGATGTCGGCTCACTCCATAGTTC
Exon 11 AAAGCATCAGGACTCCAAAAAGGAAGAAGAAAAGAAGAAGCCCCACATAAAGAAACCTCTTAATGCATTC
ATGTTGTATATGAAGGAAATGAGAGCAAAGGTCGTAGCTGAGTGCACGTTGAAAGAAAGCGCGGCCATCA
ACCAGATCCTTGGGCGGAGG
Exon 12 TGGCATGCACTGTCCAGAGAAGAGCAAGCGAAATACTACGAGCTGGCCCGGAAGGAGCGACAGCTTCATA
TGCAACTGTACCCCGGCTGGTCCGCGCGGGATAACTAT
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Supplementary 4.2:  TCF7L2 exon sequences published for NM_001146274.1. Blue font
indicates 5’ UTR sequences.
Exon 13 GGAAAGAAGAAGAAGAGGAAAAGGGACAAGCAGCCGGGAGAGACCAATG
Exon 14 AACACAGCGAATGTTTCCTAAATCCTTGCCTTTCACTTCCTCCGATTACAG
Exon 15 ACCTGAGCGCTCCTAAGAAATGCCGAGCGCGCTTTGGCCTTGATCAACAGAATAACTGGTGCGGCCCTTG
CAG
Exon 16 ATGCAAATACTCCAAAGAAGTGTCGGGCACTGTTCGGGCTTGACCGACAGACTTTATGGTGCAAACCGTG
CAG
Exon 17 TCTTTGAATTTGGAATATTACAATG
Exon 18 GAGAAAAAAAAAGTGCGTTCGCTACATACAAGGTGAAGGCAGCTGCCTCAGCCCACCCTCTTCAGATGGA
AGCTTACTAGATTCGCCTCCCCCCTCCCCGAACCTGCTAGGCTCCCCTCCCCGAGACGCCAAGTCACAGA
CTGAGCAGACCCAGCCTCTGTCGCTGTCCCTGAAGCCCGACCCCCTGGCCCACCTGTCCATGATGCCTCC
GCCACCCGCCCTCCTGCTCGCTGAGGCCACCCACAAGGCCTCCGCCCTCTGTCCCAACGGGGCCCTGGAC
CTGCCCCCAGCCGCTTTGCAGCCTGCCGCCCCCTCCTCATCAATTGCACAGCCGTCGACTTCTTCCTTAC
ATTCCCACAGCTCCCTGGCCGGGACCCAGCCCCAGCCGCTGTCGCTCGTCACCAAGTCTTTAGAATAG
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Supplementary 4.3: Distribution of nuclear and cytosolic TCF7L2 protein isoforms detected
by western blotting in normal CD34+ HPC from CB at different stage of culture. Protein
extracts were prepared from indicated samples and the blots were probed with monoclonal
TCF7L2 antibody (exon11/Leu330 epitope). Loading controls used to show purity of each
fraction were probed with GAPDH and Histone H1.
                                   CD34+CB day5       CD34+CB day13      CD34+CB day22
                                     C               N             C        N C              N
TCF7L2 (exon 11)
GAPDH
Histone H1
72 kDa
56/58 kDa
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Supplementary 5.1: Proliferative activity of shRNA transduced U937-pBAR-VubiR
reporter cell lines.  Proliferation was counted as cell number /ml (x105).  Relative proliferation
shown for each shRNA target is relative to the control.
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M0        M1 M2          M3 M4 M5 M6        (FAB)
Supplementary 6.1: TCF7L2 gene expression in AML patients  (n = 98). Data was obtained
from GC-RMA normalised expression generated by HG-U133 Plus2.0 Affymetrix  probe set
212759_s_at.
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orm
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ed
TC
F7
L2
 ex
pre
ssi
on
)
Probe-set
ID
number
Gene name Gene symbol RefSeq ID (NCBI)
Probe -set ID
HG-U133 Plus2.0
1
ATP-binding cassette, subfamily B, member 4
isoform A ABCB1 NM_000443 209994_s_at
2 ABCB1 NM_000443 209993_at
3 adenomatous polyposis coli APC NM_000038 216933_x_at
4 APC NM_000038 203526_s_at
5 APC NM_000038 203525_s_at
6 APC NM_000038 203527_s_at
7 APC NM_000038 215310_at
8 adenomatosis polyposis coli 2 APC2 NM_005883 217174_s_at
9 APC2 NM_005883 205320_at
10 atonal homolog 1 ATOH1 NM_005172 221336_at
11 axin 1 isoform a AXIN1 NM_003502 212849_at
12 axin 2 AXIN2 NM_004655 224498_x_at
13 AXIN2 NM_004655 222695_s_at
14 AXIN2 NM_004655 224176_s_at
15 AXIN2 NM_004655 222696_at
16 osteocalcin preproprotein BGLAP NM_199173 206956_at
17
baculoviral IAP repeat-containing protein 5
isoform 2 BIRC5 NM_001012270 202095_s_at
18 BIRC5 NM_001012270 210334_x_at
19 BIRC5 NM_001012270 202094_at
20 bone morphogenetic protein 4 preproprotein BMP4 NM_001202 211518_s_at
21
beta-transducin repeat containing protein
isoform 2 BTRC NM_003939 1563620_at
22 BTRC NM_003939 216091_s_at
23 BTRC NM_003939 222374_at
24 BTRC NM_003939 224471_s_at
25 BTRC NM_003939 204901_at
26 calcyclin binding protein isoform 2 CACYBP NM_001007214 210691_s_at
27 CACYBP NM_001007214 201381_x_at
28 CACYBP NM_001007214 211761_s_at
29 CACYBP NM_001007214 201382_at
30
calcium/calmodulin-dependent protein kinase
II alpha isoform 1 CAMK2A NM_015981 207613_s_at
31 CAMK2A NM_015981 213108_at
32
calcium/calmodulin-dependent protein kinase
II beta isoform 1 CAMK2B NM_001220 209956_s_at
33 CAMK2B NM_001220 210404_x_at
34 CAMK2B NM_001220 211483_x_at
35 CAMK2B NM_001220 213276_at
36 CAMK2B NM_001220 34846_at
37
calcium/calmodulin-dependent protein kinase
II delta isoform 3 CAMK2D NM_001221 231793_s_at
38 CAMK2D NM_001221 224994_at
39 CAMK2D NM_001221 225019_at
40 CAMK2D NM_001221 228555_at
41 CAMK2D NM_001221 230749_s_at
42
calcium/calmodulin-dependent protein kinase
II gamma isoform 4 CAMK2G NM_001222 212669_at
43 CAMK2G NM_001222 214322_at
44 CAMK2G NM_001222 212757_s_at
45 cyclin D1 CCND1 NM_053056 208711_s_at
46 CCND1 NM_053056 208712_at
47 cyclin D2 CCND2 NM_001759 200951_s_at
48 CCND2 NM_001759 200952_s_at
49 CCND2 NM_001759 200953_s_at
50 cyclin D3 isoform 1 CCND3 NM_001136017 201700_at
51 CCND3 NM_001136017 1562028_at
52 CD44 antigen isoform 1 precursor CD44 NM_000610 210916_s_at
53 CD44 NM_000610 1557905_s_at
54 CD44 NM_000610 204490_s_at
55 CD44 NM_000610 209835_x_at
56 CD44 NM_000610 204489_s_at
57 CD44 NM_000610 229221_at
58 CD44 NM_000610 212063_at
59 CD44 NM_000610 212014_x_at
60 CD44 NM_000610 1565868_at
61 CD44 NM_000610 234411_x_at
62 CD44 NM_000610 216056_at
63 CD44 NM_000610 217523_at
64 CD44 NM_000610 234418_x_at
65
cyclin-dependent kinase inhibitor 2A isoform
1 CDKN2A NM_000077 211156_at
66 CDKN2A NM_000077 209644_x_at
67 CDKN2A NM_000077 207039_at
68 caudal type homeobox 1 CDX1 NM_001804 206430_at
69 caudal type homeobox 4 CDX4 NM_005193 221340_at
70 cerberus 1 CER1 NM_005454 221378_at
71
chromodomain helicase DNA binding protein
8 CHD8 NM_020920 212571_at
72 calcium binding protein P22 CHP NM_007236 207993_s_at
73 CHP NM_007236 214665_s_at
74 hepatocellular carcinoma antigen gene 520 CHP2 NM_022097 206149_at
75 claudin 1 CLDN1 NM_021101 218182_s_at
76 CLDN1 NM_021101 222549_at
77
 cAMP Response Element-Binding Protein
(CREB-binding protein) CREBBP NM_001079846 211808_s_at
78 CREBBP NM_001079846 202160_at
79 CREBBP NM_001079846 228177_at
80 casein kinase 1, alpha 1 isoform 1 CSNK1A1 NM_001025105 206562_s_at
81 CSNK1A1 NM_001025105 213086_s_at
82 CSNK1A1 NM_001025105 213860_x_at
83 CSNK1A1 NM_001025105 208867_s_at
84 CSNK1A1 NM_001025105 208865_at
85 CSNK1A1 NM_001025105 1556006_s_at
86 CSNK1A1 NM_001025105 208866_at
87 CSNK1A1 NM_001025105 226920_at
88 CSNK1A1 NM_001025105 240221_at
89 casein kinase I epsilon E CSNK1E NM_001894 202332_at
90 CSNK1E NM_001894 226858_at
91 CSNK1E NM_001894 222015_at
92 CSNK1E NM_001894 234943_at
93 CSNK1E NM_001894 225756_at
94 casein kinase I epsilon G3 CSNK1G3 NM_001031812 220768_s_at
95 CSNK1G3 NM_001031812 229702_at
96 CSNK1G3 NM_001031812 227767_at
97 casein kinase II alpha 1 subunit isoform a CSNK2A1 NM_001895 212073_at
98 CSNK2A1 NM_001895 212075_s_at
99 CSNK2A1 NM_001895 206075_s_at
100 CSNK2A1 NM_001895 212072_s_at
101 CSNK2A1 NM_001895 229216_s_at
102 casein kinase 2, alpha prime polypeptide CSNK2A2 NM_001896 203575_at
103 CSNK2A2 NM_001896 224922_at
104 casein kinase 2, beta polypeptide CSNK2B NM_001320 201390_s_at
105 CSNK2B NM_001320 231777_at
106 C-terminal binding protein 1 isoform 2 CTBP1 NM_001012614 203392_s_at
107 CTBP1 NM_001012614 212863_x_at
108 CTBP1 NM_001012614 213980_s_at
109 CTBP1 NM_001012614 1557714_at
110 C-terminal binding protein 2 isoform 1 CTBP2 NM_001083914 210554_s_at
111 CTBP2 NM_001083914 201220_x_at
112 CTBP2 NM_001083914 210835_s_at
113 CTBP2 NM_001083914 201218_at
114 CTBP2 NM_001083914 201219_at
115 CTBP2 NM_001083914 215377_at
116
cytotoxic T-lymphocyte-associated protein 4
isoform b precursor CTLA4 NM_001037631 234362_s_at
117 CTLA4 NM_001037631 221331_x_at
118 CTLA4 NM_001037631 231794_at
119 CTLA4 NM_001037631 236341_at
120 CTLA4 NM_001037631 234895_at
121
catenin (cadherin-associated protein), beta 1,
88kDa CTNNB1 NM_001098209 201533_at
122 CTNNB1 NM_001098209 1554411_at
123 CTNNB1 NM_001098209 223679_at
124
cadherin; E-cadherin;cadherin-associated
protein), delta 1; Cadherin-associated Src
substrate; ctenin delta 1 isoform1ABC CTNND1 NM_001085458 211240_x_at
125 CTNND1 NM_001085458 208862_s_at
126 CTNND1 NM_001085458 208407_s_at
127 CTNND1 NM_001085458 1557944_s_at
128 cullin 1 CUL1 NM_003592 207614_s_at
129 CUL1 NM_003592 238509_at
130 CXXC finger 4 CXXC4 NM_025212 220277_at
131 CXXC4 NM_025212 229774_at
132 cysteine-rich, angiogenic inducer, 61 CYR61 NM_001554 210764_s_at
133 CYR61 NM_001554 201289_at
134
dishevelled associated activator of
morphogenesis 1 DAAM1 NM_014992 226666_at
135 DAAM1 NM_014992 216060_s_at
136 DAAM1 NM_014992 244062_at
137 DAAM1 NM_014992 232552_at
138
dishevelled associated activator of
morphogenesis 2 DAAM2 NM_015345 212793_at
139 dickkopf homolog 1 precursor DKK1 NM_012242 204602_at
140 dickkopf homolog 2 precursor DKK2 NM_014421 219908_at
141 DKK2 NM_014421 224199_at
142 dickkopf homolog 3 precursor DKK3 NM_001018057 221127_s_at
143 DKK3 NM_001018057 230508_at
144 DKK3 NM_001018057 221126_at
145 DKK3 NM_001018057 214247_s_at
146 DKK3 NM_001018057 202196_s_at
147 dickkopf homolog 4 precursor DKK4 NM_014420 206619_at
148 delta-like 1 DLL1 NM_005618 227938_s_at
149 DLL1 NM_005618 224215_s_at
150 dishevelled 1 DVL-1 NM_004421 203230_at
151 dishevelled 2 DVL-2 NM_004422 218759_at
152 DVL-2 NM_004422 57532_at
153 dishevelled, dsh homolog 3 DVL-3 NM_004423 201907_x_at
154 DVL-3 NM_004423 201908_at
155 ectodysplasin A isoform EDA-A2 EDA NM_001005609 211130_x_at
156 EDA NM_001005609 206217_at
157 EDA NM_001005609 211131_s_at
158 EDA NM_001005609 211128_at
159 EDA NM_001005609 211129_x_at
160 EDA NM_001005609 211127_x_at
161 ectodysplasin A receptor precursor EDAR NM_022336 220048_at
162 endothelin 1 EDN1 NM_001955 218995_s_at
163 EDN1 NM_001955 222802_at
164 EDN1 NM_001955 1564630_at
165 ephrin-B1 precursor EFNB1 NM_004429 202711_at
166 ephrin B2 EFNB2 NM_004093 202669_s_at
167 EFNB2 NM_004093 202668_at
168
epidermal growth factor receptor isoform a
precursor EGFR NM_005228 211607_x_at
169 EGFR NM_005228 210984_x_at
170 EGFR NM_005228 201983_s_at
171 EGFR NM_005228 211550_at
172 EGFR NM_005228 1565483_at
173 EGFR NM_005228 1565484_x_at
174 EGFR NM_005228 201984_s_at
175 EGFR NM_005228 211551_at
176 E1A binding protein p300 EP300 NM_001429 213579_s_at
177 EP300 NM_001429 202221_s_at
178 F-box and WD repeat domain containing 2 FBXW2 NM_012164 218941_at
179 FBXW2 NM_012164 209630_s_at
180 FBXW2 NM_012164 235195_at
181 FBXW2 NM_012164 241736_at
182 FBXW2 NM_012164 1560752_at
183 fibroblast growth factor 18 precursor FGF18 NM_003862 211485_s_at
184 FGF18 NM_003862 206987_x_at
185 FGF18 NM_003862 211029_x_at
186 FGF18 NM_003862 214284_s_at
187 FGF18 NM_003862 231382_at
188 FGF18 NM_003862 206986_at
189 fibroblast growth factor 20 FGF20 NM_019851 220394_at
190 fibroblast growth factor 4 precursor FGF4 NM_002007 1552982_a_at
191 FGF4 NM_002007 206783_at
192 fibroblast growth factor 9 precursor FGF9 NM_002010 239178_at
193 FGF9 NM_002010 206404_at
194 fibronectin 1 isoform 3 preproprotein FN1 NM_002026 214701_s_at
195 FN1 NM_002026 210495_x_at
196 FN1 NM_002026 211719_x_at
197 FN1 NM_002026 216442_x_at
198 FN1 NM_002026 212464_s_at
199 FN1 NM_002026 214702_at
200 FN1 NM_002026 1558199_at
201 FOS-like antigen 1 FOSL1 NM_005438 204420_at
202 forkhead box N1 FOXN1 NM_003593 207683_at
203
frequently rearranged in advanced T-cell
lymphoma 1 FRAT-1 NM_005479 219889_at
204
frequently rearranged in advanced T-cell
lymphomas 2 FRAT-2 NM_012083 209864_at
205 frizzled-related protein FRZB NM_001463 203698_s_at
206 FRZB NM_001463 203697_at
207 follistatin isoform FST317 precursor FST NM_006350 204948_s_at
208 FST NM_006350 226847_at
209 FST NM_006350 207345_at
210 frizzled homolog1 FZD1 NM_003505 204452_s_at
211 FZD1 NM_003505 204451_at
212 frizzled homolog 10 FZD10 NM_007197 219764_at
213 frizzled homolog 2 FZD2 NM_001466 210220_at
214 frizzled homolog 3 FZD3 NM_017412 219683_at
215 frizzled homolog 4 FZD4 NM_012193 224337_s_at
216 FZD4 NM_012193 218665_at
217 frizzled homolog 5 FZD5 NM_003468 206136_at
218 FZD5 NM_003468 221245_s_at
219 frizzled homolog 6 FZD6 NM_003506 203987_at
220 frizzled homolog 7 FZD7 NM_003507 203705_s_at
221 FZD7 NM_003507 203706_s_at
222 frizzled homolog 8 FZD8 NM_031866 227405_s_at
223 FZD8 NM_031866 216587_s_at
224 FZD8 NM_031866 224325_at
225 frizzled homolog 9 FZD9 NM_003508 207639_at
226 Gastrin GAST NM_000805 208138_at
227 gastrulation brain homeo box 2 GBX2 NM_001485 210560_at
228 connexin 43 GJA1 NM_000165 201667_at
229 gap junction protein, beta 6 GJB6 NM_001110219 231771_at
230 glucagon-like peptide 1 receptor GLP1R NM_002062 208391_s_at
231 GLP1R NM_002062 211232_x_at
232 GLP1R NM_002062 208390_s_at
233 GLP1R NM_002062 208400_at
234 GLP1R NM_002062 208401_s_at
235 gremlin 2 precursor GREM2 NM_022469 220794_at
236 GREM2 NM_022469 240509_s_at
237 GREM2 NM_022469 235504_at
238 glycogen synthase kinase 3 beta isoform 2 GSK3B NM_001146156 209945_s_at
239 GSK3B NM_001146156 242336_at
240 GSK3B NM_001146156 226183_at
241 GSK3B NM_001146156 226191_at
242 inhibitor of DNA binding 2 ID2 NM_002166 213931_at
243 ID2 NM_002166 201565_s_at
244 ID2 NM_002166 201566_x_at
245
insulin-like growth factor 1 isoform 4
preproprotein IGF1 NM_000618 211577_s_at
246 IGF1 NM_000618 209542_x_at
247 IGF1 NM_000618 209540_at
248 IGF1 NM_000618 209541_at
249
insulin-like growth factor 2 isoform 1
precursor IGF2 NM_000612 210881_s_at
250 IGF2 NM_000612 202410_x_at
251 IGF2 NM_000612 202409_at
252 interleukin 6 precursor IL6 NM_000600 205207_at
253 interleukin 8 precursor IL8 NM_000584 211506_s_at
254 IL8 NM_000584 202859_x_at
255 integrin-linked kinase ILK NM_001014794 201234_at
256 iroquois homeobox 3 IRX3 NM_024336 229638_at
257 islet-1 ISL1 NM_002202 206104_at
258
immunoglobulin superfamily containing
leucine-rich repeat ISLR NM_005545 207191_s_at
259 jagged 1 precursor JAG1 NM_000214 209098_s_at
260 JAG1 NM_000214 209097_s_at
261 JAG1 NM_000214 216268_s_at
262 JAG1 NM_000214 209099_x_at
263 JAG1 NM_000214 231183_s_at
264 jun oncogene JUN NM_002228 201465_s_at
265 JUN NM_002228 201466_s_at
266 JUN NM_002228 201464_x_at
267 junction plakoglobin JUP NM_002230 201015_s_at
268
kringle-containing transmembrane protein 2
isoform b precursor KREMEN2 NM_024507 219692_at
269 keratin 14 KRT14 NM_000526 209351_at
270 keratin 5 KRT5 NM_000424 201820_at
271 L1 cell adhesion molecule isoform 1 precursor L1CAM NM_000425 204585_s_at
272 L1CAM NM_000425 204584_at
273 low density lipoprotein receptor precursor LDLR NM_000527 217173_s_at
274 LDLR NM_000527 202067_s_at
275 LDLR NM_000527 202068_s_at
276 LDLR NM_000527 217103_at
277 LDLR NM_000527 217005_at
278 LDLR NM_000527 217183_at
279 lymphoid enhancer- binding factor - Lef LEF1 NM_001130713 210948_s_at
280 LEF1 NM_001130713 221558_s_at
281 LEF1 NM_001130713 221557_s_at
282
leucine-rich repeat-containing G protein-
coupled receptor 5 LGR5 NM_003667 210393_at
283 LGR5 NM_003667 213880_at
284
low density lipoprotein receptor-related
protein 5 LRP5 NM_002335 229591_at
285 LRP5 NM_002335 209468_at
286
low density lipoprotein receptor-related
protein 6 LRP6 NM_002336 34697_at
287 LRP6 NM_002336 205606_at
288 LRP6 NM_002336 225745_at
289
mitogen-activated protein kinase kinase kinase
7 isoform A MAP3K7 NM_003188 211536_x_at
290 MAP3K7 NM_003188 211537_x_at
291 MAP3K7 NM_003188 206854_s_at
292 MAP3K7 NM_003188 206853_s_at
293 mitogen-activated protein kinase 10 isoform 1 MAPK10 NM_002753 204813_at
294
mitogen-activated protein kinase 8 isoform
JNK1 alpha1 MAPK8 NM_002750 210477_x_at
295 MAPK8 NM_002750 210671_x_at
296 MAPK8 NM_002750 226048_at
297 MAPK8 NM_002750 226046_at
298 MAPK8 NM_002750 229664_at
299
mitogen-activated protein kinase 9 isoform
JNK2 gamma MAPK9 NM_001135044 210570_x_at
300 MAPK9 NM_001135044 203218_at
301 MAPK9 NM_001135044 225781_at
302
microphthalmia-associated transcription factor
isoform 4 MITF NM_000248 207233_s_at
303 MITF NM_000248 226066_at
304 MITF NM_000248 1554874_at
305 matrix metalloproteinase 2 isoform b MMP2 NM_001127891 201069_at
306 MMP2 NM_001127891 1566678_at
307 MMP2 NM_001127891 1566677_at
308 matrix metalloproteinase 26 preproprotein MMP26 NM_021801 220541_at
309 matrix metalloproteinase 7 preproprotein MMP7 NM_002423 204259_at
310 matrix metalloproteinase 9 preproprotein MMP9 NM_004994 203936_s_at
311
myc proto-oncogene protein, Transcription
factor p64 ,  v-myc avian myelocytomatosis
viral oncogene homolog MYC NM_002467 202431_s_at
312 c-myc binding protein MYCBP NM_012333 203360_s_at
313 MYCBP NM_012333 203359_s_at
314 MYCBP NM_012333 203361_s_at
315 Nanog homeobox NANOG NM_024865 220184_at
316 norrin precursor NDP NM_000266 206022_at
317 neurogenic differentiation 1 NEUROD1 NM_002500 206282_at
318 NEUROD1 NM_002500 1556057_s_at
319 neurogenin 1 NEUROG1 NM_006161 208497_x_at
320 nuclear factor of activated T-cells 5 isoform NFAT5 NM_001113178 215092_s_at
321 NFAT5 NM_001113178 208003_s_at
322 NFAT5 NM_001113178 224984_at
323
nuclear factor of activated T-cells, cytosolic
component 1 isoform B NFATC1 NM_006162 209664_x_at
324 NFATC1 NM_006162 208196_x_at
325 NFATC1 NM_006162 211105_s_at
326 NFATC1 NM_006162 210162_s_at
327
nuclear factor of activated T-cells,
cytoplasmic, calcineurin-dependent 2 isoform NFATC2 NM_001136021 224542_s_at
328 NFATC2 NM_001136021 231801_at
329 NFATC2 NM_001136021 226991_at
330
nuclear factor of activated T-cells,
cytoplasmic, calcineurin-dependent 3 isoform NFATC3 NM_004555 210555_s_at
331 NFATC3 NM_004555 207416_s_at
332 NFATC3 NM_004555 210556_at
333
nuclear factor of activated T-cells,
cytoplasmic, calcineurin-dependent 4 isoform NFATC4 NM_001136022 205897_at
334 NFATC4 NM_001136022 236270_at
335 NFATC4 NM_001136022 213345_at
336 naked cuticle homolog 1 NKD1 NM_033119 1553115_at
337 naked cuticle homolog 2 NKD2 NM_033120 232201_at
338 NK2 transcription factor related, locus 2 NKX2-2 NM_002509 206915_at
339 nemo like kinase NLK NM_016231 222590_s_at
340 NLK NM_016231 218318_s_at
341 NLK NM_016231 222589_at
342 nitric oxide synthase 2A NOS2 NM_000625 210037_s_at
343
neuronal cell adhesion molecule isoform A
precursor NRCAM NM_001037132 204105_s_at
344 NRCAM NM_001037132 216959_x_at
345
platelet-activating factor acetylhydrolase,
isoform Ib, subunit 1 (45kDa) PAFAH1B1 NM_000430 200815_s_at
346 PAFAH1B1 NM_000430 200813_s_at
347 PAFAH1B1 NM_000430 200816_s_at
348 PAFAH1B1 NM_000430 211547_s_at
349
paired-like homeodomain transcription factor
2 isoform c PITX2 NM_000325 207558_s_at
350 plasminogen activator, urokinase isoform 2 PLAU NM_001145031 211668_s_at
351 PLAU NM_001145031 205479_s_at
352
phosphoinositide-specific phospholipase C
beta 1 isoform a PLCB1 NM_015192 211925_s_at
353 PLCB1 NM_015192 213222_at
354 PLCB1 NM_015192 215687_x_at
355 phospholipase C, beta 2 PLCB2 NM_004573 204046_at
356 PLCB2 NM_004573 210388_at
357 phospholipase C beta 3 PLCB3 NM_000932 213384_x_at
358 phospholipase C beta 4 isoform a PLCB4 NM_000933 203895_at
359 PLCB4 NM_000933 203896_s_at
360 PLCB4 NM_000933 240728_at
361 porcupine isoform A PORCN NM_022825 219483_s_at
362 periostin, osteoblast specific factor isoform 2 POSTN NM_001135934 1555778_a_at
363 POSTN NM_001135934 1555777_at
364 POSTN NM_001135934 210809_s_at
365 POSTN NM_001135934 214981_at
366 POU class 5 homeobox 1B POU5F1 NM_001159542 208286_x_at
367 POU5F1B NM_001159542 214532_x_at
368
peroxisome proliferative activated receptor,
delta isoform 1 PPARD NM_006238 242218_at
369 PPARD NM_006238 210636_at
370 PPARD NM_006238 37152_at
371 PPARD NM_006238 208044_s_at
372
protein phosphatase 2, catalytic subunit, alpha
isoform PPP2CA NM_002715 208652_at
373
protein phosphatase 2, catalytic subunit, beta
isoform PPP2CB NM_001009552 201375_s_at
374 PPP2CB NM_001009552 201374_x_at
375
alpha isoform of regulatory subunit A, protein
phosphatase 2 PPP2R1A NM_014225 200695_at
376
beta isoform of regulatory subunit A, protein
phosphatase 2 isoform a PPP2R1B NM_002716 202884_s_at
377 PPP2R1B NM_002716 222351_at
378 PPP2R1B NM_002716 202886_s_at
379 PPP2R1B NM_002716 202883_s_at
380 PPP2R1B NM_002716 202885_s_at
381
protein phosphatase 2, regulatory subunit B
(B56), alpha isoform PPP2R5A NM_006243 202187_s_at
382 PPP2R5A NM_006243 202186_x_at
383
beta isoform of regulatory subunit B56,
protein phosphatase 2A PPP2R5B NM_006244 204611_s_at
384 PPP2R5B NM_006244 635_s_at
385
gamma isoform of regulatory subunit B56,
protein phosphatase 2A PPP2R5C NM_001161725 1554365_a_at
386 PPP2R5C NM_001161725 213305_s_at
387 PPP2R5C NM_001161725 1554364_at
388 PPP2R5C NM_001161725 201877_s_at
389 PPP2R5C NM_001161725 214083_at
390 PPP2R5C NM_001161725 1557718_at
391
delta isoform of regulatory subunit B56,
protein phosphatase 2A isoform 1 PPP2R5D NM_006245 211159_s_at
392 PPP2R5D NM_006245 202513_s_at
393
epsilon isoform of regulatory subunit B56,
protein phosphatase 2A PPP2R5E NM_006246 203338_at
394 PPP2R5E NM_006246 229322_at
395
protein phosphatase 3, catalytic subunit, alpha
isoform isoform PPP3CA NM_000944 202425_x_at
396 PPP3CA NM_000944 202457_s_at
397 PPP3CA NM_000944 202429_s_at
398
protein phosphatase 3, catalytic subunit, beta
isoform PPP3CB NM_001142353 202432_at
399 PPP3CB NM_001142353 209817_at
400
protein phosphatase 3, catalytic subunit,
gamma PPP3CC NM_005605 207000_s_at
401 PPP3CC NM_005605 32541_at
402 PPP3CC NM_005605 213950_s_at
403 PPP3CC NM_005605 32540_at
404
protein phosphatase 3, regulatory subunit B,
alpha isoform PPP3R1 NM_000945 204507_s_at
405 PPP3R1 NM_000945 204506_at
406
protein phosphatase 3 regulatory subunit B,
beta isoform PPP3R2 NM_147180 231304_at
407 PPP3R2 NM_147180 244782_at
408 prickle homolog 1 PRICKLE1 NM_001144881 226065_at
409 PRICKLE1 NM_001144881 230708_at
410 PRICKLE1 NM_001144881 226069_at
411 PRICKLE1 NM_001144881 232811_x_at
412 prickle-like 2 PRICKLE2 NM_198859 225968_at
413
cAMP-dependent protein kinase catalytic
subunit alpha isoform 1 PRKACA NM_002730 216234_s_at
414 PRKACA NM_002730 202801_at
415
cAMP-dependent protein kinase catalytic
subunit beta isoform 2 PRKACB NM_002731 202742_s_at
416 PRKACB NM_002731 202741_at
417 PRKACB NM_002731 235780_at
418
protein kinase, cAMP-dependent, catalytic,
gamma PRKACG NM_002732 207228_at
419 protein kinase C, alpha PRKCA NM_002737 206923_at
420 PRKCA NM_002737 213093_at
421 PRKCA NM_002737 215195_at
422 PRKCA NM_002737 1560074_at
423 PRKCA NM_002737 215194_at
424 protein kinase C, beta isoform 2 PRKCB NM_002738 209685_s_at
425 PRKCB NM_002738 207957_s_at
426 PRKCB NM_002738 228795_at
427 PRKCB NM_002738 227824_at
428 PRKCB NM_002738 227817_at
429 PRKCB NM_002738 230437_s_at
430 protein kinase C, delta PRKCD NM_006254 202545_at
431 protein kinase C, epsilon PRKCE NM_005400 239011_at
432 PRKCE NM_005400 236459_at
433 PRKCE NM_005400 226101_at
434 PRKCE NM_005400 206248_at
435 protein kinase C, gamma PRKCG NM_002739 206270_at
436 PRKCG NM_002739 236195_x_at
437 protein kinase C, eta PRKCH NM_006255 206099_at
438 PRKCH NM_006255 218764_at
439 protein kinase C, iota PRKCI NM_002740 209677_at
440 PRKCI NM_002740 209678_s_at
441 PRKCI NM_002740 213518_at
442 protein kinase C, theta PRKCQ NM_006257 210039_s_at
443 PRKCQ NM_006257 210038_at
444 protein kinase C, zeta isoform 2 PRKCZ NM_001033581 202178_at
445 PRKCZ NM_001033581 1569748_at
446 Protein kinase D1 PRKD1 NM_002742 205880_at
447 PRKD1 NM_002742 217705_at
448 protein kinase, X-linked PRKX NM_005044 204060_s_at
449 PRKX NM_005044 204061_at
450 protein kinase, Y-linked PRKY NM_002760 206279_at
451 presenilin 1 isoform I-467 PSEN1 NM_000021 203460_s_at
452 PSEN1 NM_000021 207782_s_at
453 PSEN1 NM_000021 226577_at
454 PSEN1 NM_000021 238816_at
455 PSEN1 NM_000021 1559206_at
456 PSEN1 NM_000021 1567443_x_at
457 presenilin 2 isoform 1 PSEN2 NM_000447 204261_s_at
458 PSEN2 NM_000447 204262_s_at
459 PSEN2 NM_000447 211373_s_at
460
prostaglandin-endoperoxide synthase 2
precursor PTGS2 NM_000963 1554997_a_at
461 PTGS2 NM_000963 204748_at
462 pituitary tumor-transforming protein 1 PTTG1 NM_004219 203554_x_at
463 pituitary tumor-transforming  2 PTTG2 NM_006607 214557_at
464
ras-related C3 botulinum toxin substrate 1
isoform Rac1 RAC1 NM_006908 208641_s_at
465 RAC1 NM_006908 208640_at
466 RAC1 NM_006908 1567458_s_at
467 RAC1 NM_006908 1567457_at
468 ras-related C3 botulinum toxin substrate 2 RAC2 NM_002872 207419_s_at
469 RAC2 NM_002872 213603_s_at
470
ras-related C3 botulinum toxin substrate 3 (rho
family, small GTP binding protein Rac3) RAC3 NM_005052 206103_at
471 retinoic acid receptor, gamma isoform 1 RARG NM_000966 204188_s_at
472 RARG NM_000966 204189_at
473 RARG NM_000966 217178_at
474 ring-box 1 RBX1 NM_014248 218117_at
475 ret proto-oncogene isoform c RET NM_020630 205879_x_at
476 RET NM_020630 215771_x_at
477 RET NM_020630 211421_s_at
478 ras homolog gene family, member A RHOA NM_001664 200059_s_at
479 RHOA NM_001664 1555814_a_at
480 RHOA NM_001664 240337_at
481 ras homolog gene family, member U RHOU NM_021205 223169_s_at
482
Rho-associated, coiled-coil containing protein
kinase 1 ROCK1 NM_005406 213044_at
483 ROCK1 NM_005406 235854_x_at
484 ROCK1 NM_005406 214578_s_at
485 ROCK1 NM_005406 230239_at
486
Rho-associated, coiled-coil containing protein
kinase 2 ROCK2 NM_004850 211504_x_at
487 ROCK2 NM_004850 202762_at
488
Receptor tyrosine kinase-like orphan receptor
2 precurso ROR2 NM_004560 205578_at
489 R-spondin1 RSPO1 NM_001038633 241450_at
490 runt-related transcription factor 2 isoform b RUNX2 NM_001015051 216994_s_at
491 RUNX2 NM_001015051 221282_x_at
492 RUNX2 NM_001015051 221283_at
493 RUNX2 NM_001015051 232231_at
494 RUNX2 NM_001015051 236858_s_at
495 RUNX2 NM_001015051 236859_at
496 RuvB-like 1 RUVBL1 NM_003707 201614_s_at
497 sal-like 4 SALL4 NM_020436 229661_at
498 SALL4 NM_020436 236501_at
499 SUMO1/sentrin/SMT3 specific protease 2 SENP2 NM_021627 218122_s_at
500 SENP2 NM_021627 222523_at
501 secreted frizzled-related protein 1 SFRP1 NM_003012 202036_s_at
502 SFRP1 NM_003012 202035_s_at
503 SFRP1 NM_003012 202037_s_at
504 secreted frizzled-related protein 2 SFRP2 NM_003013 223121_s_at
505 SFRP2 NM_003013 223122_s_at
506 secreted frizzled-related protein 4 SFRP4 NM_003014 204051_s_at
507 SFRP4 NM_003014 204052_s_at
508 secreted frizzled-related protein 5 SFRP5 NM_003015 207468_s_at
509
splicing factor, arginine/serine-rich 2,
interacting protein SFRS2IP NM_004719 1570507_at
510 seven in absentia homolog 1 isoform b SIAH1 NM_001006610 202980_s_at
511 SIAH1 NM_001006610 202981_x_at
512 SIAH1 NM_001006610 232365_at
513 sine oculis homeobox homolog 3 SIX3 NM_005413 206634_at
514 S-phase kinase-associated protein 1 isoform a SKP1 NM_006930 207974_s_at
515 SKP1 NM_006930 200718_s_at
516 SKP1 NM_006930 200711_s_at
517 SKP1 NM_006930 200719_at
518
Sma- and Mad-related protein 2 isoform
1 ,SMAD family member 2 SMAD2 NM_001003652 203076_s_at
519 SMAD2 NM_001003652 203077_s_at
520 SMAD2 NM_001003652 226563_at
521 SMAD2 NM_001003652 203075_at
522 SMAD2 NM_001003652 235598_at
523 SMAD2 NM_001003652 239271_at
524
mothers against decapentaplegic homolog 3
isoform 2 SMAD3 NM_001145102 205397_x_at
525 SMAD3 NM_001145102 205398_s_at
526 SMAD3 NM_001145102 205396_at
527 SMAD3 NM_001145102 218284_at
528 mothers against decapentaplegic homolog 4 SMAD4 NM_005359 1565703_at
529 SMAD4 NM_005359 202527_s_at
530 SMAD4 NM_005359 235725_at
531 SMAD4 NM_005359 202526_at
532 SMAD4 NM_005359 1565702_at
533 snail 1 homolog SNAI1 NM_005985 219480_at
534 snail 2 SNAI2 NM_003068 213139_at
535 snail homolog 3 SNAI3 NM_178310 1560228_at
536 SRY-box 17 SOX17 NM_022454 230943_at
537 SOX17 NM_022454 219993_at
538 transcription factor SOX9 SOX9 NM_000346 202935_s_at
539 SOX9 NM_000346 202936_s_at
540 Sp5 transcription factor SP5 NM_001003845 235845_at
541
stimulated by retinoic acid gene 6 homolog
isoform a STRA6 NM_001142617 221701_s_at
542 STRA6 NM_001142617 1569334_at
543 STRA6 NM_001142617 1569335_a_at
544 transcription factor T T NM_003181 206524_at
545 transducin beta-like 1X isoform a TBL1X NM_001139466 201867_s_at
546 TBL1X NM_001139466 201869_s_at
547 TBL1X NM_001139466 201868_s_at
548 TBL1X NM_001139466 213400_s_at
549 TBL1X NM_001139466 1570293_at
550 TBL1X NM_001139466 213401_s_at
551 transducin (beta)-like 1 X-linked receptor 1 TBL1XR1 NM_024665 222634_s_at
552 TBL1XR1 NM_024665 221428_s_at
553 TBL1XR1 NM_024665 223013_at
554 TBL1XR1 NM_024665 222633_at
555 TBL1XR1 NM_024665 235890_at
556 TBL1XR1 NM_024665 233633_at
557 transducin beta-like 1Y TBL1Y NM_033284 211462_s_at
558 transcription factor 12 isoform b TCF12 NM_003205 208986_at
559 TCF12 NM_003205 215611_at
560 TCF12 NM_003205 235925_at
561 transcription factor 4 isoform a TCF4 NM_001083962 222146_s_at
562 TCF4 NM_001083962 203753_at
563 TCF4 NM_001083962 212385_at
564 TCF4 NM_001083962 212386_at
565 TCF4 NM_001083962 212387_at
566 TCF4 NM_001083962 228837_at
567 TCF4 NM_001083962 212382_at
568 TCF4 NM_001083962 213891_s_at
569 T cell factor ,TCF1 TCF7 NM_001134851 205255_x_at
570 TCF7 NM_001134851 205254_x_at
571 HMG-box transcription factor ,TCF-3 TCF7L1 NM_031283 221016_s_at
572 transcription factor 7-like 2 isoform 1,TCF4 TCF7L2 NM_001146274 212759_s_at
573 TCF7L2 NM_001146274 212762_s_at
574 TCF7L2 NM_001146274 216511_s_at
575 TCF7L2 NM_001146274 216035_x_at
576 TCF7L2 NM_001146274 216037_x_at
577 TCF7L2 NM_001146274 212761_at
578 TCF7L2 NM_001146274 236094_at
579 T-cell lymphoma invasion and metastasis 1 TIAM1 NM_003253 206409_at
580 TIAM1 NM_003253 213135_at
581 transducin-like enhancer protein 1*groucho TLE1 NM_005077 203220_s_at
582 TLE1 NM_005077 203222_s_at
583 TLE1 NM_005077 203221_at
584
transducin-like enhancer protein 3 isoform b
*groucho TLE3 NM_001105192 206472_s_at
585
tumor necrosis factor receptor superfamily,
member 19 isoform 1 precursor TNFRSF19 NM_018647 224090_s_at
586 TNFRSF19 NM_018647 223827_at
587 TNFRSF19 NM_018647 227812_at
588
tumor necrosis factor ligand superfamily,
member 11 isoform 1 TNFSF11 NM_003701 211153_s_at
589 TNFSF11 NM_003701 210643_at
590
tumor necrosis factor (ligand) superfamily,
member 9 TNFSF9 NM_003811 206907_at
591 tumor protein p53 isoform a TP53 NM_000546 211300_s_at
592 TP53 NM_000546 201746_at
593 twist TWIST1 NM_000474 213943_at
594 twist homolog 2 TWIST2 NM_057179 229404_at
595 TWIST2 NM_057179 1554163_at
596 vang-like 1 VANGL1 NM_138959 229997_at
597 VANGL1 NM_138959 219330_at
598 VANGL1 NM_138959 229134_at
599 VANGL1 NM_138959 229492_at
600 vang-like 2 VANGL2 NM_020335 226029_at
601 versican isoform 2 precursor VCAN NM_001126336 215646_s_at
602 VCAN NM_001126336 211571_s_at
603 VCAN NM_001126336 204620_s_at
604 VCAN NM_001126336 221731_x_at
605 VCAN NM_001126336 204619_s_at
606
vascular endothelial growth factor A isoform a
precursor VEGFA NM_001025366 210513_s_at
607 VEGFA NM_001025366 210512_s_at
608 VEGFA NM_001025366 212171_x_at
609 VEGFA NM_001025366 211527_x_at
610 vascular endothelial growth factor B VEGFB NM_003377 203683_s_at
611
vascular endothelial growth factor C
preproprotein VEGFC NM_005429 209946_at
612 WNT inhibitory factor 1 precursor WIF1 NM_007191 204712_at
613
WNT1 inducible signaling pathway protein 1
isoform 1 precursor WISP1 NM_003882 211312_s_at
614 WISP1 NM_003882 206796_at
615
WNT1 inducible signaling pathway protein 2
precursor WISP2 NM_003881 205792_at
616
wingless-type MMTV integration site family,
member 1 WNT1 NM_005430 208570_at
617
wingless-type MMTV integration site family,
member 10A WNT10A NM_025216 223709_s_at
618
wingless-type MMTV integration site family,
member 10B WNT10B NM_003394 206213_at
619
wingless-type MMTV integration site family,
member 11 WNT11 NM_004626 206737_at
620
wingless-type MMTV integration site family,
member 16 WNT16 NM_016087 221113_s_at
621 WNT16 NM_016087 224022_x_at
622
wingless-type MMTV integration site family,
member 2 WNT2 NM_003391 205648_at
623
wingless-type MMTV integration site family,
member 2B WNT2B NM_004185 206459_s_at
624 WNT2B NM_004185 206458_s_at
625
wingless-type MMTV integration site family,
member 3 WNT3 NM_030753 221455_s_at
626 WNT3 NM_030753 231743_at
627 WNT3 NM_030753 229103_at
628
wingless-type MMTV integration site family,
member 4 WNT4 NM_030761 208606_s_at
629 WNT4 NM_030761 230751_at
630 WNT4 NM_030761 1556689_a_at
631
Wingless-type MMTV integration site family,
member 5A WNT5A NM_003392 205990_s_at
632 WNT5A NM_003392 213425_at
633
Wingless-type MMTV integration site family,
member 5B WNT5B NM_030775 223537_s_at
634 WNT5B NM_030775 221029_s_at
635
wingless-type MMTV integration site family,
member 6 WNT6 NM_006522 71933_at
636 WNT6 NM_006522 221609_s_at
637 WNT6 NM_006522 222086_s_at
638 WNT6 NM_006522 221608_at
639
wingless-type MMTV integration site family,
member 7A WNT7A NM_004625 210248_at
640
wingless-type MMTV integration site family,
member 7B WNT7B NM_058238 217681_at
641 WNT7B NM_058238 238105_x_at
642
wingless-type MMTV integration site family,
member 8A WNT8A NM_058244 224259_at
643
wingless-type MMTV integration site family,
member 8B WNT8B NM_003393 207612_at
644
wingless-type MMTV integration site family,
member 9A WNT9A NM_003395 1553045_at
645 WNT9A NM_003395 230643_at
646
wingless-type MMTV integration site family,
member 9B WNT9B NM_003396 1552973_at
647 Wilms tumor 1 isoform A WT1 NM_000378 216953_s_at
648 WT1 NM_000378 206067_s_at
649
zinc finger, RAN-binding domain containing 1
protein ZRANB1 NM_017580 225131_at
650 ZRANB1 NM_017580 225138_at
651 ZRANB1 NM_017580 225130_at
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